U.S. patent application number 13/791796 was filed with the patent office on 2013-07-25 for pyrido[4,3-b]indoles and methods of use.
This patent application is currently assigned to MEDIVATION TECHNOLOGIES, INC.. The applicant listed for this patent is Medivation Technologies, Inc.. Invention is credited to Sarvajit CHAKRAVARTY, Rajendra Parasmal JAIN.
Application Number | 20130190328 13/791796 |
Document ID | / |
Family ID | 43032567 |
Filed Date | 2013-07-25 |
United States Patent
Application |
20130190328 |
Kind Code |
A1 |
JAIN; Rajendra Parasmal ; et
al. |
July 25, 2013 |
PYRIDO[4,3-B]INDOLES AND METHODS OF USE
Abstract
New heterocyclic compounds that may be used to modulate a
histamine receptor in an individual are described.
Pyrido[4,3-b]indoles are described, as are pharmaceutical
compositions comprising the compounds and methods of using the
compounds in a variety of therapeutic applications, including the
treatment of a cognitive disorder, psychotic disorder,
neurotransmitter-mediated disorder and/or a neuronal disorder.
Inventors: |
JAIN; Rajendra Parasmal;
(Pune, IN) ; CHAKRAVARTY; Sarvajit; (Mountain
View, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Medivation Technologies, Inc.; |
San Francisco |
CA |
US |
|
|
Assignee: |
MEDIVATION TECHNOLOGIES,
INC.
San Francisco
CA
|
Family ID: |
43032567 |
Appl. No.: |
13/791796 |
Filed: |
March 8, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13318123 |
Feb 8, 2012 |
|
|
|
PCT/US2010/033053 |
Apr 29, 2010 |
|
|
|
13791796 |
|
|
|
|
61181262 |
May 26, 2009 |
|
|
|
Current U.S.
Class: |
514/255.05 ;
514/256; 514/292; 544/333; 544/405; 546/85 |
Current CPC
Class: |
A61P 25/00 20180101;
C07D 471/04 20130101; A61P 43/00 20180101; A61P 25/28 20180101;
A61P 25/18 20180101 |
Class at
Publication: |
514/255.05 ;
546/85; 514/292; 544/333; 514/256; 544/405 |
International
Class: |
C07D 471/04 20060101
C07D471/04 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 29, 2009 |
IN |
1136MUM2009 |
Claims
1. A compound of the formula (A): ##STR00099## wherein: R.sup.1,
R.sup.2, R.sup.3 and R.sup.4 are independently H, halo,
C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy, provided that R.sup.3 is other than methyl or
chloro when R.sup.1, R.sup.2 and R.sup.4 are each H and X is OH and
Y is methyl; R.sup.5 is unsubstituted C.sub.1-C.sub.8 alkyl or a
C.sub.1-C.sub.8 alkyl substituted with a perhaloalkyl moiety;
R.sup.6 is H or an unsubstituted C.sub.1-C.sub.8 alkyl; X is OH,
C.sub.1-C.sub.8 alkyl or is taken together with Y to form a
cyclopropyl moiety; and Y is H, C.sub.1-C.sub.8 alkyl or is taken
together with X to form a cyclopropyl moiety, or a salt thereof,
such as a pharmaceutically acceptable salt thereof, or solvate of
the foregoing.
2. The compound of claim 1, wherein R.sup.5 is methyl, ethyl,
cyclopropyl, trifluoromethyl, trifluoroethyl, isopropyl,
tert-butyl, sec-butyl, 2-methylbutyl, cyclobutyl, cyclopentyl, or
cyclohexyl.
3. The compound of claim 2, wherein R.sup.5 is methyl.
4. The compound of claim 1, wherein R.sup.3 is halo or
C.sub.1-C.sub.8 unsubstituted alkyl.
5. The compound of claim 4, wherein R.sup.3 is chloro or
methyl.
6. The compound of claim 1, wherein X is OH and Y is
C.sub.1-C.sub.8 alkyl.
7. The compound of claim 6, wherein Y is methyl.
8. A compound of the formula (B): ##STR00100## wherein: R.sup.7 is
H, hydroxyl, nitro, cyano, halo, C.sub.1-C.sub.8 perhaloalkyl,
substituted or unsubstituted C.sub.1-C.sub.8 alkyl, substituted or
unsubstituted C.sub.2-C.sub.8 alkenyl, substituted or unsubstituted
C.sub.2-C.sub.8 alkynyl, substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, C.sub.1-C.sub.8
perhaloalkoxy, C.sub.1-C.sub.8 alkoxy, aryloxy, carboxyl,
carbonylalkoxy, thiol, substituted or unsubstituted heterocyclyl,
substituted or unsubstituted aralkyl, thioalkyl, substituted or
unsubstituted amino, acylamino, aminoacyl, aminocarbonylamino,
aminocarbonyloxy, aminosulfonyl, sulfonylamino, sulfonyl,
carbonylalkylenealkoxy, alkylsulfonylamino or acyl; and Z is H,
halo or C.sub.1-C.sub.8 alkyl, or a salt thereof, such as a
pharmaceutically acceptable salt thereof, or solvate of the
foregoing.
9. The compound of claim 8, wherein R.sup.7 is halo or
C.sub.1-C.sub.8 unsubstituted alkyl.
10. The compound of claim 9, wherein R.sup.7 is chloro or
methyl.
11. The compound of claim 8, wherein Z is H or halo.
12. A compound of the formula (C2): ##STR00101## wherein: R.sup.1,
R.sup.2, R.sup.3 and R.sup.4 are independently H, halo,
C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy; R.sup.5 is C.sub.1-C.sub.6 unsubstituted
alkyl or CF.sub.3; R.sup.8 is a substituted or unsubstituted aryl
or a substituted or unsubstituted heteroaryl; and X is a
C.sub.4-C.sub.6 unsubstituted n-alkyl or cycloalkyl or a
C.sub.3-C.sub.6 unsubstituted branched alkyl, or a salt thereof,
such as a pharmaceutically acceptable salt thereof, or solvate of
the foregoing.
13. The compound of claim 12, wherein R.sup.5 is CH.sub.3.
14. The compound of claim 12, wherein X is a C.sub.4-C.sub.6
unsubstituted n-alkyl or cycloalkyl or a C.sub.3-C.sub.6
unsubstituted branched alkyl.
15. The compound of claim 12, wherein R.sup.3 is halo or
C.sub.1-C.sub.8 unsubstituted alkyl.
16. The compound of claim 13, wherein R.sup.3 is chloro or
methyl.
17. The compound of claim 16, wherein R.sup.8 is a substituted or
unsubstituted pyridyl, phenyl, pyrimidinyl, pyrazinyl, imidazolyl,
oxazolyl, oxadiazolyl, furanyl, pyrrolyl or thiophenyl group.
18. A compound of the formula (D2): ##STR00102## wherein: R.sup.1,
R.sup.2, R.sup.3 and R.sup.4 are independently H, halo,
C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy; X is H or a C.sub.1-C.sub.3 unsubstituted
alkyl; and V is a halo, or a salt thereof, such as a
pharmaceutically acceptable salt thereof, or solvate of the
foregoing.
19. The compound of claim 18, wherein X is H.
20. The compound of claim 18, wherein X is CH.sub.3.
21. The compound of claim 18, wherein R.sup.3 is halo or
C.sub.1-C.sub.8 unsubstituted alkyl.
22. The compound of claim 21, wherein R.sup.3 is chloro or
methyl.
23. A compound of the formula (E2): ##STR00103## wherein: R.sup.1,
R.sup.2, R.sup.3 and R.sup.4 are independently H, halo,
C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy; R.sup.8 is 6-pyrimidyl, 2-pyrazinyl,
3-methyl-4-pyridyl or a phenyl substituted either: (i) with at
least one alkoxy or hydroxyl group or (ii) with at least two halo
groups; and R.sup.9 is an unsubstituted C.sub.1-C.sub.3 alkyl, or a
salt thereof, such as a pharmaceutically acceptable salt thereof,
or solvate of the foregoing.
24. The compound of claim 23, wherein R.sup.9 is methyl.
25. A compound of the formula (F2): ##STR00104## wherein: R.sup.1,
R.sup.2, R.sup.3 and R.sup.4 are independently H, halo,
C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy; R.sup.5 is ##STR00105## where T is 3 or 4 X
is H or OH; Y is H or C.sub.1-C.sub.8 alkyl; and R.sup.8 is a
substituted or unsubstituted heteroaryl, or a salt thereof, such as
a pharmaceutically acceptable salt thereof, or solvate of the
foregoing.
26. The compound of claim 25, wherein R.sup.3 is halo or
C.sub.1-C.sub.8 unsubstituted alkyl.
27. The compound of claim 26, wherein R.sup.3 is chloro or
methyl.
28. The compound of claim 25, wherein X is OH and Y is
C.sub.1-C.sub.8 alkyl.
29. The compound of claim 28, wherein Y is methyl.
30. The compound of claim 25, wherein R.sup.8 is a substituted or
unsubstituted pyridyl, phenyl, pyrimidinyl, pyrazinyl, imidazolyl,
oxazolyl, oxadiazolyl, furanyl, pyrrolyl or thiophenyl group.
31. A compound of the formula (G): ##STR00106## wherein: R.sup.1,
R.sup.2 and R.sup.4 are independently H, halo, C.sub.1-C.sub.8
unsubstituted alkyl or C.sub.1-C.sub.8 unsubstituted alkoxy;
R.sup.3 is methyl or chloro, provided that R.sup.3 is methyl when
R.sup.8 is a substituted heteroaryl; X is H or OH; Y is H or
C.sub.1-C.sub.8 alkyl; and R.sup.8 is a substituted or
unsubstituted heteroaryl, or a salt thereof, such as a
pharmaceutically acceptable salt thereof, or solvate of the
foregoing.
32. The compound of claim 31, wherein R.sup.3 is halo or
C.sub.1-C.sub.8 unsubstituted alkyl.
33. The compound of claim 31, wherein R.sup.3 is chloro or
methyl.
34. The compound of claim 31, wherein X is OH and Y is
C.sub.1-C.sub.8 alkyl.
35. The compound of claim 34, wherein Y is methyl.
36. A compound of the formula (H): ##STR00107## wherein: R.sup.1,
R.sup.2, R.sup.3 and R.sup.4 are independently H, halo,
C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy; R.sup.5, R.sup.6 and R.sup.7 are each
independently H or unsubstituted C.sub.1-C.sub.8 alkyl; and R.sup.8
is a 6-substituted pyridin-3-yl, or a salt thereof, such as a
pharmaceutically acceptable salt thereof, or solvate of the
foregoing.
37. The compound of claim 36, wherein R.sup.3 is chloro or
methyl.
38. The compound of claim 36, wherein R.sup.5 is H or methyl.
39. A compound selected from the group consisting of:
1-Cyclohexyl-2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)--
1-(4-fluorophenyl)ethanol;
2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-fluoroph-
enyl)ethanol;
1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(3-fluoro-4-
-methoxyphenyl)propan-2-ol;
1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-methoxyp-
henyl)propan-2-ol;
1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-fluoroph-
enyl)butan-2-ol;
2-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5
(2H)-yl)-1-cyclobutyl-1-(4-fluorophenyl)ethanol;
1-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-flu-
orophenyl)hexan-2-ol;
2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5
(2H)-yl)-1-(pyridine-4-yl)ethanol;
1-(8-Fluoro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5
(2H)-yl)-2-(pyridine-4-yl)propan-2-ol;
1-(6-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5
(2H)-yl)-2-(pyridine-4-yl)propan-2-ol;
2-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5
(2H)-yl)-1-(pyridine-4-yl)ethanol;
1-(7-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5
(2H)-yl)-2-(pyridine-4-yl)propan-2-ol;
1-(6-Fluoro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrid-
ine-4-yl)propan-2-ol;
1-(2-Methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridine-4-yl)-
propan-2-ol;
4-(1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-hydroxyp-
ropan-2-yl)phenol;
1-(8-Methoxy-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyri-
dine-4-yl)propan-2-ol;
1-(7,8-Dichloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(p-
yridine-4-yl)propan-2-ol;
1-(8,9-Dichloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(p-
yridine-4-yl)propan-2-ol;
(R)-1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-meth-
oxyphenyl)propan-2-ol;
(S)-1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-meth-
oxyphenyl)propan-2-ol;
1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-methyl-
-2-(pyridine-4-yl)butan-2-ol;
1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-methyl-2-(p-
yridine-4-yl)butan-2-ol;
1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrid-
ine-4-yl)butan-2-ol;
1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridine-4-
-yl)butan-2-ol;
1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrimidin--
4-yl)propan-2-ol;
1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrim-
idin-4-yl)propan-2-ol;
1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyraz-
in-2-yl)propan-2-ol;
1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrazin-2--
yl)propan-2-ol;
1-(8-Methyl-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5(-
2H)-yl)-2-(pyridine-4-yl)propan-2-ol;
1-(2-Cyclopropyl-8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(-
pyridine-4-yl)propan-2-ol;
1-(6-Methoxy-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyri-
dine-4-yl)propan-2-ol;
1-(7-Isopropyl-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(py-
ridine-4-yl)propan-2-ol;
2-(Pyridin-4-yl)-1-(2,3,8-trimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2-
H)-yl)propan-2-ol;
3-(8-Methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-3,4-dihydro-1H-pyrido[4,3-b-
]indol-2(5H)-yl)propanenitrile;
2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-phenylethan-
one;
2-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-ph-
enylethanone;
2-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-flu-
orophenyl)ethanone;
2-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-chl-
orophenyl)ethanone;
2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-fluoroph-
enyl)ethanone
3-(5-(2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)ethyl)py-
ridine-2-yl)propan-1-amine;
8-Methyl-5-(2-(6-(trifluoromethyl)yridine-3-yl)ethyl)-2,3,4,5-tetrahydro--
1H-pyrido[4,3-b]indole;
3-(8-Methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-3,4-dihydro-1H-pyrido[4,3-b-
]indol-2(5H)-yl)propan-1-ol;
4-(8-Methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-3,4-dihydro-1H-pyrido[4,3-b-
]indol-2(5H)-yl)butan-1-ol;
2,3,8-Trimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydro-1H-p-
yrido[4,3-b]indole;
2,3,8-Trimethyl-5-(2-(6-(trifluoromethyl)yridine-3-yl)ethyl)-2,3,4,5-tetr-
ahydro-1H-pyrido[4,3-b]indole;
2,8-Dimethyl-5-(2-(yridine-4-yl)propyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3--
b]indole;
2,3,8-Trimethyl-5-(2-(6-methylpyridin-3-yl)propyl)-2,3,4,5-tetra-
hydro-1H-pyrido[4,3-b]indole;
8-Chloro-2,3-dimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydr-
o-1H-pyrido[4,3-b]indole;
2,8-Dimethyl-5-(2-methyl-2-(yridine-4-yl)propyl)-2,3,4,5-tetrahydro-1H-py-
rido[4,3-b]indole;
2,8-Dimethyl-5-((1-(yridine-4-yl)cyclopropyl)methyl)-2,3,4,5-tetrahydro-1-
H-pyrido[4,3-b]indole;
2,4,8-Trimethyl-5-(2-(6-(trifluoromethyl)yridine-3-yl)ethyl)-2,3,4,5-tetr-
ahydro-1H-pyrido[4,3-b]indole;
1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridine-4-
-yl)propan-2-ol;
1-(2-Ethyl-8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-fluo-
rophenyl)propan-2-ol;
1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrid-
ine-3-yl)propan-2-ol;
1-(8-Methyl-2-(trifluoromethyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-y-
l)-2-(6-methylpyridin-3-yl)propan-2-ol;
1-(2-Cyclopropyl-8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(-
2-methylpyridin-4-yl)propan-2-ol;
1-(8-Chloro-2-isopropyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4--
chlorophenyl)propan-2-ol;
2-(2,4-Difluorophenyl)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol--
5(2H)-yl)propan-2-ol;
1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(3-flu-
oro-4-methoxyphenyl)propan-2-ol;
(R)-1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-fluo-
rophenyl)butan-2-ol;
(R)-1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-
-fluorophenyl)hexan-2-ol;
(S)-1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridi-
ne-4-yl)butan-2-ol;
(R)-1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridi-
ne-4-yl)butan-2-ol;
1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-flu-
orophenyl)hexan-2-ol;
8-Methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2-(2,2,2-trifluoroethyl)-2,3,4-
,5-tetrahydro-1H-pyrido[4,3-b]indole;
(S)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-fluo-
rophenyl)butan-2-ol; and
(S)-1-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-
-fluorophenyl)hexan-2-ol, or a pharmaceutically acceptable salt
thereof.
40. A method of modulating a histamine receptor in an individual
comprising administering to an individual in need thereof a
compound according to any of claims 1-39.
41. A pharmaceutical composition comprising (a) a compound of any
of claims 1-39, or a pharmaceutically acceptable salt thereof, and
(b) a pharmaceutically acceptable carrier.
42. A kit comprising a compound according to any of claims 1-39 and
instructions for use.
43. A method of treating a cognitive disorder or a disorder
characterized by causing at least one symptom associated with
impaired cognition comprising administering to an individual in
need thereof an effective amount of a compound of any of claims
1-39, or a pharmaceutically acceptable salt thereof.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority benefit of Indian Patent
Application No. 1136/MUM/2009, filed Apr. 29, 2009, and U.S.
Provisional Patent Application No. 61/181,262, filed May 26, 2009,
the disclosures of each of which are hereby incorporated herein by
reference in their entireties.
STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED
RESEARCH
[0002] Not applicable.
BACKGROUND OF THE INVENTION
[0003] Neurotransmitters such as histamine, serotonin, dopamine and
norepinephrine mediate a large number of processes in the central
nervous system (CNS) as well as outside the CNS. Abnormal
neurotransmitter levels are associated with a wide variety of
diseases and conditions including, but not limited to, Alzheimer's
disease, Parkinson's Disease, autism, Guillain-Barre syndrome, mild
cognitive impairment, schizophrenia (such as cognitive impairment
associated with schizophrenia (CIAS), positive symptoms,
disorganized symptoms, and negative symptoms of schizophrenia),
anxiety, multiple sclerosis, stroke, traumatic brain injury, spinal
cord injury, diabetic neuropathy, fibromyalgia, bipolar disorders,
psychosis, depression, attention-deficit disorder (ADD),
attention-deficit hyperactivity disorder (ADHD) and a variety of
allergic diseases. Compounds that modulate these neurotransmitters
may be useful therapeutics.
[0004] Histamine receptors belong to the superfamily of G
protein-coupled seven transmembrane proteins. G protein-coupled
receptors constitute one of the major signal transduction systems
in eukaryotic cells. Coding sequences for these receptors, in those
regions believed to contribute to the agonist-antagonist binding
site, are strongly conserved across mammalian species. Histamine
receptors are found in most peripheral tissue and within the
central nervous system. Compounds capable of modulating a histamine
receptor may find use in therapy, e.g., histamine antagonists may
find use as antihistamines.
[0005] Dimebon is a known anti-histamine drug that has also been
characterized as a neuroprotective agent useful to treat, inter
alia, neurodegenerative diseases. Dimebon has been shown to inhibit
the death of brain cells (neurons) in preclinical models of
Alzheimer's disease and Huntington's disease, making it a novel
potential treatment for these and other neurodegenerative diseases.
In addition, dimebon has been shown to improve the mitochondrial
function of cells in the setting of cellular stress with very high
potency. For example, dimebon treatment improved mitochondrial
function and increased the number of surviving cells after
treatment with the cell toxin ionomycin in a dose dependent
fashion. Dimebon has also been shown to promote neurite outgrowth
and neurogenesis, processes important in the formation of new
and/or enhanced neuronal cell connections, and evidence of
dimebon's potential for use in additional diseases or conditions.
See, e.g., U.S. Pat. Nos. 6,187,785 and 7,071,206 and PCT Patent
Application Nos. PCT/US2004/041081, PCT/US2007/020483,
PCT/US2006/039077, PCT/US2008/077090, PCT/US2007/020516,
PCT/US2007/022645, PCT/US2007/002117, PCT/US2008/006667,
PCT/US2007/024626, PCT/US2008/009357, PCT/US2007/024623 and
PCT/US2008/008121. Hydrogenated pyrido[4,3-b]indoles and uses
thereof have been disclosed in PCT Patent Application Nos.
PCT/US2008/081390, PCT/US2009/032065, PCT/US2009/038142 and
PCT/US2009/062869. All references disclosed herein and throughout,
such as publications, patents, patent applications and published
patent applications, are incorporated herein by reference in their
entireties.
[0006] Although dimebon holds great promise as a drug for the
treatment of neurodegenerative diseases and/or diseases in which
neurite outgrowth and/or neurogenesis may be implicated in therapy,
there remains a need for new and alternative therapies for the
treatment of such diseases or conditions. In addition, there
remains a need for new and alternative antihistamine drugs,
preferably ones in which side-effects such as drowsiness are
reduced or eliminated. Compounds that exhibit enhanced and/or more
desirable properties than dimebon (e.g., superior safety and
efficacy) may find particular use in the treatment of at least
those indications for which dimebon is believed to be advantageous.
Further, compounds that exhibit a different therapeutic profile
than dimebon as determined, e.g., by in vitro and/or in vivo
assays, may find use in additional diseases and conditions.
BRIEF SUMMARY OF THE INVENTION
[0007] Compounds detailed herein are described as histamine
receptor modulators. In one aspect, the histamine receptor
modulator is a compound that binds to or inhibits binding of a
ligand to a histamine (e.g., H.sub.1 and/or H.sub.2 and/or H.sub.3)
receptor or mimics an activity of such a histamine receptor. In
some embodiments, the histamine receptor modulator inhibits binding
of a ligand by at least about or about any one of 10%, 20%, 30%,
40%, 50%, 60%, 70%, 80%, 90%, 95% or 100% as determined in the
assays described herein. Compositions comprising the compounds are
provided, as are kits comprising the compounds as well as methods
of using and making the compounds. The compounds provided herein
may find use in treating neurodegenerative diseases. Compounds
provided may also find use in treating diseases and/or conditions
in which modulation of aminergic G protein-coupled receptors and/or
neurite outgrowth may be implicated in therapy. Compounds disclosed
herein may find use in the methods disclosed herein, including use
in treating, preventing, delaying the onset and/or delaying the
development of a cognitive disorder, psychotic disorder,
neurotransmitter-mediated disorder and/or a neuronal disorder in an
individual in need thereof, such as humans.
[0008] Compounds of the formula (A) are provided:
##STR00001##
wherein:
[0009] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy, provided that R.sup.3 is other than methyl or
chloro when R.sup.1, R.sup.2 and R.sup.4 are each H and X is OH and
Y is methyl;
[0010] R.sup.5 is unsubstituted C.sub.1-C.sub.8 alkyl or a
C.sub.1-C.sub.8 alkyl substituted with a perhaloalkyl moiety;
[0011] R.sup.6 is H or an unsubstituted C.sub.1-C.sub.8 alkyl;
[0012] X is OH, C.sub.1-C.sub.8 alkyl or is taken together with Y
to form a cyclopropyl moiety; and
[0013] Y is H, C.sub.1-C.sub.8 alkyl or is taken together with X to
form a cyclopropyl moiety,
[0014] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0015] Also provided are compounds of the formula (B):
##STR00002##
wherein:
[0016] R.sup.7 is H, hydroxyl, nitro, cyano, halo, C.sub.1-C.sub.8
perhaloalkyl, substituted or unsubstituted C.sub.1-C.sub.8 alkyl,
substituted or unsubstituted C.sub.2-C.sub.8 alkenyl, substituted
or unsubstituted C.sub.2-C.sub.8 alkynyl, substituted or
unsubstituted aryl, substituted or unsubstituted heteroaryl,
C.sub.1-C.sub.8 perhaloalkoxy, C.sub.1-C.sub.8 alkoxy, aryloxy,
carboxyl, carbonylalkoxy, thiol, substituted or unsubstituted
heterocyclyl, substituted or unsubstituted aralkyl, thioalkyl,
substituted or unsubstituted amino, acylamino, aminoacyl,
aminocarbonylamino, aminocarbonyloxy, aminosulfonyl, sulfonylamino,
sulfonyl, carbonylalkylenealkoxy, alkylsulfonylamino or acyl;
and
[0017] Z is H, halo or C.sub.1-C.sub.8 alkyl,
[0018] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0019] Compounds of the formula (C1) are also embraced:
##STR00003##
wherein:
[0020] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0021] R.sup.8 is a substituted or unsubstituted aryl or a
substituted or unsubstituted heteroaryl; and
[0022] X is a C.sub.4-C.sub.6 unsubstituted alkyl,
[0023] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0024] In one variation of formula (C1), R.sup.1, R.sup.2, R.sup.3
and R.sup.4 are as defined for formula (A).
[0025] Compounds of the formula (C2) are also provided:
##STR00004##
wherein:
[0026] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0027] R.sup.5 is C.sub.1-C.sub.6 unsubstituted alkyl or
CF.sub.3;
[0028] R.sup.8 is a substituted or unsubstituted aryl or a
substituted or unsubstituted heteroaryl; and
[0029] X is a C.sub.4-C.sub.6 unsubstituted n-alkyl or cycloalkyl
or a C.sub.3-C.sub.6 unsubstituted branched alkyl,
[0030] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0031] In another embodiment, compounds of the formula (C3) are
provided,
##STR00005##
wherein:
[0032] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0033] R.sup.5 is a C.sub.1-C.sub.6 unsubstituted alkyl, or
CF.sub.3;
[0034] R.sup.8 is a substituted or unsubstituted aryl or a
substituted or unsubstituted heteroaryl; and
[0035] X is a C.sub.1-C.sub.6 unsubstituted alkyl,
[0036] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0037] Compounds of the formula (D1) are also provided:
##STR00006##
wherein:
[0038] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy; and
[0039] V is a halo,
[0040] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0041] In one variation of formula (D1), R.sup.1, R.sup.2, R.sup.3
and R.sup.4 are as defined for formula (A).
[0042] Compounds of the formula (D2) are also provided:
##STR00007##
wherein:
[0043] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0044] X is H or a C.sub.1-C.sub.3 unsubstituted alkyl; and
[0045] V is a halo,
[0046] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0047] In another embodiment, compounds of the formula (D2) are
provided, wherein X is C.sub.1-C.sub.3 unsubstituted alkyl.
[0048] Compounds of the formula (E1) are also detailed herein:
##STR00008##
wherein:
[0049] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0050] R.sup.8 is 6-pyrimidyl, 3-methyl-4-pyridyl or a phenyl
substituted either: (i) with at least one alkoxy or hydroxyl group
or (ii) with at least two halo groups; and
[0051] R.sup.9 is an unsubstituted C.sub.1-C.sub.3 alkyl,
[0052] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0053] In a particular variation of formula (E1), R.sup.1, R.sup.2,
R.sup.3 and R.sup.4 are as defined for formula (A).
[0054] In another embodiment, compounds of the formula (E2) are
provided,
##STR00009##
wherein:
[0055] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0056] R.sup.8 is 6-pyrimidyl, 2-pyrazinyl, 3-methyl-4-pyridyl or a
phenyl substituted either: (i) with at least one alkoxy or hydroxyl
group or (ii) with at least two halo groups; and
[0057] R.sup.9 is an unsubstituted C.sub.1-C.sub.3 alkyl,
[0058] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0059] Also provided are compounds of the formula (F1):
##STR00010##
wherein:
[0060] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0061] R.sup.5 is
##STR00011##
where T is 3 or 4;
[0062] X is H or OH;
[0063] Y is H or C.sub.1-C.sub.8 alkyl; and
[0064] R.sup.8 is a substituted or unsubstituted heteroaryl,
[0065] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0066] In one variation of formula (F1), R.sup.1, R.sup.2, R.sup.3
and R.sup.4 are as defined for formula (A).
[0067] In another embodiment, compounds of the formula (F2) are
provided,
##STR00012##
wherein:
[0068] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0069] R.sup.5 is
##STR00013##
where T is 3 or 4
[0070] X is H or OH;
[0071] Y is H or C.sub.1-C.sub.8 alkyl; and
[0072] R.sup.8 is a substituted or unsubstituted heteroaryl,
[0073] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0074] Compounds of the formula (G) are also detailed herein:
##STR00014##
wherein:
[0075] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0076] R.sup.3 is methyl or chloro, provided that R.sup.3 is methyl
when R.sup.8 is a substituted heteroaryl;
[0077] X is H or OH;
[0078] Y is H or C.sub.1-C.sub.8 alkyl; and
[0079] R.sup.8 is a substituted or unsubstituted heteroaryl,
[0080] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0081] In one variation of formula (G), R.sup.1, R.sup.2, R.sup.3
and R.sup.4 are as defined for formula (A).
[0082] Compounds of the formula (H) are also detailed herein:
##STR00015##
wherein:
[0083] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0084] R.sup.5, R.sup.6 and R.sup.7 are each independently H or
unsubstituted C.sub.1-C.sub.8 alkyl; and
[0085] R.sup.8 is a 6-substituted pyridin-3-yl,
[0086] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0087] In one variation of formula (H), R.sup.1, R.sup.2, R.sup.3
and R.sup.4 are as defined for formula A.
[0088] Various other compounds are detailed herein, including
compounds of Table 1. In one variation, compounds of the invention
exclude compound 1-4 of Table 1.
[0089] The invention also includes all salts of compounds referred
to herein, such as pharmaceutically acceptable salts. A
pharmaceutically acceptable salt intends ionic interactions and not
a covalent bond. As such, an N-oxide is not considered a salt.
Examples of pharmaceutically acceptable salts include those listed
in Berge et al., Pharmaceutical Salts, J. Pharm. Sci. 1977 January;
66(1):1-19. The invention also includes any or all of the
stereochemical forms, including any enantiomeric or diastereomeric
forms, of the compounds described. Unless stereochemistry is
explicitly indicated in a chemical structure or name, the structure
or name is intended to embrace all possible stereoisomers of a
compound depicted. All forms of the compounds are also embraced by
the invention, such as crystalline or non-crystalline forms of the
compounds. Compositions comprising a compound of the invention are
also intended, such as a composition of substantially pure
compound, including a specific stereochemical form thereof.
Compositions comprising a mixture of compounds of the invention in
any ratio are also embraced by the invention, including mixtures of
two or more stereochemical forms of a compound of the invention in
any ratio, such that racemic, non-racemic, enantio-enriched and
scalemic mixtures of a compound are embraced, or mixtures
thereof.
[0090] Compounds of the invention may be presented in the form of
chemical structures or names. Chemical structures and names have
been generated using graphical software, e.g., ChemBioDraw Ultra
11.0 (CambridgeSoft Co.), which includes a facility to generate
IUPAC-standard names from ChemDraw structures, and vice-versa,
based on Beilstein's AutoNom conversion algorithms.
[0091] The invention is also directed to pharmaceutical
compositions comprising a compound of the invention and a
pharmaceutically acceptable carrier or excipient. Kits comprising a
compound of the invention and instructions for use are also
embraced by this invention. Compounds as detailed herein or a
pharmaceutically acceptable salt thereof are also provided for the
manufacture of a medicament for the treatment of a cognitive
disorder, psychotic disorder, neurotransmitter-mediated disorder or
a neuronal disorder.
[0092] In one aspect, compounds of the invention are used to treat,
prevent, delay the onset and/or delay the development of any one or
more of the following: cognitive disorders, psychotic disorders,
neurotransmitter-mediated disorders and/or neuronal disorders in
individuals in need thereof, such as humans. In one variation,
compounds of the invention are used to treat, prevent, delay the
onset and/or delay the development of diseases or conditions for
which the modulation of an aminergic G protein-coupled receptor is
believed to be or is beneficial. In one variation, compounds of the
invention are used to treat, prevent, delay the onset and/or delay
the development of any one or more of diseases or conditions for
which neurite outgrowth and/or neurogenesis and/or neurotrophic
effects are believed to be or are beneficial. In another variation,
compounds of the invention are used to treat, prevent, delay the
onset and/or delay the development of diseases or conditions for
which the modulation of an aminergic G protein-coupled receptor and
neurite outgrowth and/or neurogenesis and/or neurotrophic effects
are believed to be or are beneficial. In one variation, the disease
or condition is a cognitive disorder, psychotic disorder,
neurotransmitter-mediated disorder and/or a neuronal disorder.
[0093] In another aspect, compounds of the invention are used to
improve cognitive function and/or reduce psychotic effects in an
individual, comprising administering to an individual in need
thereof an amount of a compound described herein or a
pharmaceutically acceptable salt thereof effective to improve
cognitive function and/or reduce psychotic effects.
[0094] In a further aspect, compounds of the invention are used to
stimulate neurite outgrowth and/or promote neurogenesis and/or
enhance neurotrophic effects in an individual comprising
administering to an individual in need thereof an amount of a
compound described herein or a pharmaceutically acceptable salt
thereof effective to stimulate neurite outgrowth and/or to promote
neurogenesis and/or to enhance neurotrophic effects. Synapse loss
is associated with a variety of neurodegenerative diseases and
conditions including Alzheimer's disease, schizophrenia,
Huntington's disease, Parkinson's disease, amyotrophic lateral
sclerosis, stroke, head trauma and spinal cord injury. Compounds of
the invention that stimulate neurite outgrowth may have a benefit
in these settings.
[0095] In another aspect, compounds described herein are used to
modulate an aminergic G protein-coupled receptor comprising
administering to an individual in need thereof an amount of a
compound described herein or a pharmaceutically acceptable salt
thereof effective to modulate an aminergic G protein-coupled
receptor. In one variation, a compound of the invention modulates
at least one of the following receptors: adrenergic receptor (e.g.,
.alpha..sub.1D, .alpha..sub.2A and/or .alpha..sub.2B), serotonin
receptor (e.g., 5-HT.sub.2A, 5-HT.sub.2C, 5-HT.sub.6 and/or
5-HT.sub.7), dopamine receptor (e.g., D.sub.2L) and histamine
receptor (e.g., H.sub.1, H.sub.2 and/or H.sub.3). In another
variation, at least two of the following receptors are modulated:
adrenergic receptor (e.g., .alpha..sub.1D, .alpha..sub.2A and/or
.alpha..sub.2B), serotonin receptor (e.g., 5-HT.sub.2A,
5-HT.sub.2C, 5-HT.sub.6 and/or 5-HT.sub.7), dopamine receptor
(e.g., D.sub.2L) and histamine receptor (e.g., H.sub.1, H.sub.2
and/or H.sub.3). In another variation, at least three of the
following receptors are modulated: adrenergic receptor (e.g.,
.alpha..sub.1D, .alpha..sub.2A and/or .alpha..sub.2B), serotonin
receptor (e.g., 5-HT.sub.2A, 5-HT.sub.2C, 5-HT.sub.6 and/or
5-HT.sub.7), dopamine receptor (e.g., D.sub.2L) and histamine
receptor (e.g., H.sub.1, H.sub.2 and/or H.sub.3). In another
variation, each of the following receptors is modulated: adrenergic
receptor (e.g., .alpha..sub.1D, .alpha..sub.2A and/or
.alpha..sub.2B), serotonin receptor (e.g., 5-HT.sub.2A,
5-HT.sub.2C, 5-HT.sub.6 and/or 5-HT.sub.7), dopamine receptor
(e.g., D.sub.2L) and histamine receptor (e.g., H.sub.1, H.sub.2
and/or H.sub.3). In another variation, at least one of the
following receptors is modulated: .alpha..sub.1D, .alpha..sub.2A,
.alpha..sub.2B, 5-HT.sub.2A, 5-HT.sub.2C, 5-HT.sub.6, 5-HT.sub.7,
D.sub.2L, H.sub.1, H.sub.2 and H.sub.3. In another variation, at
least one of the following receptors is modulated: .alpha..sub.1D,
.alpha..sub.2A, .alpha..sub.2B, 5-HT.sub.2A, 5-HT.sub.2C,
5-HT.sub.6, 5-HT.sub.7, D.sub.2, H.sub.1, H.sub.2 and H.sub.3. In
another variation, at least two or three or four or five or six or
seven or eight or nine or ten or eleven of the following receptors
are modulated: .alpha..sub.1D, .alpha..sub.2A, .alpha..sub.2B,
5-HT.sub.2A, 5-HT.sub.2C, 5-HT.sub.6, 5-HT.sub.7, D.sub.2L,
H.sub.1, H.sub.2 and H.sub.3. In another variation, at least two or
three or four or five or six or seven or eight or nine or ten or
eleven of the following receptors are modulated: .alpha..sub.1D,
.alpha..sub.2A, .alpha..sub.2B, 5-HT.sub.2A, 5-HT.sub.2C,
5-HT.sub.6, 5-HT.sub.7, D.sub.2, H.sub.1, H.sub.2 and H.sub.3. In a
particular variation, at least dopamine receptor D.sub.2 is
modulated. In still another variation, at least dopamine receptor
D.sub.2L is modulated. In another particular variation, at least
dopamine receptor D.sub.2 and serotonin receptor 5-HT.sub.2A are
modulated. In another particular variation, at least dopamine
receptor D.sub.2L and serotonin receptor 5-HT.sub.2A are modulated.
In a further particular variation, at least adrenergic receptors
.alpha..sub.1D, .alpha..sub.2A, .alpha..sub.2B and serotonin
receptor 5-HT.sub.6 are modulated. In another particular variation,
at least adrenergic receptors .alpha..sub.1D, .alpha..sub.2A,
.alpha..sub.2B, serotonin receptor 5-HT.sub.6 and one or more of
serotonin receptor 5-HT.sub.7, 5-HT.sub.2A, 5-HT.sub.2C and
histamine receptor H.sub.1 and H.sub.2 are modulated. In a further
particular variation, histamine receptor H.sub.1 is modulated. In
another variation, compounds of the invention exhibit any receptor
modulation activity detailed herein and further stimulate neurite
outgrowth and/or neurogenesis and/or enhance neurotrophic effects.
In one variation, compounds detailed herein inhibit binding of a
ligand to histamine receptor H.sub.1 and/or H.sub.2 by less than
about 80% as determined by a suitable assay known in the art such
as the assays described herein. In another variation, binding of a
ligand to histamine receptor H.sub.1 and/or H.sub.2 is inhibited by
less than about any of 75%, 70%, 65%, 60%, 55%, or 50% as
determined by a suitable assay known in the art such as the assays
described herein. In a further variation, compounds detailed
herein: (a) inhibit binding of a ligand to histamine receptor
H.sub.1 and/or H.sub.2 by less than about 80% (which can in
different variations be less than about any of 75%, 70%, 65%, 60%,
55%, or 50%) as determined by a suitable assay known in the art
such as the assays described herein and (b) inhibit binding of a
ligand to dopamine receptor D.sub.2L by greater than about any of
80%, 85%, 90%, 95%, 100% or between about 85% and about 95% or
between about 90% and about 100%, as determined in a suitable assay
known in the art such as the assays described herein. In a further
variation, compounds detailed herein: (a) inhibit binding of a
ligand to histamine receptor H.sub.1 and/or H.sub.2 by less than
about 80% (which can in different variations be less than about any
of 75%, 70%, 65%, 60%, 55%, or 50%) as determined by a suitable
assay known in the art such as the assays described herein and (b)
inhibit binding of a ligand to a dopamine receptor D.sub.2 by
greater than about any of 80%, 85%, 90%, 95%, 100% or between about
85% and about 95% or between about 90% and about 100%, as
determined in a suitable assay known in the art such as the assays
described herein.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0096] For use herein, unless clearly indicated otherwise, use of
the terms "a", "an" and the like refers to one or more.
[0097] As used herein, reference to "about" a value or parameter
herein includes (and describes) embodiments that are directed to
that value or parameter per se. For example, description referring
to "about X" includes description of "X".
[0098] As used herein, the term "aminergic G protein-coupled
receptors" refers to a family of transmembrane proteins involved in
cellular communication Aminergic G protein coupled receptors are
activated by biogenic amines and represent a subclass of the
superfamily of G protein coupled receptors, which are structurally
characterized by seven transmembrane helices. Aminergic G
protein-coupled receptors include but are not limited to adrenergic
receptors, serotonin receptors, dopamine receptors, histamine
receptors and imidazoline receptors.
[0099] As used herein, the term "adrenergic receptor modulator"
intends and encompasses a compound that binds to or inhibits
binding of a ligand to an adrenergic receptor or reduces or
eliminates or increases or enhances or mimics an activity of an
adrenergic receptor. As such, an "adrenergic receptor modulator"
encompasses both an adrenergic receptor antagonist and an
adrenergic receptor agonist. In some aspects, the adrenergic
receptor modulator binds to or inhibits binding to a ligand to an
.alpha.1-adrenergic receptor (e.g., .alpha..sub.1A, .alpha..sub.1D
and/or .alpha..sub.1D) and/or a .alpha..sub.2-adrenergic receptor
(e.g., .alpha..sub.2A, .alpha..sub.2B and/or .alpha..sub.2C) and/or
reduces or eliminates or increases or enhances or mimics an
activity of a .alpha..sub.1-adrenergic receptor (e.g.,
.alpha..sub.1A, .alpha..sub.1D and/or .alpha..sub.1D) and/or a
.alpha..sub.2-adrenergic receptor (e.g., .alpha..sub.2A,
.alpha..sub.2B and/or .alpha..sub.2C) in a reversible or
irreversible manner. In some aspects, the adrenergic receptor
modulator inhibits binding of a ligand by at least about or about
any one of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100%
as determined in the assays described herein. In some aspects, the
adrenergic receptor modulator reduces an activity of an adrenergic
receptor by at least or about any of 10%, 20%, 30%, 40%, 50%, 60%,
70%, 80%, 90%, 95% or 100% as compared to the corresponding
activity in the same subject prior to treatment with the adrenergic
receptor modulator or compared to the corresponding activity in
other subjects not receiving the adrenergic receptor modulator. In
some aspects, the adrenergic receptor modulator enhances an
activity of an adrenergic receptor by at least about or about any
of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100 or 200%
or 300% or 400% or 500% or more as compared to the corresponding
activity in the same subject prior to treatment with the adrenergic
receptor modulator or compared to the corresponding activity in
other subjects not receiving the adrenergic receptor modulator. In
some aspects, the adrenergic receptor modulator is capable of
binding to the active site of an adrenergic receptor (e.g., a
binding site for a ligand). In some embodiments, the adrenergic
receptor modulator is capable of binding to an allosteric site of
an adrenergic receptor.
[0100] As used herein, the term "dopamine receptor modulator"
intends and encompasses a compound that binds to or inhibits
binding of a ligand to a dopamine receptor or reduces or eliminates
or increases or enhances or mimics an activity of a dopamine
receptor. As such, a "dopamine receptor modulator" encompasses both
a dopamine receptor antagonist and a dopamine receptor agonist. In
some aspects, the dopamine receptor modulator binds to or inhibits
binding of a ligand to a dopamine-1 (D.sub.1) and/or a dopamine-2
(D.sub.2) receptor or reduces or eliminates or increases or
enhances or mimics an activity of a dopamine-1 (D.sub.1) and/or a
dopamine-2 (D.sub.2) receptor in a reversible or irreversible
manner. Dopamine D.sub.2 receptors are divided into two categories,
D.sub.2L, and D.sub.2S, which are formed from a single gene by
differential splicing. D.sub.2L, receptors have a longer
intracellular domain than D.sub.2S. In some embodiments, the
dopamine receptor modulator inhibits binding of a ligand by at
least about or about any one of 10%, 20%, 30%, 40%, 50%, 60%, 70%,
80%, 90%, 95% or 100% as determined in the assays described herein.
In some embodiments, the dopamine receptor modulator reduces an
activity of a dopamine receptor by at least about or about any of
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100% as
compared to the corresponding activity in the same subject prior to
treatment with the dopamine receptor modulator or compared to the
corresponding activity in other subjects not receiving the dopamine
receptor modulator. In some embodiments, the dopamine receptor
modulator enhances an activity of a dopamine receptor by at least
about or about any of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%,
95% or 100 or 200% or 300% or 400% or 500% or more as compared to
the corresponding activity in the same subject prior to treatment
with the dopamine receptor modulator or compared to the
corresponding activity in other subjects not receiving the dopamine
receptor modulator. In some embodiments, the dopamine receptor
modulator is capable of binding to the active site of a dopamine
receptor (e.g., a binding site for a ligand). In some embodiments,
the dopamine receptor modulator is capable of binding to an
allosteric site of a dopamine receptor.
[0101] As used herein, the term "serotonin receptor modulator"
intends and encompasses a compound that binds to or inhibits
binding of a ligand to a serotonin receptor or reduces or
eliminates or increases or enhances or mimics an activity of a
serotonin receptor. As such, a "serotonin receptor modulator"
encompasses both a serotonin receptor antagonist and a serotonin
receptor agonist. In some embodiments, the serotonin receptor
modulator binds to or inhibits binding of a ligand to a 5-HT.sub.1A
and/or a 5-HT.sub.1B and/or a 5-HT.sub.2A and/or a 5-HT.sub.2B
and/or a 5-HT.sub.2C and/or a 5-HT.sub.3 and/or a 5-HT.sub.4 and/or
a 5-HT.sub.6 and/or a 5-HT.sub.7 receptor or reduces or eliminates
or increases or enhances or mimics an activity of a 5-HT.sub.1A
and/or a 5-HT.sub.1B and/or a 5-HT.sub.2A and/or a 5-HT.sub.2B
and/or a 5-HT.sub.2C and/or a 5-HT.sub.3 and/or a 5-HT.sub.4 and/or
a 5-HT.sub.6 and/or a 5-HT.sub.7 receptor in a reversible or
irreversible manner. In some embodiments, the serotonin receptor
modulator inhibits binding of a ligand by at least about or about
any one of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100%
as determined in the assays described herein. In some embodiments,
the serotonin receptor modulator reduces an activity of a serotonin
receptor by at least about or about any of 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, 90%, 95% or 100% as compared to the corresponding
activity in the same subject prior to treatment with the serotonin
receptor modulator or compared to the corresponding activity in
other subjects not receiving the serotonin receptor modulator. In
some embodiments, the serotonin receptor modulator enhances an
activity of a serotonin receptor by at least about or about any of
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100 or 200% or
300% or 400% or 500% or more as compared to the corresponding
activity in the same subject prior to treatment with the serotonin
receptor modulator or compared to the corresponding activity in
other subjects not receiving the serotonin receptor modulator. In
some embodiments, the serotonin receptor modulator is capable of
binding to the active site of a serotonin receptor (e.g., a binding
site for a ligand). In some embodiments, the serotonin receptor
modulator is capable of binding to an allosteric site of a
serotonin receptor.
[0102] As used herein, the term "histamine receptor modulator"
intends and encompasses a compound that reduces or eliminates or
increases or enhances an activity of a histamine receptor. As such,
a "histamine receptor modulator" encompasses both a histamine
receptor antagonist and a histamine receptor agonist. In some
embodiments, the histamine receptor modulator reduces or eliminates
or increases or enhances an activity of a histamine receptor in a
reversible or irreversible manner. In some embodiments, the
histamine receptor modulator reduces an activity of a histamine
receptor by at least or about any of 10%, 20%, 30%, 40%, 50%, 60%,
70%, 80%, 90%, 95% or 100% as compared to the corresponding
activity in the same individual prior to treatment with the
histamine receptor modulator or compared to the corresponding
activity in like individuals not receiving the histamine receptor
modulator. In some embodiments, the histamine receptor modulator
enhances an activity of a histamine receptor by at least or about
any of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100 or
200% or 300% or 400% or 500% or more as compared to the
corresponding activity in the same individual prior to treatment
with the histamine receptor modulator or compared to the
corresponding activity in like individuals not receiving the
histamine receptor modulator. In some embodiments, the histamine
receptor modulator is capable of binding to the active site of a
histamine receptor (e.g., a binding site for a ligand). In some
embodiments, the histamine receptor modulator is capable of binding
to an allosteric site of a histamine receptor.
[0103] Unless clearly indicated otherwise, "an individual" as used
herein intends a mammal, including but not limited to a human. An
individual includes but is not limited to human, bovine, primate,
equine, canine, feline, porcine, and ovine animals. Thus, the
invention finds use in both human medicine and in the veterinary
context, including use in agricultural animals and domestic pets.
The individual may be a human who has been diagnosed with or is
suspected of having a cognitive disorder, a psychotic disorder, a
neurotransmitter-mediated disorder and/or a neuronal disorder. The
individual may be a human who exhibits one or more symptoms
associated with a cognitive disorder, a psychotic disorder, a
neurotransmitter-mediated disorder and/or a neuronal disorder. The
individual may be a human who has a mutated or abnormal gene
associated with a cognitive disorder, a psychotic disorder, a
neurotransmitter-mediated disorder and/or a neuronal disorder. The
individual may be a human who is genetically or otherwise
predisposed to developing a cognitive disorder, a psychotic
disorder, a neurotransmitter-mediated disorder and/or a neuronal
disorder.
[0104] As used herein, "treatment" or "treating" is an approach for
obtaining a beneficial or desired result, such as a clinical
result.
[0105] For purposes of this invention, beneficial or desired
clinical results include, but are not limited to, alleviation of a
symptom and/or diminishment of the extent of a symptom and/or
preventing a worsening of a symptom associated with a disease or
condition. In one variation, beneficial or desired clinical results
include, but are not limited to, alleviation of a symptom and/or
diminishment of the extent of a symptom and/or preventing a
worsening of a symptom associated with a cognitive disorder, a
psychotic disorder, a neurotransmitter-mediated disorder and/or a
neuronal disorder. Preferably, treatment of a disease or condition
with a compound of the invention or a pharmaceutically acceptable
salt thereof is accompanied by no or fewer side effects than are
associated with currently available therapies for the disease or
condition and/or improves the quality of life of the
individual.
[0106] As used herein, "delaying" development of a disease or
condition means to defer, hinder, slow, retard, stabilize and/or
postpone development of the disease or condition. This delay can be
of varying lengths of time, depending on the history of the disease
and/or individual being treated. As is evident to one skilled in
the art, a sufficient or significant delay can, in effect,
encompass prevention, in that the individual does not develop the
disease or condition. For example, a method that "delays"
development of Alzheimer's disease is a method that reduces
probability of disease development in a given time frame and/or
reduces extent of the disease in a given time frame, when compared
to not using the method. Such comparisons are typically based on
clinical studies, using a statistically significant number of
subjects. For example, Alzheimer's disease development can be
detected using standard clinical techniques, such as routine
neurological examination, patient interview, neuroimaging,
detecting alterations of levels of specific proteins in the serum
or cerebrospinal fluid (e.g., amyloid peptides and Tau),
computerized tomography (CT) or magnetic resonance imaging (MRI).
Similar techniques are known in the art for other diseases and
conditions. Development may also refer to disease progression that
may be initially undetectable and includes occurrence, recurrence
and onset.
[0107] As used herein, an "at risk" individual is an individual who
is at risk of developing a cognitive disorder, a psychotic
disorder, a neurotransmitter-mediated disorder and/or a neuronal
disorder that can be treated with a compound of the invention. An
individual "at risk" may or may not have a detectable disease or
condition, and may or may not have displayed detectable disease
prior to the treatment methods described herein. "At risk" denotes
that an individual has one or more so-called risk factors, which
are measurable parameters that correlate with development of a
disease or condition and are known in the art. An individual having
one or more of these risk factors has a higher probability of
developing the disease or condition than an individual without
these risk factor(s). These risk factors include, but are not
limited to, age, sex, race, diet, history of previous disease,
presence of precursor disease, genetic (i.e., hereditary)
considerations, and environmental exposure. For example,
individuals at risk for Alzheimer's disease include, e.g., those
having relatives who have experienced this disease and those whose
risk is determined by analysis of genetic or biochemical markers.
Genetic markers of risk for Alzheimer's disease include mutations
in the APP gene, particularly mutations at position 717 and
positions 670 and 671 referred to as the Hardy and Swedish
mutations, respectively (Hardy, Trends Neurosci., 20:154-9, 1997).
Other markers of risk are mutations in the presenilin genes (e.g.,
PS1 or PS2), ApoE4 alleles, family history of Alzheimer's disease,
hypercholesterolemia and/or atherosclerosis. Other such factors are
known in the art for other diseases and conditions.
[0108] As used herein, the term "pro-cognitive" includes but is not
limited to an improvement of one or more mental processes such as
memory, attention, perception and/or thinking, which may be
assessed by methods known in the art.
[0109] As used herein, the term "neurotrophic" effects includes but
is not limited to effects that enhance neuron function such as
growth, survival and/or neurotransmitter synthesis.
[0110] As used herein, the term "cognitive disorders" refers to and
intends diseases and conditions that are believed to involve or be
associated with or do involve or are associated with progressive
loss of structure and/or function of neurons, including death of
neurons, and where a central feature of the disorder may be the
impairment of cognition (e.g., memory, attention, perception and/or
thinking). These disorders include pathogen-induced cognitive
dysfunction, e.g., HIV associated cognitive dysfunction and Lyme
disease associated cognitive dysfunction. Examples of cognitive
disorders include Alzheimer's Disease, Huntington's Disease,
Parkinson's Disease, schizophrenia, amyotrophic lateral sclerosis
(ALS), autism, mild cognitive impairment (MCI), stroke, traumatic
brain injury (TBI) and age-associated memory impairment (AAMI).
[0111] As used herein, the term "psychotic disorders" refers to and
intends mental diseases or conditions that are believed to cause or
do cause abnormal thinking and perceptions. Psychotic disorders are
characterized by a loss of reality which may be accompanied by
delusions, hallucinations (perceptions in a conscious and awake
state in the absence of external stimuli which have qualities of
real perception, in that they are vivid, substantial, and located
in external objective space), personality changes and/or
disorganized thinking. Other common symptoms include unusual or
bizarre behavior, as well as difficulty with social interaction and
impairment in carrying out the activities of daily living.
Exemplary psychotic disorders are schizophrenia, bipolar disorders,
psychosis, anxiety and depression.
[0112] As used herein, the term "neurotransmitter-mediated
disorders" refers to and intends diseases or conditions that are
believed to involve or be associated with or do involve or are
associated with abnormal levels of neurotransmitters such as
histamine, serotonin, dopamine, norepinephrine or impaired function
of aminergic G protein-coupled receptors. Exemplary
neurotransmitter-mediated disorders include spinal cord injury,
diabetic neuropathy, allergic diseases and diseases involving
geroprotective activity such as age-associated hair loss
(alopecia), age-associated weight loss and age-associated vision
disturbances (cataracts). Abnormal neurotransmitter levels are
associated with a wide variety of diseases and conditions
including, but not limited, to Alzheimer's disease, Parkinson's
Disease, autism, Guillain-Barre syndrome, mild cognitive
impairment, schizophrenia, anxiety, multiple sclerosis, stroke,
traumatic brain injury, spinal cord injury, diabetic neuropathy,
fibromyalgia, bipolar disorders, psychosis, depression and a
variety of allergic diseases.
[0113] As used herein, the term "neuronal disorders" refers to and
intends diseases or conditions that are believed to involve, or be
associated with, or do involve or are associated with neuronal cell
death and/or impaired neuronal function or decreased neuronal
function. Exemplary neuronal indications include neurodegenerative
diseases and disorders such as Alzheimer's disease, Huntington's
disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease,
canine cognitive dysfunction syndrome (CCDS), Lewy body disease,
Menkes disease, Wilson disease, Creutzfeldt-Jakob disease, Fahr
disease, an acute or chronic disorder involving cerebral
circulation, such as ischemic or hemorrhagic stroke or other
cerebral hemorrhagic insult, age-associated memory impairment
(AAMI), mild cognitive impairment (MCI), injury-related mild
cognitive impairment (MCI), post-concussion syndrome,
post-traumatic stress disorder, adjuvant chemotherapy, traumatic
brain injury (TBI), neuronal death mediated ocular disorder,
macular degeneration, age-related macular degeneration, autism,
including autism spectrum disorder, Asperger syndrome, and Rett
syndrome, an avulsion injury, a spinal cord injury, myasthenia
gravis, Guillain-Barre syndrome, multiple sclerosis, diabetic
neuropathy, fibromyalgia, neuropathy associated with spinal cord
injury, schizophrenia, bipolar disorder, psychosis, anxiety or
depression.
[0114] As used herein, the term "neuron" represents a cell of
ectodermal embryonic origin derived from any part of the nervous
system of an animal. Neurons express well-characterized
neuron-specific markers, including neurofilament proteins, NeuN
(Neuronal Nuclei marker), MAP2, and class III tubulin. Included as
neurons are, for example, hippocampal, cortical, midbrain
dopaminergic, spinal motor, sensory, sympathetic, septal
cholinergic, and cerebellar neurons.
[0115] As used herein, the term "neurite outgrowth" or "neurite
activation" refers to the extension of existing neuronal processes
(e.g., axons and dendrites) and the growth or sprouting of new
neuronal processes (e.g., axons and dendrites). Neurite outgrowth
or neurite activation may alter neural connectivity, resulting in
the establishment of new synapses or the remodeling of existing
synapses.
[0116] As used herein, the term "neurogenesis" refers to the
generation of new nerve cells from undifferentiated neuronal
progenitor cells, also known as multipotential neuronal stem cells.
Neurogenesis actively produces new neurons, astrocytes, glia,
Schwann cells, oligodendrocytes and/or other neural lineages. Much
neurogenesis occurs early in human development, though it continues
later in life, particularly in certain localized regions of the
adult brain.
[0117] As used herein, the term "neural connectivity" refers to the
number, type, and quality of connections ("synapses") between
neurons in an organism. Synapses form between neurons, between
neurons and muscles (a "neuromuscular junction"), and between
neurons and other biological structures, including internal organs,
endocrine glands, and the like. Synapses are specialized structures
by which neurons transmit chemical or electrical signals to each
other and to non-neuronal cells, muscles, tissues, and organs.
Compounds that affect neural connectivity may do so by establishing
new synapses (e.g., by neurite outgrowth or neurite activation) or
by altering or remodeling existing synapses. Synaptic remodeling
refers to changes in the quality, intensity or type of signal
transmitted at particular synapses.
[0118] As used herein, the term "neuropathy" refers to a disorder
characterized by altered function and/or structure of motor,
sensory, and autonomic neurons of the nervous system, initiated or
caused by a primary lesion or other dysfunction of the nervous
system. Patterns of peripheral neuropathy include polyneuropathy,
mononeuropathy, mononeuritis multiplex and autonomic neuropathy.
The most common form is (symmetrical) peripheral polyneuropathy,
which mainly affects the feet and legs. A radiculopathy involves
spinal nerve roots, but if peripheral nerves are also involved the
term radiculoneuropathy is used. The form of neuropathy may be
further broken down by cause, or the size of predominant fiber
involvement, e.g., large fiber or small fiber peripheral
neuropathy. Central neuropathic pain can occur in spinal cord
injury, multiple sclerosis, and some strokes, as well as
fibromyalgia. Neuropathy may be associated with varying
combinations of weakness, autonomic changes and sensory changes.
Loss of muscle bulk or fasciculations, a particular fine twitching
of muscle may also be seen. Sensory symptoms encompass loss of
sensation and "positive" phenomena including pain. Neuropathies are
associated with a variety of disorders, including diabetes (e.g.,
diabetic neuropathy), fibromyalgia, multiple sclerosis, and herpes
zoster infection, as well as with spinal cord injury and other
types of nerve damage.
[0119] As used herein, the term "Alzheimer's disease" refers to a
degenerative brain disorder characterized clinically by progressive
memory deficits, confusion, behavioral problems, inability to care
for oneself, gradual physical deterioration and, ultimately, death.
Histologically, the disease is characterized by neuritic plaques,
found primarily in the association cortex, limbic system and basal
ganglia. The major constituent of these plaques is amyloid beta
peptide (A.beta.), which is the cleavage product of beta amyloid
precursor protein (.beta.APP or APP). APP is a type I transmembrane
glycoprotein that contains a large ectopic N-terminal domain, a
transmembrane domain and a small cytoplasmic C-terminal tail.
Alternative splicing of the transcript of the single APP gene on
chromosome 21 results in several isoforms that differ in the number
of amino acids. A.beta. appears to have a central role in the
neuropathology of Alzheimer's disease. Familial forms of the
disease have been linked to mutations in APP and the presenilin
genes (Tanzi et al., 1996, Neurobiol. Dis., 3:159-168; Hardy, 1996,
Ann. Med., 28:255-258). Diseased-linked mutations in these genes
result in increased production of the 42-amino acid form of
A.beta., the predominant form found in amyloid plaques.
Mitochondrial dysfunction has also been reported to be an important
component of Alzheimer's disease (Bubber et al., Mitochondrial
abnormalities in Alzheimer brain: Mechanistic Implications, Ann
Neurol., 2005, 57(5), 695-703; Wang et al., "Insights into
amyloid-.beta.-induced mitochondrial dysfunction in Alzheimer
disease," Free Radical Biology & Medicine, 2007, 43, 1569-1573;
Swerdlow et al., "Mitochondria in Alzheimer's disease," Int. Rev.
Neurobiol. 2002, 53, 341-385; and Reddy et al., "Are mitochondria
critical in the pathogenesis of Alzheimer's disease?," Brain Res
Rev. 2005, 49(3), 618-32). It has been proposed that mitochondrial
dysfunction has a causal relationship with neuronal function
(including neurotransmitter synthesis and secretion) and viability.
Compounds which stabilize mitochondria may therefore have a
beneficial impact on Alzheimer's patients.
[0120] As used herein, the term "Huntington's disease" refers to a
fatal neurological disorder characterized clinically by symptoms
such as involuntary movements, cognition impairment or loss of
cognitive function and a wide spectrum of behavioral disorders.
Common motor symptoms associated with Huntington's disease include
chorea (involuntary writhing and spasming), clumsiness, and
progressive loss of the abilities to walk, speak (e.g., exhibiting
slurred speech) and swallow. Other symptoms of Huntington's disease
can include cognitive symptoms such as loss of intellectual speed,
attention and short-term memory and/or behavioral symptoms that can
span the range of changes in personality, depression, irritability,
emotional outbursts and apathy. Clinical symptoms typically appear
in the fourth or fifth decade of life. Huntington's disease is a
devastating and often protracted illness, with death usually
occurring approximately 10-20 years after the onset of symptoms.
Huntington's disease is inherited through a mutated or abnormal
gene encoding an abnormal protein called the mutant huntingtin
protein; the mutated huntingtin protein produces neuronal
degeneration in many different regions of the brain. The
degeneration focuses on neurons located in the basal ganglia,
structures deep within the brain that control many important
functions including coordinating movement, and on neurons on the
outer surface of the brain or cortex, which controls thought,
perception and memory.
[0121] "Amyotrophic lateral sclerosis" or "ALS" is used herein to
denote a progressive neurodegenerative disease that affects upper
motor neurons (motor neurons in the brain) and/or lower motor
neurons (motor neurons in the spinal cord) and results in motor
neuron death. As used herein, the term "ALS" includes all of the
classifications of ALS known in the art, including, but not limited
to classical ALS (typically affecting both lower and upper motor
neurons), Primary Lateral Sclerosis (PLS, typically affecting only
the upper motor neurons), Progressive Bulbar Palsy (PBP or Bulbar
Onset, a version of ALS that typically begins with difficulties
swallowing, chewing and speaking), Progressive Muscular Atrophy
(PMA, typically affecting only the lower motor neurons) and
familial ALS (a genetic version of ALS).
[0122] The term "Parkinson's disease" as used herein refers to any
medical condition wherein an individual experiences one or more
symptoms associated with Parkinson's disease, such as without
limitation one or more of the following symptoms: rest tremor,
cogwheel rigidity, bradykinesia, postural reflex impairment,
symptoms having good response to 1-dopa treatment, the absence of
prominent oculomotor palsy, cerebellar or pyramidal signs,
amyotrophy, dyspraxia and/or dysphasia. In a specific embodiment,
the present invention is utilized for the treatment of a
dopaminergic dysfunction-related disorder. In a specific
embodiment, the individual with Parkinson's disease has a mutation
or polymorphism in a synuclein, parkin or NURR1 nucleic acid that
is associated with Parkinson's disease. In one embodiment, the
individual with Parkinson's disease has defective or decreased
expression of a nucleic acid or a mutation in a nucleic acid that
regulates the development and/or survival of dopaminergic
neurons.
[0123] As used herein, the term "canine cognitive dysfunction
syndrome," or "CCDS" refers to an age-related deterioration of
mental function typified by multiple cognitive impairments that
affect an afflicted canine's ability to function normally. The
decline in cognitive ability that is associated with CCDS cannot be
completely attributed to a general medical condition such as
neoplasia, infection, sensory impairment, or organ failure.
Diagnosis of CCDS in canines, such as dogs, is generally a
diagnosis of exclusion, based on thorough behavior and medical
histories and the presence of clinical symptoms of CCDS that are
unrelated to other disease processes. Owner observation of
age-related changes in behavior is a practical means used to detect
the possible onset of CCDS in aging domestic dogs. A number of
laboratory cognitive tasks may be used to help diagnose CCDS, while
blood counts, chemistry panels and urinalysis can be used to rule
out other underlying diseases that could mimic the clinical
symptoms of CCDS. Symptoms of CCDS include memory loss, which in
domestic dogs may be manifested by disorientation and/or confusion,
decreased or altered interaction with family members and/or
greeting behavior, changes in sleep-wake cycle, decreased activity
level, and loss of house training or frequent, inappropriate
elimination. A canine suffering from CCDS may exhibit one or more
of the following clinical or behavioral symptoms: decreased
appetite, decreased awareness of surroundings, decreased ability to
recognize familiar places, people or other animals, decreased
hearing, decreased ability to climb up and down stairs, decreased
tolerance to being alone, development of compulsive behavior or
repetitive behaviors or habits, circling, tremors or shaking,
disorientation, decreased activity level, abnormal sleep wake
cycles, loss of house training, decreased or altered responsiveness
to family members, and decreased or altered greeting behavior. CCDS
can dramatically affect the health and well-being of an afflicted
canine. Moreover, the companionship offered by a pet with CCDS can
become less rewarding as the severity of the disease increases and
its symptoms become more severe.
[0124] As used herein, the term "age-associated memory impairment"
or "AAMI" refers to a condition that may be identified as GDS stage
2 on the global deterioration scale (GDS) (Reisberg, et al. (1982)
Am. J. Psychiatry 139: 1136-1139) which differentiates the aging
process and progressive degenerative dementia in seven major
stages. The first stage of the GDS is one in which individuals at
any age have neither subjective complaints of cognitive impairment
nor objective evidence of impairment. These GDS stage 1 individuals
are considered normal. The second stage of the GDS applies to those
generally elderly persons who complain of memory and cognitive
functioning difficulties such as not recalling names as well as
they could five or ten years previously or not recalling where they
have placed things as well as they could five or ten years
previously. These subjective complaints appear to be very common in
otherwise normal elderly individuals. AAMI refers to persons in GDS
stage 2, who may differ neurophysiologically from elderly persons
who are normal and free of subjective complaints, e.g., GDS stage
1. For example, AAMI subjects have been found to have more
electrophysiologic slowing on a computer analyzed EEG than GDS
stage 1 elderly persons (Prichep, John, Ferris, Reisberg, et al.
(1994) Neurobiol. Aging 15:85-90).
[0125] As used herein, the term "mild cognitive impairment" or
"MCI" refers to a type of cognitive disorder characterized by a
more pronounced deterioration in cognitive functions than is
typical for normal age-related decline. As a result, elderly or
aged patients with MCI have greater than normal difficulty
performing complex daily tasks and learning, but without the
inability to perform normal social, everyday, and/or professional
functions typical of patients with Alzheimer's disease, or other
similar neurodegenerative disorders eventually resulting in
dementia. MCI is characterized by subtle, clinically manifest
deficits in cognition, memory, and functioning, amongst other
impairments, which are not of sufficient magnitude to fulfill
criteria for diagnosis of Alzheimer's disease or other dementia.
MCI also encompasses injury-related MCI, defined herein as
cognitive impairment resulting from certain types of injury, such
as nerve injury (e.g., battlefield injuries, including
post-concussion syndrome, and the like), neurotoxic treatment
(i.e., adjuvant chemotherapy resulting in "chemo brain" and the
like), and tissue damage resulting from physical injury or other
neurodegeneration, which is separate and distinct from mild
cognitive impairment resulting from stroke, ischemia, hemorrhagic
insult, blunt force trauma, and the like.
[0126] As used herein, the term "traumatic brain injury" or "TBI"
refers to a brain injury caused by a sudden trauma, such as a blow
or jolt or a penetrating head injury, which disrupts the function
or damages the brain. Symptoms of TBI can range from mild, moderate
to severe and can significantly affect many cognitive (deficits of
language and communication, information processing, memory, and
perceptual skills), physical (ambulation, balance, coordination,
fine motor skills, strength, and endurance), and psychological
skills.
[0127] "Neuronal death mediated ocular disease" intends an ocular
disease in which death of the neuron is implicated in whole or in
part. The disease may involve death of photoreceptors. The disease
may involve retinal cell death. The disease may involve ocular
nerve death by apoptosis. Particular neuronal death mediated ocular
diseases include but are not limited to macular degeneration,
glaucoma, retinitis pigmentosa, congenital stationary night
blindness (Oguchi disease), childhood onset severe retinal
dystrophy, Leber congenital amaurosis, Bardet-Biedle syndrome,
Usher syndrome, blindness from an optic neuropathy, Leber's
hereditary optic neuropathy, color blindness and Hansen-Larson-Berg
syndrome.
[0128] As used herein, the term "macular degeneration" includes all
forms and classifications of macular degeneration known in the art,
including, but not limited to diseases that are characterized by a
progressive loss of central vision associated with abnormalities of
Bruch's membrane, the choroid, the neural retina and/or the retinal
pigment epithelium. The term thus encompasses disorders such as
age-related macular degeneration (ARMD) as well as rarer,
earlier-onset dystrophies that in some cases can be detected in the
first decade of life. Other maculopathies include North Carolina
macular dystrophy, Sorsby's fundus dystrophy, Stargardt's disease,
pattern dystrophy, Best disease, and Malattia Leventinese.
[0129] As used herein, the term "autism" refers to a brain
development disorder that impairs social interaction and
communication and causes restricted and repetitive behavior,
typically appearing during infancy or early childhood. The
cognitive and behavioral defects are thought to result in part from
altered neural connectivity. Autism encompasses related disorders
sometimes referred to as "autism spectrum disorder," as well as
Asperger syndrome and Rett syndrome.
[0130] As used herein, the term "nerve injury" or "nerve damage"
refers to physical damage to nerves, such as avulsion injury (e.g.,
where a nerve or nerves have been torn or ripped) or spinal cord
injury (e.g., damage to white matter or myelinated fiber tracts
that carry sensation and motor signals to and from the brain).
Spinal cord injury can occur from many causes, including physical
trauma (e.g., car accidents, sports injuries, and the like), tumors
impinging on the spinal column, developmental disorders, such as
spina bifida, and the like.
[0131] As used herein, the term "myasthenia gravis" or "MG" refers
to a non-cognitive neuromuscular disorder caused by immune-mediated
loss of acetylcholine receptors at neuromuscular junctions of
skeletal muscle. Clinically, MG typically appears first as
occasional muscle weakness in approximately two-thirds of patients,
most commonly in the extraocular muscles. These initial symptoms
eventually worsen, producing drooping eyelids (ptosis) and/or
double vision (diplopia), often causing the patient to seek medical
attention. Eventually, many patients develop general muscular
weakness that may fluctuate weekly, daily, or even more frequently.
Generalized MG often affects muscles that control facial
expression, chewing, talking, swallowing, and breathing; before
recent advances in treatment, respiratory failure was the most
common cause of death.
[0132] As used herein, the term "Guillain-Barre syndrome" refers to
a non-cognitive disorder in which the body's immune system attacks
part of the peripheral nervous system. The first symptoms of this
disorder include varying degrees of weakness or tingling sensations
in the legs. In many instances the weakness and abnormal sensations
spread to the arms and upper body. These symptoms can increase in
intensity until certain muscles cannot be used at all and, when
severe, the patient is almost totally paralyzed. In these cases the
disorder is life threatening--potentially interfering with
breathing and, at times, with blood pressure or heart rate--and is
considered a medical emergency. Most patients, however, recover
from even the most severe cases of Guillain-Barre syndrome,
although some continue to have a certain degree of weakness.
[0133] As used herein, the term "multiple sclerosis" or "MS" refers
to an autoimmune condition in which the immune system attacks the
central nervous system (CNS), leading to demyelination of neurons.
It may cause numerous symptoms, many of which are non-cognitive,
and often progresses to physical disability. MS affects the areas
of the brain and spinal cord known as the white matter. White
matter cells carry signals between the grey matter areas, where the
processing is done, and the rest of the body. More specifically, MS
destroys oligodendrocytes which are the cells responsible for
creating and maintaining a fatty layer, known as the myelin sheath,
which helps the neurons carry electrical signals. MS results in a
thinning or complete loss of myelin and, less frequently, the
cutting (transection) of the neuron's extensions or axons. When the
myelin is lost, the neurons can no longer effectively conduct their
electrical signals. Almost any neurological symptom can accompany
the disease. MS takes several forms, with new symptoms occurring
either in discrete attacks (relapsing forms) or slowly accumulating
over time (progressive forms). Most people are first diagnosed with
relapsing-remitting MS but develop secondary-progressive MS (SPMS)
after a number of years. Between attacks, symptoms may go away
completely, but permanent neurological problems often persist,
especially as the disease advances.
[0134] As used herein, the term "schizophrenia" refers to a
chronic, mental disorder characterized by one or more positive
symptoms (e.g., delusions and hallucinations) and/or negative
symptoms (e.g., blunted emotions and lack of interest) and/or
disorganized symptoms (e.g., disorganized thinking and speech or
disorganized perception and behavior). Schizophrenia as used herein
includes all forms and classifications of schizophrenia known in
the art, including, but not limited to catatonic type, hebephrenic
type, disorganized type, paranoid type, residual type or
undifferentiated type schizophrenia and deficit syndrome and/or
those described in American Psychiatric Association: Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, Washington
D.C., 2000 or in International Statistical Classification of
Diseases and Related Health Problems, or otherwise known to those
of skill in the art.
[0135] "Cognitive impairment associated with schizophrenia" or
"CIAS" includes neuropyschological deficits in attention, working
memory, verbal learning, and problem solving. These deficits are
believed to be linked to impairment in functional status (e.g.,
social behavior, work performance, and activities of daily
living).
[0136] As used herein "geroprotective activity" or "geroprotector"
means a biological activity that slows down ageing and/or prolongs
life and/or increases or improves the quality of life via a
decrease in the amount and/or the level of intensity of pathologies
or conditions that are not life-threatening but are associated with
the aging process and which are typical for elderly people.
Pathologies or conditions that are not life-threatening but are
associated with the aging process include such pathologies or
conditions as loss of sight (cataract), deterioration of the
dermatohairy integument (alopecia), and an age-associated decrease
in weight due to the death of muscular and/or fatty cells.
[0137] As used herein, attention-deficit hyperactivity disorder
(ADHD) is the most common child neuropsychiatric condition present
in school-aged children, affecting about 5-8% of this population.
ADHD refers to a chronic disorder that initially manifests in
childhood and is characterized by hyperactivity, impulsivity,
and/or inattention. ADHD is characterized by persistent patterns of
inattention and/or impulsivity-hyperactivity that are much more
extreme than is observed in individuals at the same developmental
level or stage. There is considerable evidence, from family and
twin studies, that ADHD has a significant genetic component. This
disorder is thought to be due to an interaction of environmental
and genetic factors. ADHD includes all known types of ADHD. For
example, Diagnostic & Statistical Manual for Mental Disorders
(DSM-IV) identifies three subtypes of ADHD: (1) ADHD, Combined Type
which is characterized by both inattention and
hyperactivity-impulsivity symptoms; (2) ADHD, Predominantly
Inattentive Type which is characterized by inattention but not
hyperactivity-impulsivity symptoms; and (3) ADHD, Predominantly
Hyperactive-Impulsive Type which is characterized by
Hyperactivity-impulsivity but not inattention symptoms.
[0138] As used herein, attention-deficit disorder (ADD) refers to a
disorder in processing neural stimuli that is characterized by
distractibility and impulsivity that can result in inability to
control behavior and can impair an individual's social, academic,
or occupational function and development. ADD may be diagnosed by
known methods, which may include observing behavior and diagnostic
interview techniques.
[0139] As used herein "allergic disease" refers to a disorder of
the immune system which is characterized by excessive activation of
mast cells and basophils and production of IgE immunoglobulins,
resulting in an extreme inflammatory response. It represents a form
of hypersensitivity to an environmental substance known as allergen
and is an acquired disease. Common allergic reactions include
eczema, hives, hay fever, asthma, food allergies, and reactions to
the venom of stinging insects such as wasps and bees. Allergic
reactions are accompanied by an excessive release of histamines,
and can thus be treated with antihistaminic agents.
[0140] As used herein, by "combination therapy" is meant a therapy
that includes two or more different compounds. Thus, in one aspect,
a combination therapy comprising a compound detailed herein and
another compound is provided. In some variations, the combination
therapy optionally includes one or more pharmaceutically acceptable
carriers or excipients, non-pharmaceutically active compounds,
and/or inert substances. In various embodiments, treatment with a
combination therapy may result in an additive or even synergistic
(e.g., greater than additive) result compared to administration of
a single compound of the invention alone. In some embodiments, a
lower amount of each compound is used as part of a combination
therapy compared to the amount generally used for individual
therapy. Preferably, the same or greater therapeutic benefit is
achieved using a combination therapy than by using any of the
individual compounds alone. In some embodiments, the same or
greater therapeutic benefit is achieved using a smaller amount
(e.g., a lower dose or a less frequent dosing schedule) of a
compound in a combination therapy than the amount generally used
for individual compound or therapy. Preferably, the use of a small
amount of compound results in a reduction in the number, severity,
frequency, and/or duration of one or more side-effects associated
with the compound.
[0141] As used herein, the term "effective amount" intends such
amount of a compound of the invention which in combination with its
parameters of efficacy and toxicity, as well as based on the
knowledge of the practicing specialist should be effective in a
given therapeutic form. As is understood in the art, an effective
amount may be in one or more doses, e.g., a single dose or multiple
doses may be required to achieve the desired treatment endpoint. An
effective amount may be considered in the context of administering
one or more therapeutic agents, and a single agent may be
considered to be given in an effective amount if, in conjunction
with one or more other agents, a desirable or beneficial result may
be or is achieved. Suitable doses of any of the co-administered
compounds may optionally be lowered due to the combined action
(e.g., additive or synergistic effects) of the compounds.
[0142] As used herein, "unit dosage form" refers to physically
discrete units, suitable as unit dosages, each unit containing a
predetermined quantity of active ingredient calculated to produce
the desired therapeutic effect in association with the required
pharmaceutical carrier. Unit dosage forms may contain a single or a
combination therapy.
[0143] As used herein, the term "controlled release" refers to a
drug-containing formulation or fraction thereof in which release of
the drug is not immediate, e.g., with a "controlled release"
formulation, administration does not result in immediate release of
the drug into an absorption pool. The term encompasses depot
formulations designed to gradually release the drug compound over
an extended period of time. Controlled release formulations can
include a wide variety of drug delivery systems, generally
involving mixing the drug compound with carriers, polymers or other
compounds having the desired release characteristics (e.g.,
pH-dependent or non-pH-dependent solubility, different degrees of
water solubility, and the like) and formulating the mixture
according to the desired route of delivery (e.g., coated capsules,
implantable reservoirs, injectable solutions containing
biodegradable capsules, and the like).
[0144] As used herein, by "pharmaceutically acceptable" or
"pharmacologically acceptable" is meant a material that is not
biologically or otherwise undesirable, e.g., the material may be
incorporated into a pharmaceutical composition administered to a
patient without causing any significant undesirable biological
effects or interacting in a deleterious manner with any of the
other components of the composition in which it is contained.
Pharmaceutically acceptable carriers or excipients have preferably
met the required standards of toxicological and manufacturing
testing and/or are included on the Inactive Ingredient Guide
prepared by the U.S. Food and Drug administration.
[0145] "Pharmaceutically acceptable salts" are those salts which
retain at least some of the biological activity of the free
(non-salt) compound and which can be administered as drugs or
pharmaceuticals to an individual. Such salts, for example, include:
(1) acid addition salts, formed with inorganic acids such as
hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,
phosphoric acid, and the like; or formed with organic acids such as
acetic acid, oxalic acid, propionic acid, succinic acid, maleic
acid, tartaric acid and the like; (2) salts formed when an acidic
proton present in the parent compound either is replaced by a metal
ion, e.g., an alkali metal ion, an alkaline earth ion, or an
aluminum ion; or coordinates with an organic base. Acceptable
organic bases include ethanolamine, diethanolamine, triethanolamine
and the like. Acceptable inorganic bases include aluminum
hydroxide, calcium hydroxide, potassium hydroxide, sodium
carbonate, sodium hydroxide, and the like. Further examples of
pharmaceutically acceptable salts include those listed in Berge et
al., Pharmaceutical Salts, J. Pharm. Sci. 1977 January; 66(1):1-19.
Pharmaceutically acceptable salts can be prepared in situ in the
manufacturing process, or by separately reacting a purified
compound of the invention in its free acid or base form with a
suitable organic or inorganic base or acid, respectively, and
isolating the salt thus formed during subsequent purification. It
should be understood that a reference to a pharmaceutically
acceptable salt includes the solvent addition forms or crystal
forms thereof, particularly solvates or polymorphs. Solvates
contain either stoichiometric or non-stoichiometric amounts of a
solvent, and are often formed during the process of
crystallization. Hydrates are formed when the solvent is water, or
alcoholates are formed when the solvent is alcohol. Polymorphs
include the different crystal packing arrangements of the same
elemental composition of a compound. Polymorphs usually have
different X-ray diffraction patterns, infrared spectra, melting
points, density, hardness, crystal shape, optical and electrical
properties, stability, and solubility. Various factors such as the
recrystallization solvent, rate of crystallization, and storage
temperature may cause a single crystal form to dominate.
[0146] The term "excipient" as used herein means an inert or
inactive substance that may be used in the production of a drug or
pharmaceutical, such as a tablet containing a compound of the
invention as an active ingredient. Various substances may be
embraced by the term excipient, including without limitation any
substance used as a binder, disintegrant, coating,
compression/encapsulation aid, cream or lotion, lubricant,
solutions for parenteral administration, materials for chewable
tablets, sweetener or flavoring, suspending/gelling agent, or wet
granulation agent. Binders include, e.g., carbomers, povidone,
xanthan gum, etc.; coatings include, e.g., cellulose acetate
phthalate, ethylcellulose, gellan gum, maltodextrin, enteric
coatings, etc.; compression/encapsulation aids include, e.g.,
calcium carbonate, dextrose, fructose dc (dc="directly
compressible"), honey dc, lactose (anhydrate or monohydrate;
optionally in combination with aspartame, cellulose, or
microcrystalline cellulose), starch dc, sucrose, etc.;
disintegrants include, e.g., croscarmellose sodium, gellan gum,
sodium starch glycolate, etc.; creams or lotions include, e.g.,
maltodextrin, carrageenans, etc.; lubricants include, e.g.,
magnesium stearate, stearic acid, sodium stearyl fumarate, etc.;
materials for chewable tablets include, e.g., dextrose, fructose
dc, lactose (monohydrate, optionally in combination with aspartame
or cellulose), etc.; suspending/gelling agents include, e.g.,
carrageenan, sodium starch glycolate, xanthan gum, etc.; sweeteners
include, e.g., aspartame, dextrose, fructose dc, sorbitol, sucrose
dc, etc.; and wet granulation agents include, e.g., calcium
carbonate, maltodextrin, microcrystalline cellulose, etc.
[0147] "Alkyl" refers to and includes saturated linear, branched,
or cyclic univalent hydrocarbon structures and combinations
thereof. Particular alkyl groups are those having 1 to 20 carbon
atoms (a "C.sub.1-C.sub.20 alkyl"). More particular alkyl groups
are those having 1 to 8 carbon atoms (a "C.sub.1-C.sub.8 alkyl").
When an alkyl residue having a specific number of carbons is named,
all geometric isomers having that number of carbons are intended to
be encompassed and described; thus, for example, "butyl" is meant
to include n-butyl, sec-butyl, iso-butyl, tert-butyl and
cyclobutyl; "propyl" includes n-propyl, iso-propyl and cyclopropyl.
This term is exemplified by groups such as methyl, t-butyl,
n-heptyl, octyl, cyclohexylmethyl, cyclopropyl and the like.
Cycloalkyl is a subset of alkyl and can consist of one ring, such
as cyclohexyl, or multiple rings, such as adamantyl. A cycloalkyl
comprising more than one ring may be fused, spiro or bridged, or
combinations thereof. A preferred cycloalkyl is a saturated cyclic
hydrocarbon having from 3 to 13 annular carbon atoms. A more
preferred cycloalkyl is a saturated cyclic hydrocarbon having from
3 to 7 annular carbon atoms (a "C.sub.3-C.sub.7 cycloalkyl"). A
saturated cyclic hydrocarbon having from 3 to 8 annular carbon
atoms is also embraced (a "C.sub.3-C.sub.8 cycloalkyl"). Examples
of cycloalkyl groups include adamantyl, decahydronaphthalenyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
[0148] "Alkylene" refers to the same residues as alkyl, but having
bivalency. Examples of alkylene include methylene (--CH.sub.2--),
ethylene (--CH.sub.2CH.sub.2--), propylene
(--CH.sub.2CH.sub.2CH.sub.2--), butylene
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--) and the like.
[0149] "Alkenyl" refers to an unsaturated hydrocarbon group having
at least one site of olefinic unsaturation (i.e., having at least
one moiety of the formula C.dbd.C) and preferably having from 2 to
10 carbon atoms and more preferably 2 to 8 carbon atoms. Examples
of alkenyl include but are not limited to
--CH.sub.2--CH.dbd.CH--CH.sub.3 and
--CH.sub.2--CH.sub.2-cyclohexenyl, where the ethyl group of the
latter example can be attached to the cyclohexenyl moiety at any
available position on the ring.
[0150] Cycloalkenyl is a subset of alkenyl and can consist of one
ring, such as cyclohexyl, or multiple rings, such as norbornenyl. A
more preferred cycloalkenyl is an unsaturated cyclic hydrocarbon
having from 3 to 8 annular carbon atoms (a "C.sub.3-C.sub.8
cycloalkenyl"). Examples of cycloalkenyl groups include
cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and the
like.
[0151] "Alkynyl" refers to an unsaturated hydrocarbon group having
at least one site of acetylenic unsaturation (i.e., having at least
one moiety of the formula C.ident.C) and preferably having from 2
to 10 carbon atoms and more preferably 3 to 8 carbon atoms. Alkynyl
groups having 2 to 8 carbon atoms, and the like, is embraced.
[0152] "Substituted alkyl" refers to an alkyl group having from 1
to 5 substituents including, but not limited to, substituents such
as alkoxy, substituted alkoxy, acyl, acyloxy, carbonylalkoxy,
acylamino, substituted or unsubstituted amino, aminoacyl,
aminocarbonylamino, aminocarbonyloxy, aryl, substituted aryl,
heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy,
cyano, halo, hydroxyl, nitro, carboxyl, thiol, thioalkyl,
substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted heterocyclyl, substituted or
unsubstituted aralkyl, aminosulfonyl, sulfonylamino, sulfonyl, oxo,
carbonylalkylenealkoxy and the like.
[0153] "Substituted alkenyl" refers to alkenyl group having from 1
to 5 substituents s including, but not limited to, substituents
such as alkoxy, substituted alkoxy, acyl, acyloxy, carbonylalkoxy,
acylamino, substituted or unsubstituted amino, aminoacyl,
aminocarbonylamino, aminocarbonyloxy, aryl, substituted aryl,
heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy,
cyano, halo, hydroxyl, nitro, carboxyl, thiol, thioalkyl,
substituted or unsubstituted alkyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted heterocyclyl, substituted or
unsubstituted aralkyl, aminosulfonyl, sulfonylamino, sulfonyl, oxo,
carbonylalkylenealkoxy and the like.
[0154] "Substituted alkynyl" refers to alkynyl groups having from 1
to 5 substituents including, but not limited to, groups such as
alkoxy, substituted alkoxy, acyl, acyloxy, carbonylalkoxy,
acylamino, substituted or unsubstituted amino, aminoacyl,
aminocarbonylamino, aminocarbonyloxy, aryl, substituted aryl,
heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy,
cyano, halo, hydroxyl, nitro, carboxyl, thiol, thioalkyl,
substituted or unsubstituted alkyl, substituted or unsubstituted
alkenyl, substituted or unsubstituted heterocyclyl, substituted or
unsubstituted aralkyl, aminosulfonyl, sulfonylamino, sulfonyl, oxo,
carbonylalkylenealkoxy and the like.
[0155] "Acyl" refers to the groups H--C(O)--, alkyl-C(O)--,
substituted alkyl-C(O)--, alkenyl-C(O)--, substituted
alkenyl-C(O)--, alkynyl-C(O)--, substituted alkynyl-C(O)--,
aryl-C(O)--, substituted aryl-C(O)--, heteroaryl-C(O)--,
substituted heteroaryl-C(O)--, heterocyclic-C(O)--, and substituted
heterocyclic-C(O)--, wherein alkyl, substituted alkyl, alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl,
substituted cycloalkyl, aryl, substituted aryl, heteroaryl,
substituted heteroaryl, heterocyclic and substituted heterocyclic
are as defined herein.
[0156] "Acyloxy" refers to the groups H--C(O)O--, alkyl-C(O)O--,
substituted alkyl-C(O)O--, alkenyl-C(O)O--, substituted
alkenyl-C(O)O--, alkynyl-C(O)O--, substituted alkynyl-C(O)O--,
aryl-C(O)O--, substituted aryl-C(O)O--, heteroaryl-C(O)O--,
substituted heteroaryl-C(O)O--, heterocyclic-C(O)O--, and
substituted heterocyclic-C(O)O--, wherein alkyl, substituted alkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
cycloalkyl, substituted cycloalkyl, aryl, substituted aryl,
heteroaryl, substituted heteroaryl, heterocyclic and substituted
heterocyclic are as defined herein.
[0157] In one variation, acyloxy is a cycloalkyl-C(O)O--,
substituted cycloalkyl-C(O)O-moiety.
[0158] "Heterocycle", "heterocyclic", or "heterocyclyl" refers to a
saturated or an unsaturated non-aromatic group having a single ring
or multiple condensed rings, and having from 1 to 10 annular carbon
atoms and from 1 to 4 annular heteroatoms, such as nitrogen, sulfur
or oxygen. A heterocycle comprising more than one ring may be
fused, spiro or bridged, or any combination thereof. In fused ring
systems, one or more of the rings can be aryl or heteroaryl. A
heterocycle having more than one ring where at least one ring is
aromatic may be connected to the parent structure at either a
non-aromatic ring position or at an aromatic ring position. In one
variation, a heterocycle having more than one ring where at least
one ring is aromatic is connected to the parent structure at a
non-aromatic ring position.
[0159] "Substituted heterocyclic" or "substituted heterocyclyl"
refers to a heterocycle group which is substituted with from 1 to 3
substituents including, but not limited to, substituents such as
alkoxy, substituted alkoxy, acyl, acyloxy, carbonylalkoxy,
acylamino, substituted or unsubstituted amino, aminoacyl,
aminocarbonylamino, aminocarbonyloxy, aryl, substituted aryl,
heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy,
cyano, halo, hydroxyl, nitro, carboxyl, thiol, thioalkyl,
substituted or unsubstituted alkyl, substituted or unsubstituted
alkenyl, substituted or unsubstituted alkynyl, substituted or
unsubstituted aralkyl, aminosulfonyl, sulfonylamino, sulfonyl, oxo,
carbonylalkylenealkoxy and the like. In one variation, a
substituted heterocycle is a heterocycle substituted with an
additional ring, wherein the additional ring may be aromatic or
non-aromatic.
[0160] "Aryl" or "Ar" refers to an unsaturated aromatic carbocyclic
group having a single ring (e.g., phenyl) or multiple condensed
rings (e.g., naphthyl or anthryl) which condensed rings may or may
not be aromatic. In one variation, the aryl group contains from 6
to 14 annular carbon atoms. An aryl group having more than one ring
where at least one ring is non-aromatic may be connected to the
parent structure at either an aromatic ring position or at a
non-aromatic ring position. In one variation, an aryl group having
more than one ring where at least one ring is non-aromatic is
connected to the parent structure at an aromatic ring position.
[0161] "Heteroaryl" or "HetAr" refers to an unsaturated aromatic
carbocyclic group having from 2 to 10 annular carbon atoms and at
least one annular heteroatom, including but not limited to
heteroatoms such as nitrogen, oxygen and sulfur. A heteroaryl group
may have a single ring (e.g., pyridyl, furyl) or multiple condensed
rings (e.g., indolizinyl, benzothienyl) which condensed rings may
or may not be aromatic. A heteroaryl group having more than one
ring where at least one ring is non-aromatic may be connected to
the parent structure at either an aromatic ring position or at a
non-aromatic ring position. In one variation, a heteroaryl group
having more than one ring where at least one ring is non-aromatic
is connected to the parent structure at an aromatic ring
position.
[0162] "Substituted aryl" refers to an aryl group having 1 to 5
substituents including, but not limited to, groups such as alkoxy,
substituted alkoxy, acyl, acyloxy, carbonylalkoxy, acylamino,
substituted or unsubstituted amino, aminoacyl, aminocarbonylamino,
aminocarbonyloxy, heteroaryl, substituted heteroaryl, aryloxy,
substituted aryloxy, cyano, halo, hydroxyl, nitro, carboxyl, thiol,
thioalkyl, substituted or unsubstituted alkyl, substituted or
unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted heterocyclyl, substituted or
unsubstituted aralkyl, aminosulfonyl, sulfonylamino, sulfonyl, oxo,
carbonylalkylenealkoxy and the like.
[0163] In one variation, a substituted aryl comprises an aryl group
substituted by an aryl and/or substituted aryl substituent.
[0164] "Substituted heteroaryl" refers to a heteroaryl group having
1 to 5 substituents including, but not limited to, groups such as
alkoxy, substituted alkoxy, acyl, acyloxy, carbonylalkoxy,
acylamino, substituted or unsubstituted amino, aminoacyl,
aminocarbonylamino, aminocarbonyloxy, aryl, substituted aryl,
heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy,
cyano, halo, hydroxyl, nitro, carboxyl, thiol, thioalkyl,
substituted or unsubstituted alkyl, substituted or unsubstituted
alkenyl, substituted or unsubstituted alkynyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted aralkyl,
aminosulfonyl, sulfonylamino, sulfonyl, oxo, carbonylalkylenealkoxy
and the like.
[0165] In one variation, a substituted heteroaryl comprises a
heteroaryl group substituted by a heteroaryl and/or substituted
heteroaryl substituent.
[0166] "Aralkyl" refers to a residue in which an aryl moiety is
attached to an alkyl residue and wherein the aralkyl group may be
attached to the parent structure at either the aryl or the alkyl
residue. Preferably, an aralkyl is connected to the parent
structure via the alkyl moiety. A "substituted aralkyl" refers to a
residue in which an aryl moiety is attached to a substituted alkyl
residue and wherein the aralkyl group may be attached to the parent
structure at either the aryl or the alkyl residue.
[0167] In one variation, an aralkyl is a fused ring system where at
least one cycloalkyl moiety is fused with at least one aryl
moiety.
[0168] When an aralkyl is connected to the parent structure via the
alkyl moiety, it may also be referred to as an "alkaryl". More
particular alkaryl groups are those having 1 to 3 carbon atoms in
the alkyl moiety (a "C.sub.1-C.sub.3 alkaryl").
[0169] "Alkoxy" refers to the group alkyl-O--, which includes, by
way of example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy,
tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy,
and the like. Similarly, alkenyloxy refers to the group
"alkenyl-O--" and alkynyloxy refers to the group "alkynyl-O--".
"Substituted alkoxy" refers to the group substituted alkyl-O.
[0170] "Unsubstituted amino" refers to the group --NH.sub.2.
[0171] "Substituted amino" refers to the group --NR.sub.aR.sub.b,
where either (a) each R.sub.a and R.sub.b group is independently
selected from the group consisting of H, alkyl, substituted alkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl,
substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic,
substituted heterocyclic, provided that both R.sub.a and R.sub.b
groups are not H; or (b) R.sub.a and R.sub.b are joined together
with the nitrogen atom to form a heterocyclic or substituted
heterocyclic ring.
[0172] "Acylamino" refers to the group --C(O)NR.sub.aR.sub.b where
R.sub.a and R.sub.b are independently selected from the group
consisting of H, alkyl, substituted alkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
heteroaryl, substituted heteroaryl, heterocyclic, substituted
heterocyclic or R.sub.a and R.sub.b groups can be joined together
with the nitrogen atom to form a heterocyclic or substituted
heterocyclic ring.
[0173] "Aminocarbonylalkoxy" refers to the group
--NR.sub.aC(O)OR.sub.b where each R.sub.a and R.sub.b group is
independently selected from the group consisting of H, alkyl,
substituted alkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, heteroaryl,
substituted heteroaryl, heterocyclic and substituted
heterocyclyl.
[0174] "Aminoacyl" refers to the group --NR.sub.aC(O)R.sub.b where
each R.sub.a and R.sub.b group is independently selected from the
group consisting of H, alkyl, substituted alkyl, alkenyl,
substituted alkenyl, alkynyl, substituted alkynyl, aryl,
substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic
or substituted heterocyclic. Preferably, R.sub.a is H or alkyl.
[0175] "Aminosulfonyl" refers to the groups --NRSO.sub.2-alkyl,
--NRSO.sub.2 substituted alkyl, --NRSO.sub.2-alkenyl,
--NRSO.sub.2-substituted alkenyl, --NRSO.sub.2-alkynyl,
--NRSO.sub.2-substituted alkynyl, --NRSO.sub.2-aryl,
--NRSO.sub.2-substituted aryl, --NRSO.sub.2-heteroaryl,
--NRSO.sub.2-substituted heteroaryl, --NRSO.sub.2-heterocyclic, and
--NRSO.sub.2-substituted heterocyclic, where R is H or alkyl and
wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl,
alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl,
aryl, substituted aryl, heteroaryl, substituted heteroaryl,
heterocyclic and substituted heterocyclic are as defined
herein.
[0176] In one variation, an aminosulonyl is --NRSO.sub.2-cycloalkyl
or --NRSO.sub.2-substituted cycloalkyl.
[0177] "Sulfonylamino" refers to the groups --SO.sub.2NH.sub.2,
--SO.sub.2NR-alkyl, --SO.sub.2NR-substituted alkyl,
--SO.sub.2NR-alkenyl, --SO.sub.2NR-substituted alkenyl,
--SO.sub.2NR-alkynyl, --SO.sub.2NR-substituted alkynyl,
--SO.sub.2NR-aryl, --SO.sub.2NR-substituted aryl,
--SO.sub.2NR-heteroaryl, --SO.sub.2NR-substituted heteroaryl,
--SO.sub.2NR-heterocyclic, and --SO.sub.2NR-substituted
heterocyclic, where R is H or alkyl, or --SO.sub.2NR.sub.2, where
the two R groups are taken together and with the nitrogen atom to
which they are attached to form a heterocyclic or substituted
heterocyclic ring.
[0178] "Sulfonyl" refers to the groups --SO.sub.2-alkyl,
--SO.sub.2-substituted alkyl, --SO.sub.2-alkenyl,
--SO.sub.2-substituted alkenyl, --SO.sub.2-alkynyl,
--SO.sub.2-substituted alkynyl, --SO.sub.2-aryl,
--SO.sub.2-substituted aryl, --SO.sub.2-heteroaryl,
--SO.sub.2-substituted heteroaryl, --SO.sub.2-heterocyclic, and
--SO.sub.2-substituted heterocyclic.
[0179] "Carbonylalkylenealkoxy" refers to the group
--C(.dbd.O)--(CH.sub.2).sub.n--OR where R is a substituted or
unsubstituted alkyl and n is an integer from 1 to 100, more
preferably n is an integer from 1 to 10 or 1 to 5.
[0180] "Halo" or "halogen" refers to elements of the Group 17
series having atomic number 9 to 85. Preferred halo groups include
the radicals of fluorine, chlorine, bromine and iodine. Where a
residue is substituted with more than one halogen, it may be
referred to by using a prefix corresponding to the number of
halogen moieties attached, e.g., dihaloaryl, dihaloalkyl,
trihaloaryl etc. refer to aryl and alkyl substituted with two
("di") or three ("tri") halo groups, which may be but are not
necessarily the same halogen; thus 4-chloro-3-fluorophenyl is
within the scope of dihaloaryl. An alkyl group in which each H is
replaced with a halo group is referred to as a "perhaloalkyl." A
preferred perhaloalkyl group is trifluoroalkyl (--CF.sub.3).
Similarly, "perhaloalkoxy" refers to an alkoxy group in which a
halogen takes the place of each H in the hydrocarbon making up the
alkyl moiety of the alkoxy group. An example of a perhaloalkoxy
group is trifluoromethoxy (--OCF.sub.3).
[0181] "Carbonyl" refers to the group C.dbd.O.
[0182] "Cyano" refers to the group --CN.
[0183] "Oxo" refers to the moiety .dbd.O.
[0184] "Nitro" refers to the group --NO.sub.2.
[0185] "Thioalkyl" refers to the groups --S-alkyl.
[0186] "Alkylsulfonylamino" refers to the groups
--R.sup.1SO.sub.2NR.sub.aR.sub.b where R.sub.a and R.sub.b are
independently selected from the group consisting of H, alkyl,
substituted alkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, heteroaryl,
substituted heteroaryl, heterocyclic, substituted heterocyclic, or
the R.sub.a and R.sub.b groups can be joined together with the
nitrogen atom to form a heterocyclic or substituted heterocyclic
ring and R.sup.1 is an alkyl group.
[0187] "Carbonylalkoxy" refers to as used herein refers to the
groups --C(O)O-alkyl, --C(O)O-substituted alkyl, --C(O)O-aryl,
--C(O)O-substituted aryl, --C(O)O-alkenyl, --C(O)O-substituted
alkenyl, --C(O)O-alkynyl, --C(O)O-substituted alkynyl,
--C(O)O-heteroaryl, --C(O)O-substituted heteroaryl,
--C(O)O-heterocyclic or --C(O)O-substituted heterocyclic.
[0188] "Geminal" refers to the relationship between two moieties
that are attached to the same atom. For example, in the residue
--CH.sub.2--CHR.sup.1R.sup.2, R.sup.1 and R.sup.2 are geminal and
R.sup.1 may be referred to as a geminal R group to R.sup.2.
[0189] "Vicinal" refers to the relationship between two moieties
that are attached to adjacent atoms. For example, in the residue
--CHR.sup.1--CH.sub.2R.sup.2, R.sup.1 and R.sup.2 are vicinal and
R.sup.1 may be referred to as a vicinal R group to R.sup.2.
[0190] A composition of "substantially pure" compound means that
the composition contains no more than 15% or preferably no more
than 10% or more preferably no more than 5% or even more preferably
no more than 3% and most preferably no more than 1% impurity, which
impurity may be the compound in a different stereochemical form.
For instance, a composition of substantially pure S compound means
that the composition contains no more than 15% or no more than 10%
or no more than 5% or no more than 3% or no more than 1% of the R
form of the compound.
Compounds of the Invention
[0191] Compounds according to the invention are detailed herein,
including in the Brief Summary of the Invention and the appended
claims. The invention includes the use of all of the compounds
described herein, including any and all stereoisomers, salts and
solvates of the compounds described herein, as well as methods of
making such compounds.
[0192] Compounds of the formula (A) are provided:
##STR00016##
wherein:
[0193] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy, provided that R.sup.3 is other than methyl or
chloro when R.sup.1, R.sup.2 and R.sup.4 are each H and X is OH and
Y is methyl;
[0194] R.sup.5 is unsubstituted C.sub.1-C.sub.8 alkyl or a
C.sub.1-C.sub.8 alkyl substituted with a perhaloalkyl moiety;
[0195] R.sup.6 is H or an unsubstituted C.sub.1-C.sub.8 alkyl;
[0196] X is OH, C.sub.1-C.sub.8 alkyl or is taken together with Y
to form a cyclopropyl moiety; and
[0197] Y is H, C.sub.1-C.sub.8 alkyl or is taken together with X to
form a cyclopropyl moiety,
[0198] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0199] In a particular variation of formula (A), R.sup.6 is H. In
one variation of formula (A), R.sup.1 is H, halo or C.sub.1-C.sub.8
unsubstituted alkoxy; R.sup.2 is H; R.sup.3 is H, halo,
C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy, provided that R.sup.3 is other than methyl or
chloro when R.sup.1, R.sup.2 and R.sup.4 are each H and X is OH and
Y is methyl; R.sup.4 is H or halo; R.sup.5 is methyl; R.sup.6 is H
or methyl; X is OH, C.sub.1-C.sub.8 alkyl or is taken together with
Y to form a cyclopropyl moiety and Y is H, C.sub.1-C.sub.8 alkyl or
is taken together with X to form a cyclopropyl moiety. In another
variation of formula (A), at least two of R.sup.1, R.sup.2, R.sup.3
and R.sup.4 are halo (e.g., when R.sup.2 and R.sup.3 are chloro).
In another variation of formula (A), X is OH and Y is H, methyl,
ethyl or isopropyl. In a further variation of formula (A), R.sup.1,
R.sup.2 and R.sup.4 are H. In another variation of formula (A),
three of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are H and one is
methyl, methoxy, isopropyl, chloro or fluoro.
[0200] Also provided are compounds of the formula (B):
##STR00017##
wherein:
[0201] R.sup.7 is H, hydroxyl, nitro, cyano, halo, C.sub.1-C.sub.8
perhaloalkyl, substituted or unsubstituted C.sub.1-C.sub.8 alkyl,
substituted or unsubstituted C.sub.2-C.sub.8 alkenyl, substituted
or unsubstituted C.sub.2-C.sub.8 alkynyl, substituted or
unsubstituted aryl, substituted or unsubstituted heteroaryl,
C.sub.1-C.sub.8 perhaloalkoxy, C.sub.1-C.sub.8 alkoxy, aryloxy,
carboxyl, carbonylalkoxy, thiol, substituted or unsubstituted
heterocyclyl, substituted or unsubstituted aralkyl, thioalkyl,
substituted or unsubstituted amino, acylamino, aminoacyl,
aminocarbonylamino, aminocarbonyloxy, aminosulfonyl, sulfonylamino,
sulfonyl, carbonylalkylenealkoxy, alkylsulfonylamino or acyl;
and
[0202] Z is H, halo or C.sub.1-C.sub.8 alkyl,
[0203] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0204] In one variation of formula (B), R.sup.7 is unsubstituted
C.sub.1-C.sub.8 alkyl or halo. In another variation of formula (B),
Z is H or halo. In a further variation of formula (B), R.sup.7 is
an unsubstituted C.sub.1-C.sub.8 alkyl or halo and Z is H or halo.
In a particular variation, R.sup.7 is methyl or chloro and Z is H,
chloro or fluoro.
[0205] Compounds of the formula (C1) are provided:
##STR00018##
wherein:
[0206] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0207] R.sup.8 is a substituted or unsubstituted aryl or a
substituted or unsubstituted heteroaryl; and
[0208] X is a C.sub.4-C.sub.6 unsubstituted alkyl,
[0209] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0210] In one variation of formula (C1), R.sup.1, R.sup.2, R.sup.3
and R.sup.4 are as defined for formula (A).
[0211] Compounds of the formula (C2) are also provided:
##STR00019##
wherein:
[0212] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0213] R.sup.5 is C.sub.1-C.sub.6 unsubstituted alkyl or
CF.sub.3;
[0214] R.sup.8 is a substituted or unsubstituted aryl or a
substituted or unsubstituted heteroaryl; and
[0215] X is a C.sub.4-C.sub.6 unsubstituted n-alkyl or cycloalkyl
or a C.sub.3-C.sub.6 unsubstituted branched alkyl,
[0216] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0217] In one variation of formula (C1) or (C2), R.sup.1, R.sup.2
and R.sup.4 are each H and R.sup.3 is an unsubstituted
C.sub.1-C.sub.8 alkyl (e.g., methyl) or halo (e.g., chloro). In
another variation of formula (C1) or (C2), X is cyclohexyl,
cyclobutyl, n-butyl or iso-propyl. In a particular variation of
formula (C1) or (C2), R.sup.1, R.sup.2 and R.sup.4 are each H;
R.sup.3 is an unsubstituted C.sub.1-C.sub.8 alkyl or halo and X is
cyclohexyl, cyclobutyl, n-butyl or iso-propyl. In a further
variation of formula (C1) or (C2), R.sup.8 is a substituted aryl or
an unsubstituted heteroaryl. In one aspect, R.sup.8 of formula (C1)
or (C2) is a substituted phenyl or an unsubstituted pyridyl. In a
particular aspect, R.sup.8 of formula (C1) or (C2) is 4-halo-phenyl
or 4-pyridyl. In another variation of formula (C1) or (C2),
R.sup.1, R.sup.2 and R.sup.4 are each H; R.sup.3 is an
unsubstituted C.sub.1-C.sub.8 alkyl or halo; X is cyclohexyl,
cyclobutyl, n-butyl and R.sup.8 is a substituted phenyl. In another
variation of formula (C1) or (C2), R.sup.1, R.sup.2 and R.sup.4 are
each H; R.sup.3 is an unsubstituted C.sub.1-C.sub.8 alkyl or halo;
X is isopropyl and R.sup.8 is an unsubstituted pyridyl.
[0218] In another variation of formula (C2), R.sup.1, R.sup.2,
R.sup.3 and R.sup.4 are as defined for formula (A), R.sup.5 is
CH.sub.3 or CF.sub.3; R.sup.8 is a substituted or unsubstituted
aryl or a substituted or unsubstituted heteroaryl; and X is a
C.sub.1-C.sub.6 unsubstituted alkyl.
[0219] Compounds of the formula (D1) are also provided:
##STR00020##
wherein:
[0220] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy; and
[0221] V is a halo,
[0222] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0223] In one variation of (D1), R.sup.1, R.sup.2, R.sup.3 and
R.sup.4 are as defined for formula (A).
[0224] Compounds of the formula (D2) are also provided:
##STR00021##
wherein:
[0225] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0226] X is H or a C.sub.1-C.sub.3 unsubstituted alkyl; and
[0227] V is a halo,
[0228] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0229] In one variation of formula (D1) or (D2), R.sup.1, R.sup.2
and R.sup.4 are H and R.sup.3 is an unsubstituted C.sub.1-C.sub.8
alkyl such as methyl. In another variation of formula (D1) or (D2),
V is fluoro.
[0230] In another variation of formula (D2), R.sup.1, R.sup.2,
R.sup.3 and R.sup.4 are independently H, halo, C.sub.1-C.sub.8
unsubstituted alkyl or C.sub.1-C.sub.8 unsubstituted alkoxy or are
as defined for formula (A); X is a C.sub.1-C.sub.3 unsubstituted
alkyl; and V is a halo.
[0231] Compounds of the formula (E1) are also detailed herein:
##STR00022##
wherein:
[0232] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy; and
[0233] R.sup.8 is 6-pyrimidyl, 3-methyl-4-pyridyl or a phenyl
substituted either: (i) with at least one alkoxy or hydroxyl group
or (ii) with at least two halo groups;
[0234] R.sup.9 is an unsubstituted C.sub.1-C.sub.3alkyl;
[0235] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0236] In one variation of (E1), R.sup.1, R.sup.2, R.sup.3 and
R.sup.4 are as defined for formula (A).
[0237] Compounds of the formula (E2) are also detailed herein:
##STR00023##
wherein:
[0238] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0239] R.sup.8 is 6-pyrimidyl, 2-pyrazinyl, 3-methyl-4-pyridyl or a
phenyl substituted either: (i) with at least one alkoxy or hydroxyl
group or (ii) with at least two halo groups; and
[0240] R.sup.9 is an unsubstituted C.sub.1-C.sub.3 alkyl;
[0241] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0242] In one variation of formula (E1) or (E2), R.sup.1, R.sup.2
and R.sup.4 are each H. In another variation of formula (E1) or
(E2), R.sup.9 is methyl. In a further variation of formula (E1) or
(E2), R.sup.1, R.sup.2 and R.sup.4 are each H and R.sup.9 is
methyl. In another variation of formula (E1) or (E2), R.sup.8 is a
phenyl substituted with at least one unsubstituted C.sub.1-C.sub.8
alkoxy group such as methoxy. In one aspect of formula (E1) or
(E2), R.sup.1, R.sup.2 and R.sup.4 are each H and R.sup.8 is a
methoxy-substituted phenyl. In another aspect of formula (E1) or
(E2), R.sup.9 is methyl and R.sup.8 is a methoxy or
hydroxyl-substituted phenyl. In another variation, R.sup.8 is a
phenyl substituted with at least two halo groups and R.sup.1,
R.sup.2 and R.sup.4 are each H.
[0243] In another variation of formula (E2), R.sup.1, R.sup.2 and
R.sup.4 are as defined for formula (A); R.sup.8 is 6-pyrimidyl,
2-pyrazinyl, 3-methyl-4-pyridyl or a phenyl substituted either: (i)
with at least one alkoxy or hydroxyl group or (ii) with at least
two halo groups; and R.sup.9 is methyl.
[0244] Also provided are compounds of the formula (F1):
##STR00024##
wherein:
[0245] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0246] R.sup.5 is
##STR00025##
where T is 3 or 4;
[0247] X is H or OH;
[0248] Y is H or C.sub.1-C.sub.8 alkyl; and
[0249] R.sup.8 is a substituted or unsubstituted heteroaryl,
[0250] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0251] In one variation of (F1), R.sup.1, R.sup.2, R.sup.3 and
R.sup.4 are as defined for formula (A).
[0252] Also provided are compounds of the formula (F2):
##STR00026##
wherein:
[0253] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0254] R.sup.5 is
##STR00027##
where T is 3 or 4
[0255] X is H or OH;
[0256] Y is H or C.sub.1-C.sub.8 alkyl; and
[0257] R.sup.8 is a substituted or unsubstituted heteroaryl,
[0258] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0259] In one variation of formula (F1) or (F2), R.sup.1, R.sup.2
and R.sup.4 are H. In another variation of formula (F1) or (F2),
R.sup.3 is unsubstituted C.sub.1-C.sub.8 alkyl. In another
variation of formula (F1) or (F2), R.sup.1, R.sup.2 and R.sup.4 are
H and R.sup.3 is unsubstituted C.sub.1-C.sub.8 alkyl. In another
variation of formula (F1) or (F2), R.sup.8 is a substituted or
unsubstituted pyridyl. When R.sup.8 is an unsubstituted pyridyl, it
may be bound to the parent structure at any available position,
e.g., 4-pyridyl. When R.sup.8 is a substituted pyridyl, in one
aspect the pyridyl is substituted with an unsubstituted
C.sub.1-C.sub.8 alkyl such as methyl. When R.sup.8 is a substituted
pyridyl, it may be bound to the parent structure at any available
ring position, e.g., 6-methyl-3-pyridyl. In a particular variation
of formula (F1) or (F2), R.sup.1, R.sup.2 and R.sup.4 are H;
R.sup.3 is unsubstituted C.sub.1-C.sub.8 alkyl and R.sup.8 is a
substituted or unsubstituted pyridyl. In a further variation of
formula (F1) or (F2), X and Y are both H. For example, in one
aspect a compound is of the formula (F1) or (F2) where R.sup.1,
R.sup.2 and R.sup.4 are H; R.sup.3 is unsubstituted C.sub.1-C.sub.8
alkyl and R.sup.8 is a substituted or unsubstituted pyridyl and X
and Y are both H.
[0260] Compounds of the formula (G) are also detailed herein:
##STR00028##
wherein:
[0261] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently H,
halo, C.sub.1-C.sub.8 unsubstituted alkyl or C.sub.1-C.sub.8
unsubstituted alkoxy;
[0262] R.sup.3 is methyl or chloro, provided that R.sup.3 is methyl
when R.sup.8 is a substituted heteroaryl;
[0263] X is H or OH;
[0264] Y is H or C.sub.1-C.sub.8 alkyl; and
[0265] R.sup.8 is a substituted or unsubstituted heteroaryl,
[0266] or a salt thereof, such as a pharmaceutically acceptable
salt thereof, or solvate of the foregoing.
[0267] In one variation of formula (G), R.sup.1, R.sup.2, R.sup.3
and R.sup.4 are as defined for formula (A).
[0268] In one aspect of formula (G), R.sup.1, R.sup.2 and R.sup.4
are each H. In another aspect of formula (G), X is H and Y is an
unsubstituted C.sub.1-C.sub.8 alkyl. In another aspect of formula
(G), X and Y are both H. In a particular variation of formula (G),
R.sup.1, R.sup.2 and R.sup.4 are each H and either (i) X and Y are
both H or (ii) X is H and Y is an unsubstituted C.sub.1-C.sub.8
alkyl such as methyl. In a particular variation, R.sup.8 is a
substituted or unsubstituted pyridyl. In a specific variation of
formula (G), R.sup.8 is a substituted or unsubstituted pyridyl and
either (i) X and Y are both H or (ii) X is H and Y is an
unsubstituted C.sub.1-C.sub.8 alkyl.
[0269] Additional compounds are detailed herein.
[0270] Examples of compounds according to the invention are
depicted in Table 1. The compounds depicted may be present as salts
even if salts are not depicted and it is understood that the
invention embraces all salts and solvates of the compounds depicted
here, as well as the non-salt and non-solvate form of the compound,
as is well understood by the skilled artisan.
TABLE-US-00001 TABLE 1 Representative Compounds According to the
Invention. Compound # Compound Structure 1-1 ##STR00029## 1-2
##STR00030## 1-3 ##STR00031## 1-4 ##STR00032## 1-5 ##STR00033## 1-6
##STR00034## 1-7 ##STR00035## 1-8 ##STR00036## 1-9 ##STR00037##
1-10 ##STR00038## 1-11 ##STR00039## 1-12 ##STR00040## 1-13
##STR00041## 1-14 ##STR00042## 1-15 ##STR00043## 1-16 ##STR00044##
1-17 ##STR00045## 1-18 ##STR00046## 1-19 ##STR00047## 1-20
##STR00048## 1-21 ##STR00049## 1-22 ##STR00050## 1-23 ##STR00051##
1-24 ##STR00052## 1-25 ##STR00053## 1-26 ##STR00054## 1-27
##STR00055## 1-28 ##STR00056## 1-29 ##STR00057## 1-30 ##STR00058##
1-31 ##STR00059## 1-32 ##STR00060## 1-33 ##STR00061## 1-34
##STR00062## 1-35 ##STR00063## 1-36 ##STR00064## 1-37 ##STR00065##
1-38 ##STR00066## 1-39 ##STR00067## 1-40 ##STR00068## 1-41
##STR00069## 1-42 ##STR00070## 1-43 ##STR00071## 1-44 ##STR00072##
1-45 ##STR00073## 1-46 ##STR00074## 1-47 ##STR00075## 1-48
##STR00076## 1-49 ##STR00077## 1-50 ##STR00078## 1-51 ##STR00079##
1-52 ##STR00080## 1-53 ##STR00081## 1-54 ##STR00082## 1-55
##STR00083## 1-56 ##STR00084## 1-57 ##STR00085## 1-58 ##STR00086##
1-59 ##STR00087## 1-60 ##STR00088## 1-61 ##STR00089## 1-62
##STR00090## 1-63 ##STR00091## 1-64 ##STR00092## 1-65 ##STR00093##
1-66 ##STR00094## 1-67 ##STR00095##
TABLE-US-00002 TABLE 1 Compound Names. Compound # Compound Name 1-1
1-Cyclohexyl-2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-y-
l)-1- (4-fluorophenyl)ethanol 1-2
2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-
fluorophenyl)ethanol 1-3
1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(3-fluor-
o-4- methoxyphenyl)propan-2-ol 1-4
1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-
methoxyphenyl)propan-2-ol 1-5
1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-
fluorophenyl)butan-2-ol 1-6
2-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-
cyclobutyl-1-(4-fluorophenyl)ethanol 1-7
1-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-
fluorophenyl)hexan-2-ol 1-8
2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(pyridin-
e-4- yl)ethanol 1-9
1-(8-Fluoro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(py-
ridine- 4-yl)propan-2-ol 1-10
1-(6-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(p-
yridine- 4-yl)propan-2-ol 1-11
2-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(p-
yridine- 4-yl)ethanol 1-12
1-(7-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(p-
yridine- 4-yl)propan-2-ol 1-13
1-(6-Fluoro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(p-
yridine- 4-yl)propan-2-ol 1-14
1-(2-Methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridine-4-
- yl)propan-2-ol 1-15
4-(1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-
hydroxypropan-2-yl)phenol 1-16
1-(8-Methoxy-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-
(pyridine-4-yl)propan-2-ol 1-17
1-(7,8-Dichloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)--
2- (pyridine-4-yl)propan-2-ol 1-18
1-(8,9-Dichloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)--
2- (pyridine-4-yl)propan-2-ol 1-19
(R)-1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-
methoxyphenyl)propan-2-ol 1-20
(S)-1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-
methoxyphenyl)propan-2-ol 1-21
1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-me-
thyl-2- (pyridine-4-yl)butan-2-ol 1-22
1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-methyl--
2- (pyridine-4-yl)butan-2-ol 1-23
1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(p-
yridine- 4-yl)butan-2-ol 1-24
1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridi-
ne-4- yl)butan-2-ol 1-25
1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrimi-
din-4- yl)propan-2-ol 1-26
1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-
(pyrimidin-4-yl)propan-2-ol 1-27
1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(p-
yrazin- 2-yl)propan-2-ol 1-28
1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrazi-
n-2- yl)propan-2-ol 1-29
1-(8-Methyl-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-pyrido[4,3-b]indo-
l-5(2H)- yl)-2-(pyridine-4-yl)propan-2-ol 1-30
1-(2-Cyclopropyl-8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-
-2- (pyridine-4-yl)propan-2-ol 1-31
1-(6-Methoxy-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-
(pyridine-4-yl)propan-2-ol 1-32
1-(7-Isopropyl-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-
- (pyridine-4-yl)propan-2-ol 1-33
2-(Pyridin-4-yl)-1-(2,3,8-trimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-
-5(2H)- yl)propan-2-ol 1-34
3-(8-Methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-3,4-dihydro-1H-pyrido[4-
,3- b]indol-2(5H)-yl)propanenitrile 1-35
2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-
phenylethanone 1-36
2-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-
phenylethanone 1-37
2-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-
- fluorophenyl)ethanone 1-38
2-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-
- chlorophenyl)ethanone 1-39
2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-
fluorophenyl)ethanone 1-40
3-(5-(2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-
yl)ethyl)pyridine-2-yl)propan-1-amine 1-41
8-Methyl-5-(2-(6-(trifluoromethyl)
yridine-3-yl)ethyl)-2,3,4,5-tetrahydro-1H- pyrido[4,3-b]indole 1-42
3-(8-Methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-3,4-dihydro-1H-pyrido[4-
,3- b]indol-2(5H)-yl)propan-1-ol 1-43
4-(8-Methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-3,4-dihydro-1H-pyrido[4-
,3- b]indol-2(5H)-yl)butan-1-ol 1-44
2,3,8-Trimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydro--
1H- pyrido[4,3-b]indole 1-45
2,3,8-Trimethyl-5-(2-(6-(trifluoromethyl)
yridine-3-yl)ethyl)-2,3,4,5- tetrahydro-1H-pyrido[4,3-b]indole 1-46
2,8-Dimethyl-5-(2-(yridine-4-yl)propyl)-2,3,4,5-tetrahydro-1H-pyrido[-
4,3- b]indole 1-47
2,3,8-Trimethyl-5-(2-(6-methylpyridin-3-yl)propyl)-2,3,4,5-tetrahydro-
-1H- pyrido[4,3-b]indole 1-48
8-Chloro-2,3-dimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetra-
hydro-1H- pyrido[4,3-b]indole 1-49
2,8-Dimethyl-5-(2-methyl-2-(yridine-4-yl)propyl)-2,3,4,5-tetrahydro-1-
H- pyrido[4,3-b]indole 1-50
2,8-Dimethyl-5-((1-(yridine-4-yl)cyclopropyl)methyl)-2,3,4,5-tetrahyd-
ro-1H- pyrido[4,3-b]indole 1-51
2,4,8-Trimethyl-5-(2-(6-(trifluoromethyl)
yridine-3-yl)ethyl)-2,3,4,5- tetrahydro-1H-pyrido[4,3-b]indole 1-52
1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridi-
ne-4- yl)propan-2-ol 1-53
1-(2-Ethyl-8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-
fluorophenyl)propan-2-ol 1-54
1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(p-
yridine- 3-yl)propan-2-ol 1-55
1-(8-Methyl-2-(trifluoromethyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2-
H)-yl)- 2-(6-methylpyridin-3-yl)propan-2-ol 1-56
1-(2-Cyclopropyl-8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-
-2-(2- methylpyridin-4-yl)propan-2-ol 1-57
1-(8-Chloro-2-isopropyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-
-(4- chlorophenyl)propan-2-ol 1-58
2-(2,4-Difluorophenyl)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]in-
dol- 5(2H)-yl)propan-2-ol 1-59
1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(3-
-fluoro- 4-methoxyphenyl)propan-2-ol 1-60
(R)-1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-
fluorophenyl)butan-2-ol 1-61
(R)-1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)--
2-(4- fluorophenyl)hexan-2-ol 1-62
(S)-1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(py-
ridine- 4-yl)butan-2-ol 1-63
(R)-1-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(py-
ridine- 4-yl)butan-2-ol 1-64
1-(8-Chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-
- fluorophenyl)hexan-2-ol 1-65
8-Methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2-(2,2,2-trifluoroethyl)-2-
,3,4,5- tetrahydro-1H-pyrido[4,3-b]indole 1-66
(S)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-
fluorophenyl)butan-2-ol 1-67
(S)-1-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)--
2-(4- fluorophenyl)hexan-2-ol
[0271] Pharmaceutical compositions of any of the compounds detailed
herein are embraced by this invention. Thus, the invention includes
pharmaceutical compositions comprising a compound of the invention
or a pharmaceutically acceptable salt thereof and a
pharmaceutically acceptable carrier or excipient. In one aspect,
the pharmaceutically acceptable salt is an acid addition salt, such
as a salt formed with an inorganic or organic acid. Pharmaceutical
compositions according to the invention may take a form suitable
for oral, buccal, parenteral, nasal, topical or rectal
administration, or a form suitable for administration by
inhalation.
[0272] A compound as detailed herein may in one aspect be in a
purified form and compositions comprising a compound in purified
forms are detailed herein. Compositions comprising a compound as
detailed herein or a salt thereof are provided, such as
compositions of substantially pure compounds. In some embodiments,
a composition containing a compound as detailed herein or a salt
thereof is in substantially pure form. Unless otherwise stated,
"substantially pure" intends a composition that contains no more
than 35% impurity, wherein the impurity denotes a compound other
than the compound comprising the majority of the composition or a
salt thereof. Taking compound 1 as an example, a composition of
substantially pure compound 1 intends a composition that contains
no more than 35% impurity, wherein the impurity denotes a compound
other than compound 1 or a salt thereof. In one variation, a
composition of substantially pure compound or a salt thereof is
provided wherein the composition contains no more than 25%
impurity. In another variation, a composition of substantially pure
compound or a salt thereof is provided wherein the composition
contains or no more than 20% impurity. In still another variation,
a composition of substantially pure compound or a salt thereof is
provided wherein the composition contains or no more than 10%
impurity. In a further variation, a composition of substantially
pure compound or a salt thereof is provided wherein the composition
contains or no more than 5% impurity. In another variation, a
composition of substantially pure compound or a salt thereof is
provided wherein the composition contains or no more than 3%
impurity. In still another variation, a composition of
substantially pure compound or a salt thereof is provided wherein
the composition contains or no more than 1% impurity. In a further
variation, a composition of substantially pure compound or a salt
thereof is provided wherein the composition contains or no more
than 0.5% impurity.
[0273] In one variation, the compounds herein are synthetic
compounds prepared for administration to an individual. In another
variation, compositions are provided containing a compound in
substantially pure form. In another variation, the invention
embraces pharmaceutical compositions comprising a compound detailed
herein and a pharmaceutically acceptable carrier. In another
variation, methods of administering a compound are provided. The
purified forms, pharmaceutical compositions and methods of
administering the compounds are suitable for any compound or form
thereof detailed herein.
General Description of Biological Assays
[0274] The binding properties of compounds disclosed herein to a
panel of aminergic G protein-coupled receptors including adrenergic
receptors, dopamine receptors, serotonin receptors, histamine
receptors and an imidazoline receptor may be determined Binding
properties may be assessed by methods known in the art, such as
competitive binding assays. In one variation, compounds are
assessed by the binding assays detailed herein. Compounds disclosed
herein may also be tested in cell-based assays or in in vivo models
for further characterization. In one aspect, compounds disclosed
herein are of any formula detailed herein and further display one
or more of the following characteristics: inhibition of binding of
a ligand to an adrenergic receptor (e.g., .alpha..sub.1D,
.alpha..sub.2A and .alpha..sub.1D), inhibition of binding of a
ligand to a serotonin receptor (e.g., 5-HT.sub.2A, 5-HT.sub.2C,
5-HT.sub.6 and 5-HT.sub.7), inhibition of binding of a ligand to a
dopamine receptor (e.g., D.sub.2L), and inhibition of binding of a
ligand to a histamine receptor (e.g., H.sub.1, H.sub.2 and
H.sub.3); agonist/antagonist activity to a serotonin receptor
(e.g., 5-HT.sub.2A, 5-HT.sub.6); agonist/antagonist activity to a
dopamine receptor (e.g., D.sub.2L, D.sub.2S); agonist/antagonist
activity to a histamine receptor (e.g., H.sub.1); activity in a
neurite outgrowth assay; efficacy in a preclinical model of memory
dysfunction associated with cholinergic dysfunction/hypofunction;
efficacy in a preclinical model of attention impulsivity and
executive function, and efficacy in a preclinical model of
schizophrenia.
[0275] In one variation, inhibition of binding of a ligand to a
receptor is measured in the assays described herein. In another
variation, inhibition of binding of a ligand is measured in an
assay known in the art. In one variation, binding of a ligand to a
receptor is inhibited by at least about 80% as determined in a
suitable assay known in the art such as the assays described
herein. In one variation, binding of a ligand to a receptor is
inhibited by greater than about any one of 80%, 85%, 90%, 95%,
100%, or between about 85% and about 95% or between about 90 and
about 100% as determined in a suitable assay known in the art such
as the assays described herein. In one variation, binding of a
ligand to a receptor is inhibited by at least about 80%.+-.20% as
determined in an assay known in the art.
[0276] In one variation, a compound of the invention inhibits
binding of a ligand to at least one receptor and as many as eleven
as detailed herein (e.g., .alpha..sub.1D, .alpha..sub.2A,
.alpha..sub.2B, 5-HT.sub.2A, 5-HT.sub.2C, 5-HT.sub.6, 5-HT.sub.7,
D.sub.2L, H.sub.1, H.sub.2, H.sub.3). In one variation, a compound
of the invention inhibits binding of a ligand to at least one
receptor and as many as eleven as detailed herein (e.g.,
.alpha..sub.1D, .alpha..sub.2A, .alpha..sub.2B, 5-HT.sub.2A,
5-HT.sub.2C, 5-HT.sub.6, 5-HT.sub.7, D.sub.2, H.sub.1, H.sub.2,
H.sub.3). In one variation, a compound of the invention inhibits
binding of a ligand to at least one and as many as eleven receptors
detailed herein and further displays agonist or antagonist activity
to one or more receptors detailed herein (e.g., serotonin receptor
5-HT.sub.2A, serotonin receptor 5-HT.sub.6, dopamine receptor
D.sub.2L, dopamine receptor D.sub.2S and histamine receptor
H.sub.1) as measured in the assays described herein. In one
variation, agonist response of serotonin receptor 5-HT.sub.2A is
inhibited by compounds of the invention by at least about any one
of 50%, 50%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150% as
determined in a suitable assay such as the assay described
herein.
[0277] In one variation, a compound of the invention displays the
above described neurotransmitter receptor binding profile, e.g.,
inhibits binding of a ligand to at least one receptor and as many
as eleven as detailed herein and further stimulates neurite
outgrowth, e.g., as measured by the assays described herein.
Certain compounds of the invention showed activity in neurite
outgrowth assays using primary neurons in culture. Data is
presented indicating that a compound of the invention has activity
comparable in magnitude to that of naturally occurring prototypical
neurotrophic proteins such as brain derived neurotrophic factor
(BDNF) and nerve growth factor (NGF). Notably, neurite outgrowth
plays a critical part of new synaptogenesis, which is beneficial
for the treatment of neuronal disorders. In one variation, neuronal
disorders include ADHD. In one variation, neurite outgrowth is
observed with a potency of about 1 .mu.M as measured in a suitable
assay known in the art such as the assays described herein. In
another variation, neurite outgrowth is observed with a potency of
about 500 nM. In a further variation, neurite outgrowth is observed
with a potency of about 50 nM. In another variation, neurite
outgrowth is observed with a potency of about 5 nM.
[0278] In another variation, a compound of the invention inhibits
binding of a ligand to at least one receptor and as many as eleven
as detailed herein, further displays agonist or antagonist activity
to one or more receptors detailed herein and further stimulates
neurite outgrowth.
[0279] In a further variation, a compound of the invention inhibits
binding of a ligand to at least one and as many as eleven receptors
as detailed herein and/or display the above described
neurotransmitter receptor binding profile and further shows
efficacy in a preclinical model of memory dysfunction associated
with cholinergic dysfunction/hypofunction, and in preclinical
models of attention/impulsivity and executive function, e.g., shows
pro-cognitive effects in a preclinical model of memory dysfunction.
Compounds of the invention have been shown to be effective in a
preclinical model of memory dysfunction associated with cholinergic
hypofunction. As H.sub.1 antagonism may contribute to sedation,
weight gain and reduced cognition, low affinity (less than about
80% inhibition of binding of Pyrilamine at 1 .mu.M in the assay
described herein) for this receptor may be associated with
pro-cognitive effects and a more desirable side effect profile.
Furthermore, compounds of the invention with increased potency as a
5-HT.sub.6 antagonist may have cognition-enhancing effects as
serotonin acting through this receptor may impair memory.
[0280] In another variation, a compound of the invention inhibits
binding of a ligand to at least one and as many as eleven receptors
as detailed herein, further shows efficacy in a preclinical model
of memory dysfunction associated with cholinergic
dysfunction/hypofunction, e.g., shows pro-cognitive effects in a
preclinical model of memory dysfunction, in preclinical models of
attention/impulsivity and executive function, and further displays
agonist or antagonist activity to one or more receptors detailed
herein.
[0281] In a further variation, a compound of the invention inhibits
binding of a ligand to at least one and as many as eleven receptors
as detailed herein, further shows efficacy in a preclinical model
of memory dysfunction associated with cholinergic
dysfunction/hypofunction, e.g., shows pro-cognitive effects in a
preclinical model of memory dysfunction, and in preclinical models
of attention/impulsivity and executive function, and further
stimulates neurite outgrowth.
[0282] In another variation, a compound of the invention inhibits
at least one and as many as eleven receptors as detailed herein,
further shows efficacy in a preclinical model of memory dysfunction
associated with cholinergic dysfunction/hypofunction, e.g., shows
pro-cognitive effects in a preclinical model of memory dysfunction,
in preclinical models of attention/impulsivity and executive
function, further displays agonist or antagonist activity to one or
more receptor detailed herein and further stimulates neurite
outgrowth.
[0283] In a further variation, a compound of the invention inhibits
binding of a ligand to at least one and as many as eleven receptors
and further possesses anti-psychotic effects as measured in a
preclinical model of schizophrenia, e.g., shows efficacy in a
preclinical model of schizophrenia.
[0284] In another variation, a compound of the invention inhibits
binding of a ligand to at least one and as many as eleven
receptors, further shows efficacy in a preclinical model of
schizophrenia and further displays agonist or antagonist activity
to one or more receptors detailed herein.
[0285] In a further variation, a compound of the invention inhibits
binding of a ligand to at least one and as many as eleven
receptors, further shows efficacy in a preclinical model of
schizophrenia and further stimulates neurite outgrowth.
[0286] In a further variation, a compound of the invention inhibits
binding of a ligand to at least one and as many as eleven
receptors, further shows efficacy in a preclinical model of memory
dysfunction associated with cholinergic dysfunction/hypofunction
such as enhancement of memory retention and reduction of memory
impairment, and in preclinical models of attention/impulsivity and
executive function, and further shows efficacy in a preclinical
model of schizophrenia.
[0287] In another variation, a compound of the invention inhibits
binding of a ligand to at least one and as many as eleven
receptors, further shows efficacy in a preclinical model of
schizophrenia, further displays agonist or antagonist activity to
one or more receptors detailed herein and further shows efficacy in
a preclinical model of memory dysfunction associated with
cholinergic dysfunction/hypofunction such as enhancement of memory
retention and reduction of memory impairment, and in preclinical
models of attention/impulsivity and executive function.
[0288] In another variation, a compound of the invention inhibits
binding of a ligand to at least one and as many as eleven
receptors, further shows efficacy in a preclinical model of
schizophrenia, further stimulates neurite outgrowth and further
shows efficacy in a preclinical model of memory dysfunction
associated with cholinergic dysfunction/hypofunction such as
enhancement of memory retention and reduction of memory impairment,
and in preclinical models of attention/impulsivity and executive
function.
[0289] In a further variation, a compound of the invention inhibits
binding of a ligand to at least one and as many as eleven receptors
detailed herein, further displays agonist or antagonist activity to
one or more receptors detailed herein, further stimulates neurite
outgrowth and further shows efficacy in a preclinical model of
schizophrenia.
[0290] In another variation, a compound of the invention inhibits
binding of a ligand to at least one and as many as eleven
receptors, further shows efficacy in a preclinical model of
schizophrenia, further displays agonist or antagonist activity to
one or more receptors detailed herein, further stimulates neurite
outgrowth and further shows efficacy in a preclinical model of
memory dysfunction associated with cholinergic
dysfunction/hypofunction such as enhancement of memory retention
and reduction of memory impairment, and in preclinical models of
attention/impulsivity and executive function.
[0291] In another variation, a compound of the invention stimulates
neurite outgrowth. In another variation, a compound of the
invention shows efficacy in a preclinical model of schizophrenia
and further stimulates neurite outgrowth. In another variation, a
compound of the invention stimulates neurite outgrowth and further
shows efficacy in a preclinical model of memory dysfunction
associated with cholinergic dysfunction/hypofunction such as
enhancement of memory retention and reduction of memory impairment,
and in preclinical models of attention/impulsivity and executive
function. In another variation, a compound of the invention shows
efficacy in a preclinical model of schizophrenia, further
stimulates neurite outgrowth and further shows efficacy in a
preclinical model of memory dysfunction associated with cholinergic
dysfunction/hypofunction such as enhancement of memory retention
and reduction of memory impairment, and in preclinical models of
attention/impulsivity and executive function.
[0292] In one aspect, compounds of the invention inhibit binding of
a ligand to adrenergic receptors .alpha..sub.1D, .alpha..sub.2A,
.alpha..sub.2B and inhibit binding of a ligand to serotonin
receptor 5-HT.sub.6. In another variation, compounds of the
invention inhibit binding of a ligand to adrenergic receptors
.alpha..sub.1D, .alpha..sub.2A, .alpha..sub.2B, to serotonin
receptor 5-HT.sub.6 and to any one or more of the following
receptors: serotonin receptor 5-HT.sub.7, 5-HT.sub.2A and
5-HT.sub.2C. In another variation, compounds of the invention
inhibit binding of a ligand to adrenergic receptors .alpha..sub.1D,
.alpha..sub.2A, .alpha..sub.2B, to serotonin receptor 5-HT.sub.6
and to any one or more of the following receptors: serotonin
receptor 5-HT.sub.7, 5-HT.sub.2A and 5-HT.sub.2C and further show
weak inhibition of binding of a ligand to histamine receptor
H.sub.1 and/or H.sub.2. In one variation, compounds of the
invention that also display strong inhibition of binding of a
ligand to the serotonin receptor 5-HT.sub.7 are particularly
desired. In another variation, compounds of the invention inhibit
binding of a ligand to adrenergic receptors .alpha..sub.1D,
.alpha..sub.2A, .alpha..sub.2B, to serotonin receptor 5-HT.sub.6
and further show weak inhibition of binding of a ligand to
histamine receptor H.sub.1 and/or H.sub.2. Weak inhibition of
binding of a ligand to the histamine H.sub.1 receptor is permitted
as agonists of this receptor have been implicated in stimulating
memory as well as weight gain. In one variation, binding to
histamine receptor H.sub.1 is inhibited by less than about 80%. In
another variation, binding of a ligand to histamine receptor
H.sub.1 is inhibited by less than about any of 75%, 70%, 65%, 60%,
55%, or 50% as determined by a suitable assay known in the art such
as the assays described herein.
[0293] In another variation, compounds of the invention inhibit
binding of a ligand to a dopamine receptor D.sub.2. In another
variation, compounds of the invention inhibit binding of a ligand
to dopamine receptor D.sub.2L. In another variation, compounds of
the invention inhibit binding of a ligand to dopamine receptor
D.sub.2 and to serotonin receptor 5-HT.sub.2A. In another
variation, compounds of the invention inhibit binding of a ligand
to dopamine receptor D.sub.2L, and to serotonin receptor
5-HT.sub.2A. In another variation, compounds of the invention
inhibit binding of a ligand to histamine receptor H.sub.1. In
certain aspects, compounds of the invention further show one or
more of the following properties: strong inhibition of binding of a
ligand to the serotonin 5-HT.sub.7 receptor, strong inhibition of
binding of a ligand to the serotonin 5-HT.sub.2A receptor, strong
inhibition of binding of a ligand to the serotonin 5-HT.sub.2C
receptor, weak inhibition of binding of a ligand to the histamine
H.sub.1 receptor, weak inhibition of binding of ligands to the
histamine H.sub.2 receptor, and antagonist activity to serotonin
receptor 5-HT.sub.2A.
[0294] In one variation, compounds of the invention show any of the
receptor binding aspects detailed herein and further display
agonist/antagonist activity to one or more of the following
receptors: serotonin receptor 5-HT.sub.2A, serotonin receptor
5-HT.sub.6, dopamine receptor D.sub.2L, dopamine receptor D.sub.2S
and histamine receptor H.sub.1. In one variation, compounds of the
invention show any of the receptor binding aspects detailed herein
and further stimulate neurite outgrowth. In one variation,
compounds of the invention show any of the receptor binding aspects
detailed herein and further show efficacy in a preclinical model of
memory dysfunction associated with cholinergic
dysfunction/hypofunction, such as enhancement of memory retention
and reduction of memory impairment and in preclinical models of
attention/impulsivity and executive function. In one variation,
compounds of the invention show any of the receptor binding aspects
detailed herein and further show efficacy in a preclinical model of
schizophrenia. In one variation, compounds of the invention show
any of the receptor binding aspects detailed herein and further
show efficacy in any one or more of agonist/antagonist assays
(e.g., to serotonin receptor 5-HT.sub.2A, 5-HT.sub.6, dopamine
receptor D.sub.2L, dopamine receptor D.sub.2S and histamine
receptor H.sub.1), neurite outgrowth, a preclinical model of memory
dysfunction associated with cholinergic dysfunction/hypofunction
and a preclinical model of schizophrenia.
[0295] In some aspects, compounds of the invention inhibit binding
of a ligand to adrenergic receptors .alpha..sub.1D, .alpha..sub.2A,
.alpha..sub.2B, serotonin receptor 5-HT.sub.6 and a dopamine
receptor D.sub.2 by at least about 80% as determined in a suitable
assay known in the art such as the assays described herein. In one
variation binding is inhibited by at least about 80% as measured in
a suitable assay such as the assays described herein. In some
aspects, compounds of the invention inhibit binding of a ligand to
adrenergic receptors .alpha..sub.1D, .alpha..sub.2A,
.alpha..sub.2B, serotonin receptor 5-HT.sub.6 and dopamine receptor
D.sub.2L by at least about 80% as determined in a suitable assay
known in the art such as the assays described herein. In one
variation binding is inhibited by at least about 80% as measured in
a suitable assay such as the assays described herein. In one
variation, binding of a ligand to a receptor is inhibited by
greater than about any one of 80%, 85%, 90%, 95%, 100%, or between
about 85% and about 95% or between about 90% and about 100% as
determined in a suitable assay known in the art such as the assays
described herein.
[0296] In some aspects, compounds of the invention display the
above described neurotransmitter receptor binding profile and
further show antipsychotic effects. It is recognized that compounds
of the invention have binding profiles similar to compounds with
antipsychotic activity and several compounds of the invention have
been shown to be effective in a preclinical model of schizophrenia.
In addition, compounds of the invention might possess the cognitive
enhancing properties of dimebon and thus add to the beneficial
pharmacology profile of these antipsychotic molecules. In one
variation, compounds of the invention display the above described
neurotransmitter receptor binding profile and further show
pro-cognitive effects in a preclinical model of memory dysfunction
such as enhancement of memory retention and reduction of memory
impairment. In another variation, compounds of the invention
display the above described neurotransmitter receptor binding
profile and do not show pro-cognitive effects in a preclinical
model of memory dysfunction, learning and memory.
[0297] In one variation, compounds of the invention demonstrate
pro-cognitive effects in a preclinical model of memory dysfunction,
learning and memory. In a further variation, compounds of the
invention possess anti-psychotic effects in a preclinical model of
schizophrenia. In a further variation, compounds of the invention
demonstrate pro-cognitive effects in a preclinical model of memory
dysfunction, learning and memory and further possess anti-psychotic
effects in a preclinical model of schizophrenia.
Overview of the Methods
[0298] A method of administering a compound of the invention to an
individual, such as a human, are detailed herein, wherein the
method comprises administering to an individual in thereof an
effective amount of compound or a salt thereof. The compounds
described herein may be used to treat, prevent, delay the onset
and/or delay the development of cognitive disorders, psychotic
disorders, neurotransmitter-mediated disorders and/or neuronal
disorders in individuals, such as humans. In one aspect, the
compounds described herein may be used to treat, prevent, delay the
onset and/or delay the development of a cognitive disorder. In one
variation, cognitive disorder as used herein includes and intends
disorders that contain a cognitive component, such as psychotic
disorders (e.g., schizophrenia) containing a cognitive component
(e.g., CIAS). In one variation, cognitive disorder includes ADHD.
In another aspect, the compounds described herein may be used to
treat, prevent, delay the onset and/or delay the development of a
psychotic disorder. In one variation, psychotic disorder as used
herein includes and intends disorders that contain a psychotic
component, for example cognitive disorders (e.g., Alzheimer's
disease) that contain a psychotic component (e.g., psychosis of
Alzheimer's Disease or dementia). In one variation, methods of
improving at least one cognitive and/or psychotic symptom
associated with schizophrenia are provided. In one aspect, methods
of improving cognition in an individual who has or is suspected of
having CIAS are provided. In a particular aspect, methods of
treating schizophrenia are provided wherein the treatment provides
for an improvement in one or more negative symptom and/or one or
more positive symptom and/or one or more disorganized symptom of
schizophrenia. In yet another aspect, the compounds described
herein may be used to treat, prevent, delay the onset and/or delay
the development of a neurotransmitter-mediated disorders disorder.
In one aspect, a neurotransmitter-mediated disorder includes ADHD.
In one embodiment, the neurotransmitter-mediated disorder includes
spinal cord injury, diabetic neuropathy, allergic diseases
(including food allergies) and diseases involving geroprotective
activity such as age-associated hair loss (alopecia),
age-associated weight loss and age-associated vision disturbances
(cataracts). In another variation, the neurotransmitter-mediated
disorder includes spinal cord injury, diabetic neuropathy,
fibromyalgia and allergic diseases (including food allergies). In
still another embodiment, the neurotransmitter-mediated disorder
includes Alzheimer's disease, Parkinson's Disease, autism,
Guillain-Barre syndrome, mild cognitive impairment, multiple
sclerosis, stroke and traumatic brain injury. In yet another
embodiment, the neurotransmitter-mediated disorder includes
schizophrenia, anxiety, bipolar disorders, psychosis, depression
and ADHD. In one variation, depression as used herein includes and
intends treatment-resistant depression, depression related to a
psychotic disorder, or depression related to a bipolar disorder. In
another aspect, the compounds described herein may be used to
treat, prevent, delay the onset and/or delay the development of a
neuronal disorder. In one aspect, the compounds described herein
may also be used to treat, prevent, delay the onset and/or delay
the development of cognitive disorders, psychotic disorders,
neurotransmitter-mediated disorders and/or neuronal disorders for
which the modulation of an aminergic G protein-coupled receptor is
believed to be or is beneficial.
[0299] The invention also provides methods of improving cognitive
functions and/or reducing psychotic effects comprising
administering to an individual in need thereof an amount of a
compound of the invention or a pharmaceutically acceptable salt
thereof effective to improve cognitive functions and/or reduce
psychotic effects. In a particular variation, a method of treating
schizophrenia is provided, wherein the treatment provides an
improvement in at least one cognitive function, such as an
improvement in a cognitive function in an individual who has or is
suspected of having CIAS. In a further variation, a method of
treating schizophrenia is provided wherein the method reduces
psychotic effects associated with schizophrenia. In one embodiment,
a method of treating schizophrenia is provided wherein the method
improves the negative symptoms of schizophrenia in an individual in
need thereof. In one embodiment, a method of treating schizophrenia
is provided wherein the method improves the positive symptoms of
schizophrenia in an individual in need thereof. In a further
variation, a method of treating schizophrenia is provided wherein
the method both improves cognitive function and reduces psychotic
effects in an individual in need thereof. A method of improving one
or more negative, positive and disorganized symptoms of
schizophrenia is also provided, where the method entails
administering a compound as detailed herein, or a pharmaceutically
acceptable salt thereof, to an individual in need of such
improvement. In one variation, a method of improving at least one
negative symptom of schizophrenia is provided, where the method
entails administering a compound as detailed herein, or a
pharmaceutically acceptable salt thereof, to an individual in need
of such improvement. In another variation, a method of improving at
least one negative and at least one positive symptom of
schizophrenia is provided, where the method entails administering a
compound as detailed herein, or a pharmaceutically acceptable salt
thereof, to an individual in need of such improvement. In yet
another variation, a method of improving at least one negative and
at least one disorganized symptom of schizophrenia is also
provided, where the method entails administering a compound as
detailed herein, or a pharmaceutically acceptable salt thereof, to
an individual in need of such improvement. In still another
variation, a method of improving at least one positive and at least
one disorganized symptom of schizophrenia is also provided, where
the method entails administering a compound as detailed herein, or
a pharmaceutically acceptable salt thereof, to an individual in
need of such improvement. In still a further variation, a method of
improving at least one negative, at least one positive and at least
one disorganized symptom of schizophrenia is provided, where the
method entails administering a compound as detailed herein, or a
pharmaceutically acceptable salt thereof, to an individual in need
of such improvement.
[0300] The invention also provides methods of stimulating neurite
outgrowth and/or promoting neurogenesis and/or enhancing
neurotrophic effects in an individual comprising administering to
an individual in need thereof an amount of a compound of the
invention or a pharmaceutically acceptable salt thereof effective
to stimulate neurite outgrowth and/or to promote neurogenesis
and/or to enhance neurotrophic effects.
[0301] The invention further encompasses methods of modulating an
aminergic G protein-coupled receptor comprising administering to an
individual in need thereof an amount of a compound of the invention
or a pharmaceutically acceptable salt thereof effective to modulate
an aminergic G protein-coupled receptor.
[0302] It is to be understood that methods described herein also
encompass methods of administering compositions comprising the
compounds of the invention.
Methods for Treating, Preventing, Delaying the Onset, and/or
Delaying the Development Cognitive Disorders, Psychotic Disorders,
Neurotransmitter-Mediated Disorders and/or Neuronal Disorders
[0303] In one aspect, the invention provides methods for treating,
preventing, delaying the onset, and/or delaying the development of
cognitive disorders, psychotic disorders, neurotransmitter-mediated
disorders and/or neuronal disorders for which the modulation of an
aminergic G protein-coupled receptor is believed to be or is
beneficial, the method comprising administering to an individual in
need thereof a compound of the invention. In some variations,
modulation of adrenergic receptor .alpha..sub.1D, .alpha..sub.2A,
.alpha..sub.2B, serotonin receptor 5-HT.sub.2A, 5-HT.sub.6,
5-HT.sub.7, histamine receptor H.sub.1 and/or H.sub.2 is expected
to be or is beneficial for the cognitive disorders, psychotic
disorders, neurotransmitter-mediated disorders and/or neuronal
disorders. In some variations, modulation of adrenergic receptor
.alpha..sub.1D, .alpha..sub.2A, .alpha..sub.2B and a serotonin
receptor 5-HT.sub.6 receptor is expected to be or is beneficial for
the cognitive disorders, psychotic disorders,
neurotransmitter-mediated disorders and/or neuronal disorders. In
some variations, modulation of adrenergic receptor .alpha..sub.1D,
.alpha..sub.2A, .alpha..sub.2B, and a serotonin receptor 5-HT.sub.6
receptor and modulation of one or more of the following receptors
serotonin 5-HT.sub.7, 5-HT.sub.2A, 5-HT.sub.2C and histamine
H.sub.1 and H.sub.2 is expected to be or is beneficial for the
cognitive disorders, psychotic disorders, neurotransmitter-mediated
disorders and/or neuronal disorders. In some variations, modulation
of a dopamine receptor D.sub.2 is expected to be or is beneficial
for the cognitive disorders, psychotic disorders,
neurotransmitter-mediated disorders and/or neuronal disorders. In
some variations, modulation of dopamine receptor D.sub.2L, is
expected to be or is beneficial for the cognitive disorders,
psychotic disorders, neurotransmitter-mediated disorders and/or
neuronal disorders. In certain variations, modulation of a dopamine
D.sub.2L, receptor and serotonin receptor 5-HT.sub.2A is expected
to be or is beneficial for the cognitive disorders, psychotic
disorders, neurotransmitter-mediated disorders and/or neuronal
disorders. In some variations, the cognitive disorders, psychotic
disorders, neurotransmitter-mediated disorders and/or neuronal
disorders are treated, prevented and/or their onset or development
is delayed by administering a compound of the invention.
Methods to Improve Cognitive Functions and/or Reduce Psychotic
Effects
[0304] The invention provides methods for improving cognitive
functions by administering a compound of the invention to an
individual in need thereof. In some variations, modulation of one
or more of adrenergic receptor .alpha..sub.1D, .alpha..sub.2A,
.alpha..sub.2B, serotonin receptor 5-HT.sub.2A, 5-HT.sub.6,
5-HT.sub.7, histamine receptor H.sub.1 and/or H.sub.2 is desirable
or expected to be desirable to improve cognitive functions. In some
variations modulation of .alpha..sub.1D, .alpha..sub.2A,
.alpha..sub.2B adrenergic receptors and a serotonin 5-HT.sub.6
receptor is desirable or expected to be desirable to improve
cognitive functions. In some variations, modulation of
.alpha..sub.1D, .alpha..sub.2A, .alpha..sub.2B adrenergic receptors
and serotonin receptor 5-HT.sub.6 and modulation of one or more of
the following receptors: serotonin receptor 5-HT.sub.7,
5-HT.sub.2A, 5-HT.sub.2C and histamine receptor H.sub.1 and
H.sub.2, is desirable or expected to be desirable to improve
cognitive functions. In another aspect, the invention encompasses
methods to reduce psychotic effects by administering a compound of
the invention to an individual in need thereof. In some
embodiments, modulation of a dopamine D.sub.2 receptor is expected
to be or is desirable to reduce psychotic effects. In some
embodiments, modulation of a dopamine D.sub.2L, receptor is
expected to be or is desirable to reduce psychotic effects. In some
embodiments, modulation of a dopamine D.sub.2 receptor and a
serotonin 5-HT.sub.2A receptor is expected to be or is desirable to
reduce psychotic effects. In some embodiments, modulation of a
dopamine D.sub.2L receptor and a serotonin 5-HT.sub.2A receptor is
expected to be or is desirable to reduce psychotic effects. In some
variations, a compound of the invention is administered to an
individual in need thereof.
Methods to Stimulate Neurite Outgrowth, Promote Neurogenesis and/or
Enhance Neurotrophic Effects
[0305] In a further aspect, the invention provides methods of
stimulating neurite outgrowth and/or enhancing neurogenesis and/or
enhancing neurotrophic effects comprising administering a compound
of the invention or pharmaceutically acceptable salt thereof under
conditions sufficient to stimulate neurite outgrowth and/or to
enhance neurogenesis and/or enhance neurotrophic effects to an
individual in need thereof. In some variations, a compound of the
invention stimulates neurite outgrowth at a potency of about 1
.mu.M as measured in a suitable assay such as the assays described
herein. In some variations, a compound of the invention stimulates
neurite outgrowth at a potency of about 500 nM as measured in a
suitable assay such as the assays described herein. In some
variations, a compound of the invention stimulates neurite
outgrowth at a potency of about 50 nM as measured in a suitable
assay such as the assays described herein. In some variations, a
compound of the invention stimulates neurite outgrowth at a potency
of about 5 nM as measured in a suitable assay such as the assays
described herein.
Methods to Modulate an Aminergic G Protein-Coupled Receptor
[0306] The invention further contemplates methods for modulating
the activity of an aminergic G-protein-coupled receptor comprising
administering a compound of the invention or pharmaceutically
acceptable salt thereof under conditions sufficient to modulate the
activity of an aminergic G protein-coupled receptor. In some
variations, the aminergic G protein-coupled receptor is a
.alpha..sub.1D, .alpha..sub.2A, .alpha..sub.2B adrenergic receptor
and a serotonin 5-HT.sub.6 receptor. In some variations, the
aminergic G protein-coupled receptor is a .alpha..sub.1D,
.alpha..sub.2A, .alpha..sub.2B adrenergic receptor and a serotonin
5-HT.sub.6 and 5-HT.sub.7 receptor. In some variations, the
aminergic G protein-coupled receptor is a .alpha..sub.1D,
.alpha..sub.2A, .alpha..sub.2B adrenergic receptor, a serotonin
5-HT.sub.6 and one or more of the following receptors: serotonin
5-HT.sub.2A and 5-HT.sub.2C and histamine H.sub.1 and H.sub.2
receptor. In some variations, the aminergic G protein-coupled
receptor is a dopamine D.sub.2 receptor. In some variations, the
aminergic G protein-coupled receptor is a dopamine D.sub.2L
receptor. In some variations, the aminergic G protein-coupled
receptor is a dopamine D.sub.2 receptor and a serotonin 5-HT.sub.2A
receptor. In some variations, the aminergic G protein-coupled
receptor is a dopamine D.sub.2L receptor and a serotonin
5-HT.sub.2A receptor. In some variations, the aminergic G
protein-coupled receptor is a histamine H.sub.1 receptor.
General Synthetic Methods
[0307] The compounds of the invention may be prepared by methods as
described in U.S. patent application Ser. No. 12/259,234 filed Oct.
27, 2008 and which is incorporated herein by reference in its
entirety and specifically with respect to the synthetic methods for
pyrido[4,3-b]indoles.
[0308] The compounds of the invention may be prepared by a number
of processes as generally described below and more specifically in
the Examples hereinafter. In the following process descriptions,
the symbols when used in the formulae depicted are to be understood
to represent those groups described above in relation to the
formulae hereinabove unless otherwise indicated.
[0309] Where it is desired to obtain a particular enantiomer of a
compound, this may be accomplished from a corresponding mixture of
enantiomers using any suitable conventional procedure for
separating or resolving enantiomers. Thus, for example,
diastereomeric derivatives may be produced by reaction of a mixture
of enantiomers, e.g., a racemate, and an appropriate chiral
compound. The diastereomers may then be separated by any convenient
means, for example by crystallization and the desired enantiomer
recovered. In another resolution process, a racemate may be
separated using chiral High Performance Liquid Chromatography.
Alternatively, if desired a particular enantiomer may be obtained
by using an appropriate chiral intermediate in one of the processes
described.
[0310] Chromatography, recrystallization and other conventional
separation procedures may also be used with intermediates or final
products where it is desired to obtain a particular isomer of a
compound or to otherwise purify a product of a reaction.
[0311] The following abbreviations are used herein: thin layer
chromatography (TLC); Hour (h); Minute (min); Second (sec); ethanol
(EtOH); dimethylsulfoxide (DMSO); N,N-dimethylformamide (DMF);
trifluoroacetic acid (TFA); tetrahydrofuran (THF); ethyl acetate
(EtOAc); Normal (N); aqueous (aq.); methanol (MeOH);
dichloromethane (DCM); retention factor (Rf); room temperature
(RT).
[0312] General methods of preparing compounds according to the
invention are depicted in exemplified methods below.
[0313] A method of synthesizing carboline intermediates used in the
synthesis of compounds of the invention is shown as General Method
1. Although identifiers such as R.sup.4 and R.sup.1 are shown in
the method below, it is understood that these moieties apply to the
compounds detailed herein even if different identifiers are used
elsewhere (e.g., Formula A uses R.sup.5 at the position indicated
by identifier R.sup.1 below and it is understood that in one
variation, R.sup.1 of General Method 1 may be the moieties detailed
herein for R.sup.5. Likewise, formula A uses identifiers
R.sup.1-R.sup.4 for substituents on the ring in which R.sup.4 is
used below and it is understood that in one variation, R.sup.4 of
General Method 1 may be the moieties detailed herein for R.sup.1,
R.sup.2, R.sup.3 and R.sup.4 and that as such, more than one
R.sup.4 may be utilized in the General Method detailed below.).
##STR00096##
[0314] Compound A (1 equiv.) and compound B (0.76-1.4 equiv.) are
mixed in a suitable solvent such as EtOH and heated at 80.degree.
C. for 16 h (overnight) after which the solvent is removed in
vacuo. The remaining residue is basified, e.g., with saturated aq.
NaHCO.sub.3. The aqueous layer is extracted with DCM and the
combined organic layers are dried over sodium sulfate, concentrated
in vacuo, and purified, e.g., by silica gel chromatography (230-400
mesh) using a suitable solvent gradient such as either a MeOH-DCM
gradient or an EtOAc-hexane gradient to give pure compound C.
[0315] A method of synthesizing epoxide intermediates used in the
synthesis of certain compounds of the invention is shown as General
Method 2. Although identifier R.sup.9 is shown in the method below,
it is understood that the moiety applies to the compounds detailed
herein even if different identifiers are used elsewhere.
##STR00097##
[0316] DMSO is added to NaH 60% dispersion in oil (1-1.8 equiv.)
and heated it to 65.degree. C. for one hour. THF (10 mL) is added
to the solution at 65.degree. C. and heating is continued for
another 10 min. The reaction mixture is then cooled to 0.degree. C.
and trimethylsulfonium iodide (1-1.2 equiv.) is added. The reaction
mixture is stirred for another 10 min after which appropriate
aldehyde/ketone (1 equiv.) is added as a solution in THF. The
reaction mixture is further stirred at RT until the reaction is
complete (monitored by TLC and LCMS). The reaction mixture is then
poured in ice water and the product is extracted in organic solvent
(ether or EtOAc), dried over sodium sulfate and concentrated at
25.degree. C. to obtain the product L.
[0317] A general method of synthesizing certain compounds detailed
herein by epoxide ring opening using a carboline is shown as
General Method 3. Although identifiers R.sup.1-R.sup.5 are shown in
the method below, it is understood that these moieties apply to the
compounds detailed herein even if different identifiers are used
elsewhere.
##STR00098##
[0318] Compound C (1 equiv.), compound L (2-7.5 equiv.) and NaH
(1-3 equiv.) are heated in DMF at 120.degree. C. for 16 h. The
contents are quenched by MeOH and evaporated to dryness. The
resulting crude product M is purified by silica gel chromatography
(230-400 mesh) using MeOH-DCM gradient followed by reverse-phase
chromatography (C-18, 500 mm.times.50 mm, Mobile Phase A=0.05% TFA
in water, B=0.05% TFA in acetonitrile, Gradient:10% B to 80% B in
30 min, injection vol. 5 mL).
[0319] The indo-5-yl alcohol compounds of Table 1 may be prepared
according to General Method 3.
[0320] Additional synthetic methods which may be adapted to arrive
at the compounds detailed herein are found in U.S. application Ser.
No. 12/259,234 and PCT Application No. PCT/US2008/081390, both
filed Oct. 27, 2008.
[0321] The methods detailed above may be adapted as known by those
of skill in the art. Particular examples of each General Method are
provided in the Examples below.
[0322] The following Examples are provided to illustrate but not
limit the invention.
[0323] All references disclosed herein are incorporated by
reference in their entireties.
EXAMPLES
Example 1
Preparation of
3-(8-methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-3,4-dihydro-1H-pyrido[4,3-b-
]indol-2(5H)-yl)propanenitrile (Compound No. 1-34)
[0324]
8-Methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydro-1H-py-
rido[4,3-b]indole (250 mg, 8.19 mmol) was taken into water (3 mL)
along with acrylonitrile (0.065 mL, 0.982 mmol) and stirred for 10
min. Ceric ammonium nitrite (133 mg, 0.245 mmol) was added to it at
once and the reaction mixture was stirred for 2 h. Product was
detected by LCMS and TLC. The reaction mixture was basified with
sat. NaHCO.sub.3 solution and extracted into EtOAc. The organic
layer was dried over anhydrous sodium sulfate, concentrated and the
crude product purified by column chromatography (Silica gel, 2-4%
MeOH in DCM) to get product 180 mg (61.43%). This was converted
into the oxalate salt (143 mg). .sup.1HNMR (CD.sub.3OD, Oxalate
salt) .delta. (ppm): 7.88 (s, 1H), 7.68-7.64 (d, 1H), 7.38-7.34 (d,
1H), 7.22 (s, 1H), 7.18-7.15 (d, 1H), 7.02-6.97 (d, 1H), 4.42 (s,
2H), 4.40-4.36 (t, 2H), 3.58-3.38 (m, 4H), 3.19-3.08 (m, 4H),
2.88-2.80 (t, 2H), 2.53 (s, 3H), 2.40 (s, 3H).
Example 2
Preparation of
2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-phenylethan-
one (Compound No. 1-35)
[0325] 2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100
mg, 5 mmol) was dissolved in NMP (1 mL). KOH (280 mg, 5 mmol) was
then added to it, followed by addition of 2-bromoacetophenone (208
mg, 1 mmol). The reaction was kept overnight at RT and was
monitored by TLC and LC/MS. The reaction was quenched by adding
water, and the compound extracted using EtOAc, which was washed
with water (2-3.times.). The organic layer was dried over sodium
sulfate and then concentrated to yield 10 mg of dark brown crude
oil, which was then purified by column chromatography using 100-200
mesh silica in 5% MeOH:DCM. .sup.1HNMR (CD.sub.3OD, TFA salt)
.delta. (ppm): 8.15 (m, 1H), 7.70 (m, 1H), 7.60 (m, 2H), 7.28 (d,
1H), 7.20 (m, 1H), 7.0 (m, 1H), 5.80 (m, 2H), 4.70 (m, 1H), 4.40
(m, 1H), 4.20 (m, 1H), 3.80 (m, 1H), 3.60 (m, 2H), 3.10 (s, 1H),
2.40 (s, 3H), 2.30 (m, 1H), 2.0 (m, 1H), 1.80 (m, 1H).
Example 3
Preparation of
2-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-phenyl-
ethanone (Compound No. 1-36)
[0326] 8-Chloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
(220 mg, 10 mmol) was dissolved in NMP (2 mL). KOH (560 mg, 0.010
mol) was then added, followed by addition of 2-bromoacetophenone
(199 mg, 0.001 mol). The reaction was kept overnight at RT and was
monitored by TLC & LC/MS. The reaction was quenched by adding
water, and extracted using EtOAc, which was then washed with water
(2-3.times.). The organic layer was dried over sodium sulfate and
then concentrated to yield 60 mg of dark brown crude oil that was
purified by column chromatography using 100-200 mesh silica gel
with 4% MeOH:DCM as eluent. .sup.1HNMR (CDCl.sub.3, TFA salt)
.delta. (ppm): 8.0 (m, 2H), 7.70 (m, 1H), 7.60 (m, 2H), 7.40 (d,
1H), 7.20 (m, 1H), 7.05 (m, 1H), 5.60 (m, 1H), 5.38 (m, 1H), 4.80
(m, 1H), 4.20 (m, 1H), 3.90 (m, 1H), 3.40 (m, 2H), 3.05 (s, 3H),
1.90 (m, 1H).
Example 4
Preparation of
2-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-flu-
orophenyl)ethanone (Compound No. 1-37)
[0327] 8-Chloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
(220 mg, 1 mmol) was dissolved in 2 mL NMP and to this was added
KOH (560 mg, 10 mmol) followed by 4-fluoro-2-bromoacetophenone (217
mg, 1 mmol). The reaction was kept overnight at RT. Water was added
and the compound extracted with EtOAc. The organic layer was washed
with water, concentrated and purified by column chromatography
using silica gel (#100-200 mesh) using 0-3% MeOH:DCM as eluent.
.sup.1HNMR (CD.sub.3OD, TFA salt) .delta. (ppm): 8.22 (m, 2H), 7.50
(s, 1H), 7.30 (m, 3H), 7.18 (m, 1H), 5.80 (m, 2H), 4.75 (m, 1H),
4.40 (m, 1H), 3.85 (m, 1H), 3.55 (m, 1H), 3.10 (m, 5H).
Example 5
Preparation of
2-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-chl-
orophenyl)ethanone (Compound No. 1-38)
[0328] 8-Chloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
(220 mg, 1 mmol) was dissolved in 2 mL NMP and to this was added
KOH (560 mg, 10 mmol) followed by
2-bromo-1-(4-chloro-phenyl)-ethanone (233 mg, 1 mmol) The reaction
was kept overnight at RT. Water was added and the compound
extracted with EtOAc. The organic layer was washed with water,
concentrated and purified by column chromatography using silica gel
(#100-200 mesh) using 0-3% MeOH:DCM as eluent. The compound was
further purified by reverse phase chromatography. .sup.1HNMR
(CD.sub.3OD, TFA salt) .delta. (ppm): 8.10 (m, 2H), 7.60 (d, 2H),
7.50 (s, 1H), 7.30 (d, 1H), 7.10 (m, 1H), 5.80 (m, 2H), 4.70 (m,
1H), 4.40 (m, 1H), 3.80 (m, 1H), 3.60 (m, 1H), 3.05 (s, 5H).
Example 6
Preparation of
2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-fluoroph-
enyl)ethanone (Compound No. 1-39)
[0329] To a solution of
2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (7 g, 0.032
mol) in 3 mL of NMP, KOH (12.7 g, 0.226 mol) was added at RT. The
reaction mixture was stirred well at RT for 20 min. Then a solution
of 2-bromo-1-(4-fluorophenyl)ethanone (6.5 g, 0.032 mol) in 2 mL
NMP was added dropwise into the reaction mixture at RT over 2-4 h.
The reaction was monitored by LCMS and TLC. The reaction mixture
was diluted with water and extracted with EtOAc. The organic layer
was dried over sodium sulfate and concentrated under reduced
pressure. The residue obtained was purified by column
chromatography, providing the desired product (1.2 g, 11.02%).
.sup.1HNMR (CDCl.sub.3, TFA salt) .delta. (ppm): 8.18-8.01 (m, 2H),
7.71 (s, 1H), 7.30 (s, 1H), 7.22-7.10 (m, 2H), 7.00 (d, 1H),
3.60-3.31 (m, 4H), 3.20-3.06 (m, 2H), 2.85-2.70 (m, 2H), 2.45 (s,
6H).
Example 7
Preparation of
3-(5-(2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)ethyl)py-
ridin-2-yl)propan-1-amine (Compound No. 1-40)
[0330] 2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100
mg, 0.005 mol) was taken into NMP (3 mL), and to it was added
finely crushed KOH (280 mg, 0.005 mol) and
2-(3-(5-vinylpyridin-2-yl)propyl)isoindoline-1,3-dione (146 mg,
0.005 mol). The reaction was heated at 120.degree. C. for 12 h. The
reaction was monitored by LCMS. After 12 h, 2 mL of water was added
to the reaction mixture and heated at 120.degree. C. for 12 h. The
reaction was monitored by LCMS. After completion of reaction the
mixture was cooled and water was added, followed by extraction with
EtOAc. The organic extract was dried over sodium sulfate and
concentrated under vacuum to yield 800 mg of crude product.
.sup.1HNMR (CDCl.sub.3, Oxalate salt) .delta. (ppm): 8.17 (s, 1H),
7.22 (s, 1H), 1.18 (d, 1H), 7.15 (d, 1H), 6.95 (m, 2H), 4.20 (t,
2H), 3.70 (s, 2H), 3.0 (t, 2H), 2.90 (t, 2H), 2.80 (t, 2H), 2.70
(t, 2H), 2.58 (s, 3H), 2.40 (s, 3H), 2.37 (m, 2H), 1.80 (t,
2H).
Example 8
Preparation of
8-methyl-5-(2-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-2,3,4,5-tetrahydro--
1H-pyrido[4,3-b]indole (Compound No. 1-41)
[0331] 5-(2-(1-p-Tolylhydrazinyl)ethyl)-2-(trifluoromethyl)pyridine
(88 mg, 0.29 mmol) was dissolved in 1,4-dioxane (2 mL) and
4-piperidone hydrate hydrochloride was added with one drop of TFA.
The reaction mixture became acidic. The mixture was heated at
100.degree. C. for 2 h. The reaction was monitored by TLC and LCMS.
After completion of reaction, the mixture was diluted with sat.
NaHCO.sub.3 solution and extracted with EtOAc. The organic extracts
were dried over anhydrous sodium sulfate and concentrated. The
compound was purified by reverse phase chromatography. .sup.1HNMR
(CD.sub.3OD, TFA salt) .delta. (ppm): 8.20 (s, 1H), 7.60 (m, 2H),
7.25 (d, 1H), 7.18 (d, 1H), 6.98 (d, 1H), 4.40 (m, 4H), 3.50 (t,
2H), 3.20 (m, 2H), 2.82 (t, 2H), 2.40 (s, 3H).
Example 9
Preparation of
3-(8-methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-3,4-dihydro-1H-pyrido[4,3-b-
]indol-2(5H)-yl)propan-1-ol (Compound No. 1-42)
[0332] A mixture of
2-methyl-5-(2-(1-p-tolylhydrazinyl)ethyl)pyridine hydrochloride
(0.6 g, 0.00216 mol), 1-(3-hydroxypropyl)piperidin-4-one (0.2 g,
0.00127 mol), and isopropanol (10 mL) was heated at 95.degree. C.
for 1 h. The reaction was monitored by TLC. After completion, the
reaction mixture was cooled to RT, basified with aq. NaOH solution
(10 mL) and extracted with EtOAc (3.times.100 mL). The organic
extract was dried over anhydrous sodium sulfate, concentrated and
purified by column chromatography (silica 100-200 mesh, desired
product was eluted in 7% MeOH/DCM.). Further purification by
preparative TLC gave the product as a yellow oil (0.22 g, 54%
yield). The product (0.1 g, 0.311 mmol) was dissolved in THF (1.0
mL). A solution of oxalic acid dihydrate (0.039 g, 0.311 mmol) in
THF (2 mL) was added and stirred for 30 min at RT. The precipitate
obtained was filtered and dried to give the oxalate salt as a
yellow colored solid (0.040 g, 31% yield). .sup.1HNMR (CD.sub.3OD,
Oxalate salt) .delta. (ppm): 7.90 (m, 1H), 7.60 (d, 1H), 7.38 (d,
1H), 7.22 (s, 1H), 7.18 (d, 1H), 7.0 (d, 1H), 4.50 (m, 2H), 4.38
(m, 2H), 3.75 (m, 2H), 3.42 (m, 3H), 3.15 (m, 2H), 2.80 (m, 2H),
2.50 (s, 3H), 2, 40 (s, 3H), 2.0 (m, 2H), 1.30 (m, 2H).
Example 10
Preparation of
4-(8-methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-3,4-dihydro-1H-pyrido[4,3-b-
]indol-2(5H)-yl)butan-1-ol (Compound No. 1-43)
[0333] A mixture of
2-methyl-5-(2-(1-p-tolylhydrazinyl)ethyl)pyridine hydrochloride
(0.6 g, 0.00216 mol), and 1-(4-hydroxybutyl)piperidin-4-one (0.24
g, 0.00108 mol), in isopropanol (10 mL), was heated at 95.degree.
C. for 5 h. After completion of reaction (monitored by TLC), the
reaction mixture was basified by addition of 2N aq. NaOH (30 mL)
and extracted with EtOAc (3.times.70 mL). The combined organic
layers were dried over sodium sulfate and concentrated. The crude
product was purified by column chromatography using silica gel
(100-200 mesh). The desired product was eluted in 10% MeOH/DCM.
Further purification by HPLC provided the title compound as the TFA
salt (0.08 g). .sup.1HNMR (CD.sub.3OD, TFA salt) .delta. (ppm):
8.22 (s, 1H), 8.10 (d, 1H), 7.70 (d, 1H), 7.25 (s, 1H), 7.10 (d,
1H), 6.90 (d, 1H), 4.70 (m, 1H), 4.45 (m, 2H), 4.38 (m, 1H), 3.90
(m, 1H), 3.70 (t, 2H), 3.55 (m, 2H), 3.40 (t, 2H), 3.20 (m, 3H),
2.70 (s, 3H), 2.40 (s, 3H), 2.0 (m, 2H), 1.70 (m, 2H).
Example 11
Preparation of
2,3,8-trimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydro-1H-p-
yrido[4,3-b]indole (Compound No. 1-44)
[0334] To a solution of
N-[2-(6-methyl-pyridin-3-yl)-ethyl]-N-p-tolyl-hydrazine (200 mg,
0.829 mmol) in dioxane (7 mL) was added
1,2-dimethyl-piperidin-4-one (137 mg, 1.078 mmol) in dioxane (3 mL)
at RT. To this mixture was added sulfuric acid (0.1 mL) at RT.
After complete addition the mixture was stirred at 85.degree. C.
for 1 h. The reaction was monitored by TLC. After completion of
reaction, the mixture was basified with NaHCO.sub.3 solution and
extracted with EtOAc (300 mL). The organic layer was dried over
sodium sulfate, concentrated under vacuum and purified by HPLC to
obtain 28.5 mg of desired compound as the TFA salt. .sup.1HNMR
(CD.sub.3OD, TFA salt) .delta. (ppm): 8.20 (s, 1H), 8.05 (d, 1H),
7.63 (d, 1H), 7.25 (s, 1H), 7.10 (d, 1H), 6.95 (d, 1H), 4.70 (m,
1H), 4.45 (t, 2H), 4.36 (m, 1H), 4.05 (m, 1H), 3.75 (m, 1H), 3.20
(m, 2H), 3.0 (m, 3H), 2.90 (m, 1H), 2.62 (s, 3H), 2.40 (s, 3H),
1.50 (d, 3H).
Example 12
Preparation of
2,3,8-trimethyl-5-(2-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-2,3,4,5-tetr-
ahydro-1H-pyrido[4,3-b]indole (Compound No. 1-45)
[0335] To a solution of
2,3,8-trimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (200 mg,
0.935 mmol) in N-methyl-2-pyrolidone (2.5 mL) was added powdered
KOH (463 mg, 8.27 mmol) and stirred for 10 min at RT.
2-Trifluoromethyl-5-vinyl pyridine (300 mg, 1.73 mmol) was added
and stirred further for 4 h at RT. The reaction was monitored by
TLC. After completion of reaction, water (10 mL) was added to the
mixture, which was then filtered. Water was added to the filtrate,
which was then extracted with EtOAc (50 mL). The organic layer was
dried over sodium sulfate, concentrated in vacuum and the residue
purified by column chromatography (100-200 mesh silica gel) to
obtain 20 mg of desired compound. The free base compound was
converted into the oxalate salt. .sup.1HNMR (CDCl.sub.3, Freebase)
.delta. (ppm): 8.40 (s, 1H), 7.45 (d, 1H), 7.25 (m, 2H), 7.10 (d,
1H), 6.98 (d, 1H), 4.22 (t, 2H), 3.82 (d, 1H), 3.62 (d, 1H), 3.50
(m, 1H), 3.10 (t, 2H), 2.80 (m, 1H), 2.45 (s, 3H), 2.38 (s, 3H),
2.10 (dd, 1H), 1.10 (d, 3H).
Example 13
Preparation of
2,8-dimethyl-5-(2-(pyridin-4-yl)propyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3--
b]indole) (Compound No. 1-46)
[0336] 2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (100
mg, 0.5 mmol) was dissolved in NMP (3 mL) and KOH (280 mg, 5 mmol)
was added with vinyl 4-(prop-1-en-2-yl)pyridine (178 mg, 1.5 mmol).
The reaction was stirred at RT for 14 h. After completion, the
mixture was diluted with water and extracted with EtOAc. The
organic layer was washed with water, concentrated and the residue
purified by HPLC. .sup.1HNMR (CD.sub.3OD, Oxalate salt) .delta.
(ppm): 8.4 (d, 2H), 7.25-7.15 (m, 4H), 7.05 (d, 1H), 4.4-4.2 (m,
3H), 3.80-3.79 (m, 2H), 3.50-3.40 (m, 2H), 3.15 (m, 1H), 3.05 (s,
3H) 2.70 (m, 1H), 2.40 (s, 3H), 1.40 (d, 3H).
Example 14
Preparation of
2,3,8-trimethyl-5-(2-(6-methylpyridin-3-yl)propyl)-2,3,4,5-tetrahydro-1H--
pyrido[4,3-b]indole (Compound No. 1-47)
[0337] A flask was charged with
2,3,8-trimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (117 mg,
0.5 mmol) and KOH (392 mg, 7 mmol) in NMP (2 mL) and heated at
140.degree. C. for 10 min. The mixture was cooled to 0.degree. C.
and to it was added 2-methyl-5-(prop-1-en-2-yl)pyridine (199 mg,
1.5 mmol) dropwise. The mixture was heated at 140.degree. C. for 2
h. The progress of the reaction was monitored by LCMS (5%
conversion). The mixture was cooled to RT, water was added and the
mixture filtered and evaporated. The solid obtained was purified by
HPLC. .sup.1HNMR (CD.sub.3OD, TFA salt) .delta. (ppm): 8.10 (m,
2H), 7.60 (m, 1H), 7.22 (s, 1H), 7.10 (d, 1H), 6.96 (d, 1H), 4.62
(m, 1H), 4.38 (m, 2H), 4.22 (m, 2H), 3.50 (m, 2H), 3.0 (s, 3H),
2.80 (s, 3H), 2.40 (s, 3H), 1.60-1.30 (m, 7H).
Example 15
Preparation of
8-chloro-2,3-dimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydr-
o-1H-pyrido[4,3-b]indole (Compound No. 1-48)
[0338] To a stirred solution of
1-(4-chlorophenyl)-1-(2-(6-methylpyridin-3-yl)ethyl)hydrazine (1 g,
3.83 mmol) in dioxane (10 mL) was added 1,2-dimethylpiperidin-4-one
(0.538 g, 4.59 mmol) and 0.5 mL of conc. sulfuric acid at RT. The
reaction was heated at 90.degree. C. for 2 h. After completion of
reaction, the mixture was basified by addition of a saturated
solution of NaHCO.sub.3. The product was extracted with EtOAc, and
the organic layer washed with water, dried over sodium sulfate and
concentrated. The solid obtained was purified by HPLC. .sup.1HNMR
(CD.sub.3OD, TFA salt) .delta. (ppm): 8.30 (s, 1H), 8.05 (d, 1H),
7.64 (d, 1H), 7.50 (s, 1H), 7.24 (d, 1H), 7.10 (d, 1H), 4.50 (t,
2H), 4.40 (m, 1H), 4.0 (m, 1H), 3.80 (m, 1H), 3.30 (m, 3H), 3.0 (m,
4H), 2.62 (s, 3H), 1.50 (d, 3H).
Example 16
Preparation of
2,8-dimethyl-5-(2-methyl-2-(pyridin-4-yl)propyl)-2,3,4,5-tetrahydro-1H-py-
rido[4,3-b]indole (Compound No. 1-49)
[0339] 2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (145
mg, 0.727 mmol), tetra n-butyl ammonium bromide (11 mg, 0.036
mmol), and 2-methyl-2-(pyridin-4-yl)propyl methanesulfonate (200
mg, 1.20 mmol) were taken into 50% NaOH (6 mL). The reaction
mixture was heated overnight at 100.degree. C. Reaction was
monitored by TLC and LCMS. After completion of the reaction, the
reaction mixture was extracted with EtOAc and water. The organic
layer was separated, dried over anhydrous sodium sulfate, and
concentrated under reduced pressure. The crude compound was
purified by column chromatography to yield 30 mg of product.
.sup.1H NMR (CDCl.sub.3, Freebase) .delta. (ppm): 8.50 (d, 2H),
7.2-7.13 (m, 3H), 6.88 (d, 2H), 4.03 (s, 2H), 3.62 (s, 2H), 2.63
(t, 2H), 2.50 (s, 3H), 2.42 (s, 3H), 2.25 (t, 2H), 1.43 (s,
6H).
Example 17
Preparation of
2,8-dimethyl-5-((1-(pyridin-4-yl)cyclopropyl)methyl)-2,3,4,5-tetrahydro-1-
H-pyrido[4,3-b]indole (Compound No. 1-50)
[0340] 2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (183
mg, 0.917 mmol), tetra n-butyl ammonium bromide (14 mg, 0.045
mmol), and (1-(pyridin-4-yl)cyclopropyl)methyl methanesulfonate
(250 mg, 1.10 mmol) were taken into 50% NaOH (6 mL). The reaction
mixture was stirred overnight at 100.degree. C. Reaction was
monitored by TLC and LCMS. After completion of the reaction,
reaction mixture was extracted with EtOAc and water. The organic
layer was separated, dried over anhydrous sodium sulfate, and
concentrated under reduced pressure. The crude compound was
purified by column chromatography to yield 37 mg of product.
.sup.1H NMR (CDCl.sub.3, Freebase) .delta. (ppm): 8.45 (d, 2H),
7.1-7.0 (m, 3H), 6.9 (d, 2H), 4.28 (s, 2H), 3.63 (s, 2H), 2.7 (t,
2H), 2.5-2.6 (m, 5H), 2.42 (s, 3H), 1.0-0.85 (m, 4H).
Example 18
Preparation of
2,4,8-trimethyl-5-(2-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-2,3,4,5-tetr-
ahydro-1H-pyrido[4,3-b]indole (Compound No. 1-51)
[0341] To a solution of
2,3,4,5-tetrahydro-2,4,8-trimethyl-1H-pyrido[4,3-b]indole (200 mg,
0.934 mmol) in N-methyl-2-pyrolidone (2.5 mL) was added powdered
KOH (463 mg, 8.27 mmol) and allow to stir for 10 min at RT.
2-Trifluoromethyl-5-vinyl pyridine (323 mg, 1.87 mmol) was added
and stirred further for 12 h at RT. The reaction was monitored by
TLC. After completion of reaction, water (10 mL) was added and the
mixture filtered. Water was added to the filtrate and the product
extracted with EtOAc (50 mL). The organic layer was dried over
sodium sulfate, evaporated in vacuum and purified by HPLC to obtain
the product.
Example 19
Preparation of
1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-2-phenylpropan-
-2-ol
[0342] Sodium hydride (38 mg, 1.6 mmol, 1.1 equiv.) was added to a
solution of 2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole
(290 mg, 1.4 mmol, 1.0 equiv.) in DMF (6 mL), and heated to
120.degree. C. for 1 h with stiffing. The reaction mixture was
cooled to 0.degree. C. and 2-methyl-2-phenyloxirane (400 mg, 2.98
mmol, 2.1 equiv.) was added dropwise over 5 min. The temperature
was raised to 120.degree. C. and stirred for 2 h. The reaction
mixture was cooled to RT and partitioned between ethyl acetate (60
mL) and water (15 mL). The organic layer was separated and the
aqueous layer was extracted with ethyl acetate (1.times.20 mL). The
combined organic layers were washed with water and followed by
brine, dried over sodium sulfate and concentrated under vacuum to
provide the crude product. The product was purified by flash column
chromatography over silica gel (230-400 mesh, deactivated with 1%
triethylamine/hexane) using a gradient of 5 to 15% methanol/ethyl
acetate to yield the free base. The pure compound was converted to
its oxalate salt. An analytical sample was prepared by dissolving
free base in 10 mL THF and treatment with 1 equiv. of oxalic acid
dihydrate.
Example 20
Preparation of
1-(8-chloro-1,2,3,4-tetrahydro-2-methylpyrido[4,3-b]indol-5-yl)-2-(3-fluo-
ro-4-methoxyphenyl)propan-2-ol (Compound No. 1-59)
[0343] Sodium hydride (38 mg, 1.6 mmol, 1.2 equiv.) was added to a
solution of
8-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (290
mg, 1.31 mmol, 1.0 equiv.) in DMF (6 mL), and heated to 120.degree.
C. for 1 h with stirring. The reaction mixture was cooled to
0.degree. C. and 2-(3-fluoro-4-methoxyphenyl)-2-methyloxirane (400
mg, 2.2 mmol, 1.7 equiv.) was added dropwise over 5 min. The
temperature was raised to 120.degree. C. and stirred for 2 h. The
reaction mixture was cooled to RT and partitioned between EtOAc (60
mL) and water (15 mL). The organic layer was separated and the
aqueous layer was extracted with EtOAc (1.times.20 mL). The
combined organic layer was washed with water and followed by brine,
dried over sodium sulfate and concentrated under vacuum to provide
the crude product. The product was purified by flash column
chromatography over silica gel (230-400 mesh, deactivated with 1%
triethylamine/hexane) using a gradient of 5 to 15% MeOH/EtOAc to
yield the free base. The pure compound was converted to its oxalate
salt. An analytical sample was prepared by dissolving free base in
10 mL THF and treatment with 1 equiv. of oxalic acid dihydrate.
.sup.1HNMR (DMSO, Oxalate salt) .delta. (ppm): 7.45 (m, 2H), 7.24
(m, 2H), 7.07 (m, 2H), 4.24 (m, 2H), 4.11 (m, 2H), 3.88 (s, 3H),
2.97 (m, 4H), 2.84 (s, 3H), 1.45 (s, 3H).
Example 21
Preparation of
1-(8-chloro-1,2,3,4-tetrahydro-2-methylpyrido[4,3-b]indol-5-yl)-2-(pyridi-
n-3-yl)propan-2-ol (Compound No. 1-54)
[0344] Sodium hydride (38 mg, 1.6 mmol, 1.2 equiv.) was added to a
solution of
8-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (290
mg, 1.3 mmol, 1.0 equiv.) in DMF (6 mL), and heated to 120.degree.
C. for 1 h with stirring. The reaction mixture was cooled to
0.degree. C. and 3-(2-methyloxiran-2-yl)pyridine (400 mg, 2.96
mmol, 2.3 equiv.) was added dropwise over 5 min. The temperature
was raised to 120.degree. C. and stirred for 2 h. The reaction
mixture was cooled to RT and partitioned between EtOAc (60 mL) and
water (15 mL). The organic layer was separated and the aqueous
layer was extracted with EtOAc (1.times.20 mL). The combined
organic layer was washed with water and followed by brine, dried
over sodium sulfate and concentrated under vacuum to provide the
crude product. The product was purified by flash column
chromatography over silica gel (230-400 mesh, deactivated with 1%
triethylamine/hexane) using a gradient of 5 to 15% MeOH/EtOAc to
yield the free base. The pure compound was converted to its oxalate
salt. An analytical sample was prepared by dissolving free base in
10 mL THF and treatment with 1 equiv. of oxalic acid dihydrate.
.sup.1HNMR (CD.sub.3OD, Oxalate salt) .delta. (ppm): 8.43 (s, 1H),
8.34 (d, 1H), 7.87 (d, 1H), 7.37 (s, 1H), 7.30 (m, 1H), 6.97 (m,
1H), 6.93 (d, 1H), 4.48 (m, 2H), 4.32 (m, 2H), 3.71 (m, 2H), 3.12
(s, 3H), 2.81 (m, 2H), 1.70 (s, 3H).
Example 22
Preparation of
1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-2-(pyridin-4-y-
l)propan-2-ol (Compound Nos. 1-52)
[0345] Sodium hydride (38 mg, 1.6 mmol, 1.14 equiv.) was added to a
solution of 2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole
(290 mg, 1.4 mmol, 1.0 equiv.) in DMF (6 mL), and heated to
120.degree. C. for 1 h with stiffing. The reaction mixture was
cooled to 0.degree. C. and 4-(2-methyloxiran-2-yl)pyridine (400 mg,
2.96 mmol, 2.1 equiv.) was added dropwise over 5 min. The
temperature was raised to 120.degree. C. and stirred for 2 h. The
reaction mixture was cooled to RT and partitioned between EtOAc (60
mL) and water (15 mL). The organic layer was separated and the
aqueous layer was extracted with EtOAc (1.times.20 mL). The
combined organic layer was washed with water and followed by brine,
dried over sodium sulfate and concentrated under vacuum to provide
the crude product. The product was purified by flash column
chromatography over silica gel (230-400 mesh, deactivated with 1%
triethylamine/hexane) using a gradient of 5 to 15% MeOH/EtOAc to
yield the free base. The pure compound was converted to its oxalate
salt. An analytical sample was prepared by dissolving free base in
10 mL THF and treatment with 1 equiv. of oxalic acid dihydrate.
.sup.1HNMR (CD.sub.3OD, Oxalate salt) .delta. (ppm): 8.38 (d, 2H),
7.50 (d, 2H), 7.15 (s, 1H), 7.06 (d, 1H), 6.86 (d, 1H), 4.45 (m,
2H), 4.31 (m, 1H), 4.22 (m, 1H), 3.61 (m, 2H), 3.19 (m, 1H), 3.06
(s, 3H), 2.78 (m, 2H), 2.35 (s, 3H), 1.60 (s, 3H).
Example 23
Preparation of
1-cyclohexyl-2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)--
1-(4-fluorophenyl)ethanol (Compound No. 1-1)
[0346] Activated magnesium turnings (480 mg, 20 g/atom) and 2-3
crystals of iodine were stirred under anhydrous conditions. The
excess of iodine was removed by heating with a heat gun. The
magnesium turnings were now yellow in color. To this was added
diethyl ether (15 mL) at 0.degree. C. and stirred for 15 min (until
the color of the magnesium becomes white). To this was added
cyclohexyl bromide (2.5 mL, 20 mmol) dropwise with constant
stiffing. The reaction mixture was stirred until a dark
grey-colored solution was obtained. Into a separate flask was
placed
2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-fluoroph-
enyl)ethanone (168 mg, 5 mmol) in THF under anhydrous conditions.
The solution of the prepared cyclohexylmagnesium bromide (5 mL) was
added dropwise. After addition, the mixture was allowed to come to
RT and stirred at RT for 2 h. The reaction was monitored by TLC and
NMR. The reaction was quenched with ice water and the product
extracted into EtOAc. The organic extracts were concentrated and
the residue purified by silica gel column chromatography (#100-200
mesh) using 0-3% MeOH:DCM as eluent. The compound was further
purified by HPLC. .sup.1HNMR (CD.sub.3OD, TFA salt) .delta. (ppm):
7.25 (m, 2H), 7.10 (d, 1H), 6.92 (m, 1H), 6.80 (m, 3H), 4.60 (m,
1H), 4.65 (m, 1H), 4.22 (m, 2H), 3.70 (m, 1H), 3.40 (m, 1H), 3.20
(m, 2H), 3.0 (s, 3H), 2.70 (m, 1H), 2.38 (s, 3H), 2.20 (m, 2H),
1.80 (m, 2H), 1.70 (m, 3H), 1.50-1.20 (m, 4H).
Example 24
Preparation of
2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-fluoroph-
enyl)ethanol (Compound No. 1-2)
[0347] Activated magnesium turnings (480 mg, 20 g/atom) and 2-3
crystals of iodine were stirred under anhydrous conditions. The
excess of iodine was removed by heating with a heat gun. The
magnesium turnings were now yellow in color. To this was added
diethyl ether (15 mL) at 0.degree. C. and stirred for 15 min (until
the color of the magnesium becomes white). To this was added
cyclopentyl bromide (480 mg, 20 g/atom) dropwise with constant
stirring. The reaction mixture was stirred until a dark
grey-colored solution was obtained. Into a separate flask was
placed the starting material (168 mg, 5 mmol) in THF under
anhydrous conditions. The solution of the prepared
cyclopentylmagnesium bromide (5 mL) was added dropwise. After
addition, the mixture was allowed to come to RT and stirred at RT
for 2 h. The reaction was monitored by TLC and NMR. The reaction
was quenched with ice water and the product extracted into EtOAc.
The organic extracts were concentrated and the residue purified by
silica gel column chromatography (#100-200 mesh) using 0-3%
MeOH:DCM as eluent. (Note: Desired compound not formed but
reduction of keto group occurs). .sup.1HNMR (DMSO, Oxalate salt)
.delta. (ppm): 7.55 (m, 3H), 7.18 (m, 3H), 6.95 (d, 1H), 4.85 (s,
1H), 4.30 (m, 2H), 4.15 (m, 2H), 3.60 (m, 2H), 3.10 (m, 3H), 2.90
(s, 3H), 2.40 (s, 3H).
Example 25
Preparation of
1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(3-fluoro-4-
-methoxyphenyl)propan-2-ol (Compound No. 1-3)
[0348] A flask was charged with sodium hydride 60% (461 mg, 1.15
mmol) in DMF and stirred at RT for 10 min
2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (0.76 g, 3.8
mmol) was added and the mixture stirred at RT for 1 h.
2-(3-Fluoro-4-methoxyphenyl)-2-methyloxirane (1 g, 5.4 mmol) was
added and the mixture stirred at RT overnight. Ice water was added
and the mixture extracted with EtOAc (3.times.). The combined
organic layers were washed with water (4.times.) and concentrated,
followed by purification of the product on silica gel (#100-200
mesh) using 0-5% MeOH:DCM as eluent. .sup.1HNMR (DMSO, Oxalate
salt) .delta. (ppm): 7.30 (m, 3H), 7.18 (s, 1H), 7.10 (d, 1H), 6.90
(d, 1H), 4.30 (m, 2H), 4.18 (d, 1H), 4.05 (d, 1H), 3.80 (s, 3H),
3.60 (m, 2H), 3.0 (m, 2H), 2.80 (s, 3H), 2.35 (s, 3H), 1.70 (m,
1H), 1.40 (s, 3H).
Example 26
Preparation of
1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-methoxyp-
henyl)propan-2-ol (Compound No. 1-4)
[0349] A flask was charged with sodium hydride 60% (0.803 mg, 20.12
mmol) in DMF and stirred at RT for 10 min
2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.28 g, 6.4
mmol) was added and the mixture stirred at RT for 1 h.
2-(4-Methoxyphenyl)-2-methyloxirane (1.5 g, 9.14 mmol) was added
and the mixture stirred at RT overnight. Ice water was added and
the mixture extracted with ethyl acetate (3.times.). The combined
organic layers were washed with water (4.times.) and concentrated,
followed by purification of the product on silica gel (#100-200
mesh) using 0-5% MeOH:DCM as eluent
Example 27a
Preparation of
1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-fluoroph-
enyl)butan-2-ol (Compound No. 1-5)
[0350]
2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-fl-
uorophenyl)ethanone (168 mg, 5 mmol) was dissolved in 10 mL
anhydrous THF. Ethyl magnesium bromide (1.5 mL, 0.0015 mol) was
then added dropwise at RT under nitrogen. The reaction mixture was
stirred at RT for 2 h. The reaction was monitored by LCMS. On
completion of the reaction, water (3 mL) was added to the reaction
mixture and the product extracted with ethyl acetate (3.times.).
The combined organic layers were washed with water, dried over
sodium sulfate, and the solvent evaporated under reduced pressure
to obtain the crude product, which was purified by HPLC. The pure
compound was isolated as the TFA salt.
Example 27b
Preparation of (R) and (S)
1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-fluoroph-
enyl)butan-2-ol (Compound Nos. 1-66 and 1-60)
[0351]
2-(2,8-Dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(4-fl-
uorophenyl)ethanone (168 mg, 5 mmol) was dissolved in 10 mL
anhydrous THF. Ethyl magnesium bromide (1.5 mL, 0.0015 mol) was
then added dropwise at RT under nitrogen. The reaction mixture was
stirred at RT for 2 h. The reaction was monitored by LCMS. On
completion of the reaction, water (3 mL) was added to the reaction
mixture and the product extracted with EtOAc (3.times.). The
combined organic layers were washed with water, dried over sodium
sulfate, and the solvent evaporated under reduced pressure to
obtain the crude product, which was purified by HPLC. The pure
compound was isolated as the TFA salt. Separation of the (R) and
(S) enantiomers was performed by chiral HPLC. .sup.1HNMR
(CD.sub.3OD, TFA salt) .delta. (ppm): 7.38 (m, 2H), 7.18 (d, 1H),
7.10 (m, 1H), 7.0 (m, 2H), 6.85 (d, 1H), 4.60 (m, 1H), 4.30 (m,
2H), 3.75 (m, 1H), 3.42 (m, 1H), 3.10 (s, 3H), 2.90 (m, 2H), 2.42
(d, 1H), 2.38 (s, 3H), 2.20 (m, 1H), 1.80 (m, 2H), 0.8 (t, 3H).
Example 28
Preparation of
2-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-cyclob-
utyl-1-(4-fluorophenyl)ethanol (Compound No. 1-6)
[0352] 8-Chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole
(1.5 g, 6 mmol) was dissolved in DMF (15 mL) and stirred for 5 min.
Sodium hydride (720 mg, 10 mmol) was then added to it portionwise
under nitrogen. This was followed by addition of
2-cyclobutyl-2-(4-fluorophenyl)oxirane (1.906 g, 18 mmol) at RT,
and the reaction mixture was stirred for 18 h. After completion of
reaction, the reaction mixture was poured into ice water and the
product extracted with EtOAc. The organic layer was washed with
water, dried over sodium sulfate and concentrated under reduced
pressure to give the crude product which was purified by silica gel
(#100-200 mesh) column chromatography using 1% MeOH in DCM as
eluent. The pure compound was converted into the oxalate salt.
.sup.1HNMR (CDCl.sub.3, Oxalate salt) .delta. (ppm): 7.30 (d, 1H),
7.20 (m, 2H), 6.95 (m, 4H), 4.20 (m, 1H), 4.0 (m, 1H), 3.80 (m,
2H), 3.10 (m, 1H), 2.70 (m, 4H), 2.50 (s, 3H), 2.20 (m, 2H), 2.0
(d, 1H), 1.80 (t, 2H), 1.70 (m, 1H).
Example 29a
Preparation of
1-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-flu-
orophenyl)hexan-2-ol (Compound No. 1-7)
[0353] 8-Chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole
(1.3 g, 5 mmol) was dissolved in DMF (10 mL) and stirred for 5 min.
Sodium hydride (709 mg, 17.7 mmol) was then added to it portionwise
under nitrogen. This was followed by addition of
2-butyl-2-(4-fluorophenyl)oxirane (3.4 g, 17.7 mmol) at RT and the
reaction mixture was stirred for 18 h. After completion of
reaction, the reaction mixture was poured into ice water and the
product extracted with ethyl acetate. The organic layer was washed
with water, dried over sodium sulfate and concentrated under
reduced pressure to give the crude product which was purified by
silica gel (#100-200 mesh) column chromatography using 1% methanol
in DCM as eluent. The pure compound was converted into the oxalate
salt.
Example 29b
Preparation of (R) and (S)
1-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-flu-
orophenyl)hexan-2-ol (Compound Nos. 1-67 and 1-61)
[0354] 8-Chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole
(1.3 g, 5 mmol) was dissolved in DMF (10 mL) and stirred for 5 min.
Sodium hydride (709 mg, 17.7 mmol) was then added to it portionwise
under nitrogen. This was followed by addition of
2-butyl-2-(4-fluorophenyl)oxirane (3.4 g, 17.7 mmol) at RT and the
reaction mixture was stirred for 18 h. After completion of
reaction, the reaction mixture was poured into ice water and the
product extracted with EtOAc. The organic layer was washed with
water, dried over sodium sulfate and concentrated under reduced
pressure to give the crude product which was purified by silica gel
(#100-200 mesh) column chromatography using 1% MeOH in DCM as
eluent. The pure compound was converted into the oxalate salt.
Separation of the (R) and (S) enantiomers was performed by chiral
HPLC. .sup.1HNMR (CDCl.sub.3, Oxalate salt) .delta. (ppm): 7.30 (m,
3H), 7.10 (d, 1H), 6.95 (m, 3H), 4.20 (m, 1H), 4.0 (m, 1H), 3.62
(m, 2H), 2.70 (m, 3H), 2.50 (s, 3H), 2.20 (m, 1H), 2.0 (m, 1H),
1.80 (m, 1H), 1.22 (m, 3H), 1.0 (m, 1H), 0.80 (t, 3H).
Example 30
Preparation of
2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(pyridin-4--
yl)ethanol (Compound No. 1-8)
[0355] Sodium hydride (2.4 g, 100 mmol) was washed with hexane and
dried under vacuum. To this was added DMF (15 mL) and cooled to
0.degree. C. Then to this was added
2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (4 g, 20
mmol) and the mixture stirred at 0.degree. C. for 30 min. Then
4-oxirannyl-pyridine (2.90 g, 23.96 mmol) was dissolved in 5 mL DMF
and added dropwise to the mixture, which was then left stirred at
RT overnight. The reaction was monitored by TLC. The reaction
mixture was poured into ice water and extracted with EtOAc
(3.times.). The combined organic layer was washed with water, dried
over anhydrous sodium sulfate and concentrated. The resultant solid
material was washed with hexane and crystallized from ethanol and
ether. .sup.1HNMR (DMSO, HCl salt) .delta. (ppm): 8.70 (d, 2H),
7.70 (d, 2H), 7.38 (m, 1H), 7.20 (s, 1H), 6.90 (d, 1H), 5.05 (m,
1H), 4.58 (m, 1H), 4.30 (m, 1H), 4.20 (m, 2H), 3.70 (m, 2H), 3.20
(m, 4H), 2.90 (s, 1H), 2.38 (s, 3H).
Example 31
Preparation of
1-(8-fluoro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrid-
in-4-yl)propan-2-ol (Compound No. 1-9)
[0356] A flask was charged with
6-fluoro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.9 g,
4.5 mmol) in DMF (20 mL) and stirred for 5 min. To this was added
NaH (60% in hexane) (1.16 g, 27.9 mmol) and stirred at RT for 10
min, followed by 4-(2-methyloxiran-2-yl)pyridine (2.5 g, 18.6 mmol)
and stirred at RT for 16 h. The progress of reaction was monitored
by TLC. The mixture was poured into ice water and filtered. The
filtrate was washed with water and concentrated. The residue was
recrystallized from ether to get pure product. .sup.1HNMR (DMSO,
HCl salt) .delta. (ppm): 8.78 (d, 2H), 8.0 (d, 2H), 7.40 (s, 1H),
7.20 (d, 1H), 6.80 (m, 1H), 6.10 (m, 1H), 4.50 (m, 1H), 4.30 (m,
2H), 4.20 (m, 1H), 3.70 (m, 2H), 3.20 (m, 2H), 2.90 (s, 3H), 1.60
(s, 3H).
Example 32
Preparation of
1-(6-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrid-
in-4-yl)propan-2-ol (Compound No. 1-10)
[0357] A flask was charged with
6-chloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.0 g,
4.5 mmol) in DMF (10 mL) and stirred for 5 min. To this was added
NaH (60% in hexane) (220 mg, 6.8 mmol) and stirred at RT for 10
min, followed by 4-(2-methyloxiran-2-yl)pyridine (1.08 g, 9 mmol)
and stirred at RT for 16 h. The progress of reaction was monitored
by TLC. The mixture was poured into ice water and filtered. The
filtrate was washed with water and concentrated. The residue was
recrystallized from ether to get pure product. .sup.1HNMR (DMSO,
HCl salt) .delta. (ppm): 8.70 (d, 2H), 7.90 (d, 2H), 7.40 (m, 1H),
7.0 (m, 2H), 6.0 (m, 1H), 4.80 (m, 1H), 4.60 (m, 2H), 4.25 (m, 2H),
3.80 (m, 2H), 2.90 (s, 3H), 1.60 (s, 3H).
Example 33
Preparation of
2-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-1-(pyrid-
in-4-yl)ethanol (Compound No. 1-11)
[0358] Sodium hydride (2.72 g, 113.33 mmol) was washed with hexane
and dried under vacuum. To this was added DMF (15 mL) and the
mixture cooled to 0.degree. C.
8-Chloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (5 g,
22.72 mmol) was added and the mixture stirred at 0.degree. C. for
30 min, followed by 4-oxirannyl-pyridine (3.3 g, 27.27 mmol)
dissolved in 5 mL DMF added dropwise. The reaction mixture was
stirred at RT overnight. The reaction was monitored by TLC. The
reaction mixture was poured into ice water and the product
extracted into EtOAc (3.times.). The combined organic layers were
washed with water, dried over anhydrous sodium sulfate and
concentrated. The resultant solid material was washed with hexane
and crystallized from ethanol and ether. .sup.1HNMR (CD.sub.3OD,
HCl salt) .delta. (ppm): 8.80 (d, 2H), 8.18 (d, 2H), 7.50 (s, 1H),
7.30 (m, 1H), 7.10 (d, 1H), 5.30 (m, 1H), 4.70 (m, 1H), 4.50 (m,
1H), 4.40 (m, 2H), 3.90 (m, 1H), 3.60 (m, 2H), 3.40 (m, 2H), 3.10
(s, 3H).
Example 34
Preparation of
1-(7-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrid-
in-4-yl)propan-2-ol (Compound No. 1-12)
[0359] A flask was charged with
7-chloro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.2 g,
5.0 mmol) in DMF (10 mL) and stirred for 5 min NaH (60% in hexane)
(654 mg, 16 mmol) was added and the mixture stirred at RT for 10
min. Then 4-(2-methyloxiran-2-yl)pyridine (1.35 g, 10 mmol) was
added and the mixture stirred at RT for 16 h. The progress of
reaction was monitored by TLC. The reaction mixture was poured into
ice water and filtered. The filtrate was washed with water and
concentrated. The residue was recrystallized from ether to get pure
product. .sup.1HNMR (DMSO, HCl salt) .delta. (ppm): 8.70 (d, 2H),
7.95 (d, 2H), 7.50 (m, 1H), 7.40 (m, 1H), 7.0 (t, 1H), 6.10 (m,
1H), 4.60 (m, 1H), 4.42-4.20 (m, 3H), 3.30 (m, 3H), 2.90 (s, 3H),
1.60 (d, 3H).
Example 35
Preparation of
1-(6-fluoro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrid-
in-4-yl)propan-2-ol (Compound No. 1-13)
[0360] A flask was charged with
6-fluoro-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.2 g,
5.8 mmol) in DMF (10 mL) and stirred for 5 min. NaH (60% in hexane)
(705 mg, 17.6 mmol) was added and the mixture stirred at RT for 10
min. Then 4-(2-methyloxiran-2-yl)pyridine (1.56 g, 11.6 mmol) was
added and the mixture stirred at RT for 16 h. The progress of
reaction was monitored by TLC. The reaction mixture was poured into
ice water and filtered. The filtrate was washed with water and
concentrated. The residue was recrystallized from ether to get pure
product. .sup.1HNMR (DMSO, HCl salt) .delta. (ppm): 8.70 (d, 2H),
8.0 (d, 2H), 7.40 (m, 1H), 7.20 (d, 1H), 6.85 (m, 1H), 6.10 (m,
1H), 4.58 (d, 1H), 4.38 (m, 2H), 4.22 (m, 1H), 3.20 (m, 3H), 2.90
(s, 3H), 1.60 (d, 3H).
Example 36
Preparation of
1-(2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-4-yl)p-
ropan-2-ol (Compound No. 1-14)
[0361] 2-Methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (740 mg,
3.9 mmol) was dissolved in DMF and the mixture stirred for 5 min.
NaH (60% in oil, 468 mg, 11.7 mmol) was added and the mixture
stirred for 10 min, followed by 4-(oxiran-2-yl)pyridine (1.0 g, 7.9
mmol) and the mixture stirred at RT for 3 h. The progress of
reaction was monitored by TLC. The reaction mixture was poured into
ice water and filtered. The filtrate was washed with water and
concentrated. The residue was recrystallized from ether to get pure
product. .sup.1HNMR (CD.sub.3OD, HCl salt) .delta. (ppm): 8.70 (d,
2H), 8.20 (d, 2H), 7.40 (m, 1H), 7.10 (m, 1H), 7.0 (m, 2H), 4.70
(d, 1H), 4.45 (m, 2H), 4.38 (m, 1H), 3.90 (m, 1H), 3.45 (m, 2H),
3.40 (m, 1H), 3.10 (s, 3H), 1.70 (d, 3H).
Example 37
Preparation of
4-(1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-hydroxyp-
ropan-2-yl)phenol (Compound No. 1-15)
[0362] To a stirred solution of
1-(1,2,3,4-tetrahydro-2,8-dimethylpyrido[4,3-b]indol-5-yl)-2-(4-methoxyph-
enyl)propan-2-ol (0.145 g, 0.39 mmol) in DCM (10 mL) at -78.degree.
C. was added borontribromide (0.293 g in 5 mL DCM). The reaction
mixture was stirred at -78.degree. C. for 30 min and then at
25.degree. C. for 1 h. The solution was poured into ice water,
saturated NaHCO.sub.3 was added, and the mixture extracted with
EtOAc. The organic layer was dried over anhydrous sodium sulfate,
and the solvent was removed under reduced pressure. The crude
product was purified by column chromatography (silica gel, 0-75%
MeOH:DCM) to give the product as an off-white solid, 20 mg.
.sup.1HNMR (CDCl.sub.3, Freebase) .delta. (ppm): 7.25 (d, 1H), 7.10
(m, 3H), 6.98 (d, 1H), 6.70 (d, 2H), 4.10 (m, 2H), 3.82 (m, 2H),
2.80 (m, 2H), 2.60 (s, 3H), 2.42 (s, 3H), 2.38 (m, 2H), 1.60 (s,
3H).
Example 38
Preparation of
1-(8-methoxy-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyri-
din-4-yl)propan-2-ol (Compound No. 1-16)
[0363] A flask was charged with
8-methoxy-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.5
g, 6.9 mmol) in DMF (15 mL) and stirred for 5 min. To this was
added NaH (60% in hexane) (828 mg, 20 mmol) and the mixture stirred
at RT for 10 min. 4-(2-Methyloxiran-2-yl)pyridine (1.89 g, 13.8
mmol) was added and the mixture stirred at RT for 16 h. The
progress of reaction was monitored by TLC. The reaction mixture was
poured into ice water and filtered. The filtrate was washed with
water and concentrated. The residue was recrystallized from ether
to get pure product. .sup.1HNMR (DMSO, D1-HCl salt) .delta. (ppm):
8.75 (m, 2H), 8.0 (dd, 2H), 7.30 (d, 1H), 6.90 (s, 1H), 6.60 (t,
1H), 6.10 (bs, 1H), 4.50 (m, 1H), 4.30 (m, 2H), 4.18 (m, 1H), 3.80
(s, 3H), 3.60 (m, 2H), 3.25 (m, 1H), 2.10 (m, 1H), 2.95 (s, 3H),
1.60 (s, 3H).
Example 39
Preparation of
1-(7,8-dichloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(p-
yridin-4-yl)propan-2-ol (Compound No. 1-17)
[0364] A flask was charged with
7,8-dichloro-2-methyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole
(1 g, 3.9 mmol) in DMF (10 mL) and stirred for 5 min. To this was
added NaH (60% in hexane) (470 mg, 11.7 mmol) and the mixture
stirred at RT for 10 min 4-(2-Methyloxiran-2-yl)pyridine (795 mg,
5.8 mmol) was added and the mixture stirred at RT for 16 h. The
progress of reaction was monitored by TLC. The reaction mixture was
poured into ice water and filtered. The filtrate was washed with
water and concentrated. The residue was recrystallized from ether
to get pure product. .sup.1HNMR (CD.sub.3OD, Formate salt) .delta.
(ppm): 8.38 (d, 2H), 7.56 (s, 1H), 7.48 (d, 2H), 7.30 (s, 1H), 4.60
(m, 2H), 4.30 (m, 2H), 3.58 (m, 1H), 3.50 (m, 1H), 3.35 (m, 1H),
3.10 (m, 1H), 3.0 (s, 3H), 1.70 (s, 3H).
Example 40
Preparation of
1-(8,9-dichloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(p-
yridin-4-yl)propan-2-ol (Compound No. 1-18)
[0365] A flask was charged with
7,8-dichloro-2-methyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole
(1 g, 3.9 mmol) in DMF (10 mL) and stirred for 5 min. To this was
added NaH (60% in hexane) (470 mg, 11.7 mmol) and the mixture
stirred at RT for 10 min 4-(2-Methyloxiran-2-yl)pyridine (795 mg,
5.8 mmol) was added and the mixture stirred at RT for 16 h. The
progress of reaction was monitored by TLC. The reaction mixture was
poured into ice water and filtered. The filtrate was washed with
water and concentrated. The residue was recrystallized from ether
to get pure product. .sup.1HNMR (CD.sub.3OD, Formate salt) .delta.
(ppm): 8.40 (m, 2H), 7.50 (d, 2H), 7.10 (m, 2H), 4.60 (m, 2H), 4.35
(m, 2H), 3.60 (m, 2H), 3.16 (m, 2H), 3.10 (s, 3H), 1.62 (s,
3H).
Example 41
Preparation of
1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-methoxyp-
henyl)propan-2-ol (Compound No. 1-19)
[0366] A flask was charged with sodium hydride 60% (0.803 mg, 20.12
mmol) in DMF and stirred at RT for 10 min. To this was added
2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.28 g, 6.4
mmol) and again stirred at RT for 1 h.
2-(4-Methoxyphenyl)-2-methyloxirane (1.5 g, 9.14 mmol) was added
and the mixture stirred at RT overnight. Ice water was added and
the mixture extracted with EtOAc (3.times.). The combined organic
layers were washed with water (4.times.) and concentrated. The
product was purified on silica gel (#100-200 mesh) using 0-5%
MeOH:DCM as eluent. .sup.1HNMR (DMSO, Oxalate salt) .delta. (ppm):
7.40 (d, 2H), 7.35 (d, 1H), 7.15 (s, 1H), 6.86 (m, 3H), 4.30 (m,
2H), 4.18 (d, 1H), 4.0 (d, 1H), 3.80 (s, 3H), 3.40 (m, 3H), 2.90
(m, 1H), 2.82 (s, 3H), 2.38 (s, 3H), 1.40 (s, 3H).
Example 42
Preparation of
1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-methoxyp-
henyl)propan-2-ol (Compound No. 1-20)
[0367] A flask was charged with sodium hydride 60% (0.803 mg, 20.12
mmol) in DMF and stirred at RT for 10 min. To this was added
2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.28 g, 6.4
mmol) and again stirred at RT for 1 h.
2-(4-Methoxyphenyl)-2-methyloxirane (1.5 g, 9.14 mmol) was added
and the mixture stirred at RT overnight. Ice water was added and
the mixture extracted with EtOAc (3.times.). The combined organic
layers were washed with water (4.times.) and concentrated. The
product was purified on silica gel (#100-200 mesh) using 0-5%
MeOH:DCM as eluent. .sup.1HNMR (DMSO, Oxalate salt) .delta. (ppm):
7.40 (d, 2H), 7.35 (d, 1H), 7.15 (s, 1H), 6.86 (m, 3H), 4.30 (m,
2H), 4.18 (d, 1H), 4.0 (d, 1H), 3.80 (s, 3H), 3.40 (m, 3H), 2.90
(m, 1H), 2.82 (s, 3H), 2.38 (s, 3H), 1.40 (s, 3H).
Example 43
Preparation of
1-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-methyl-
-2-(pyridin-4-yl)butan-2-ol (Compound No. 1-21)
[0368] To a stirred solution of sodium hydride (0.261 g, 50-60%) in
dry DMF (5 mL) at 0.degree. C. was added
8-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (0.3
g). The reaction mixture was stirred at RT for 30 min. To the
reaction mixture was added 4-(2-isopropyloxiran-2-yl)pyridine
(0.288 g in 2 mL DMF) at RT. After 12 h stiffing, the reaction
mixture was diluted with ice-water and extracted with EtOAc
(3.times.10 mL). The combined organic layers were washed with
brine, dried over anhydrous sodium sulfate and evaporated. The
crude product was triturated with diethyl ether to obtain pure
product (90 mg). .sup.1HNMR (DMSO, Oxalate salt) .delta. (ppm):
8.30 (d, 2H), 7.30 (m, 3H), 7.10 (d, 1H), 6.82 (d, 1H), 4.50 (m,
2H), 4.22 (m, 2H), 3.42 (m, 1H), 3.30 (m, 2H), 2.80 (s, 3H), 2.62
(m, 1H), 1.78 (m, 1H), 1.15 (d, 3H), 0.6 (d, 3H).
Example 44
Preparation of
1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-3-methyl-2-(p-
yridin-4-yl)butan-2-ol (Compound No. 1-22)
[0369] To a stirred solution of sodium hydride (0.192 g, 50-60%) in
dry DMF (5 mL) at 0.degree. C. was added
2,3,4,5-tetrahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole (0.3 g). The
reaction mixture was stirred at RT for 30 min. To the reaction
mixture was added 4-(2-isopropyloxiran-2-yl)pyridine (0.317 g in 2
mL DMF) at RT. After 12 h stiffing, the reaction mixture was
diluted with ice-water and extracted with EtOAc (3.times.10 mL).
The combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and evaporated. The crude product was
purified by column chromatography (silica gel 100-200 mesh, 5%
MeOH:DCM) to obtain pure product (50 mg). .sup.1HNMR (DMSO, Oxalate
salt) .delta. (ppm): 8.30 (d, 2H), 7.30 (d, 2H), 7.15 (s, 1H), 7.10
(d, 1H), 6.82 (d, 1H), 4.40 (m, 2H), 4.22 (m, 2H), 3.4 (m, 2H),
3.20 (m, 1H), 2.80 (s, 3H), 2.62 (m, 1H), 2.5 (m, 1H), 2.25 (s,
3H), 1.15 (d, 3H), 0.6 (d, 3H).
Example 45
Preparation of
1-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrid-
in-4-yl)butan-2-ol (Compound Nos. 1-23)
[0370] A flask was charged with sodium hydride (0.581 g, 50-60%) in
dry DMF (10 mL) at 0.degree. C. and to it was added
8-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (0.8
g). The reaction mixture was stirred at RT for 30 min, and then to
this was added 4-(2-ethyloxiran-2-yl)pyridine (0.758 g) dissolved
in DMF (2 mL), and stirred at RT for 12 h. The reaction mixture was
diluted with ice-water and extracted with EtOAc (3.times.30 mL).
The combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and evaporated. The crude product was
triturated with diethyl ether to obtain the desired compound.
.sup.1HNMR (DMSO, Oxalate salt) .delta. (ppm): 8.45 (d, 2H), 7.40
(m, 4H), 7.0 (d, 1H), 4.38 (m, 1H), 4.22 (m, 1H), 3.60 (m, 2H),
3.35 (m, 2H), 3.10 (m, 2H), 2.90 (s, 3H), 2.10 (m, 2H), 0.6 (t,
3H).
Example 46
Preparation of .+-., (R) and (S)
1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyridin-4--
yl)butan-2-ol (Compound Nos. 1-24, 1-62 and 1-63)
[0371] A flask was charged with sodium hydride (0.640 g, 50-60%) in
dry DMF (10 mL) at 0.degree. C. and to this was added
2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole (0.8
g). The mixture was stirred at RT for 30 min and then
4-(2-ethyloxiran-2-yl)pyridine (0.834 g) dissolved in DMF (2 mL)
was added, stirred at RT for 12 h. The reaction mixture was diluted
with ice-water and extracted with EtOAc (3.times.30 mL). The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate and evaporated. The crude product was
triturated with diethyl ether to obtain the desired compound. The
racemic compound was further separated into the (R) and (S)
enantiomers by use of chiral HPLC. .sup.1HNMR (DMSO, Oxalate salt)
.delta. (ppm): 8.45 (d, 2H), 7.42 (d, 2H), 7.30 (d, 1H), 7.10 (s,
1H), 6.82 (d, 1H), 4.30 (d, 1H), 4.18 (d, 1H), 3.60 (s, 2H), 3.50
(m, 2H), 3.38 (m, 1H), 3.0 (m, 2H), 2.90 (s, 3H), 3.32 (s, 3H),
2.10 (m, 1H), 0.6 (t, 3H).
Example 47
Preparation of
1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrimidin--
4-yl)propan-2-ol (Compound No. 1-25)
[0372] Sodium hydride (200 mg, 8.33 mmol) was washed with hexane
and dried under vacuum. DMF (4 mL) was added, resulting in a
suspension. 2,8-Dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
(400 mg, 2 mmol) in 2 mL DMF was added dropwise and stirred for 30
min at RT. 4-(2-Methyl-oxiranyl)-pyrimidine (490 mg, 3.60 mmol) in
2 mL DMF was added dropwise and the reaction mixture was stirred
overnight at RT. After the completion of reaction, the reaction
mixture was quenched with ice-cold water and extracted three times
with EtOAc. The combined organic layers were washed with water
several times followed by brine, and then dried over sodium
sulfate. The solvent was evaporated and the residue washed with
hexane and crystallized from ether-DCM and hexane to obtain 350 mg
of desired product. .sup.1HNMR (CD.sub.3OD, Oxalate salt) .delta.
(ppm): 9.10 (s, 1H), 8.50 (d, 1H), 7.50 (d, 1H), 7.10 (s, 1H), 6.95
(d, 1H), 6.80 (d, 1H), 4.40 (m, 4H), 3.60 (m, 2H), 3.40 (m, 1H),
3.20 (m, 1H), 3.0 (s, 3H), 2.50 (s, 3H), 1.60 (s, 3H).
Example 48
Preparation of
1-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrim-
idin-4-yl)propan-2-ol (Compound No. 1-26)
[0373] Sodium hydride (275 mg, 11.45 mmol) was washed with hexane
and dried under vacuum. DMF (4 mL) was added, resulting in a
suspension.
2,3,4,5-Tetrahydro-2-methyl-8-chloro-1H-pyrido[4,3-b]indole (500
mg, 2.27 mmol) dissolved in DMF (2 mL) was added dropwise and the
reaction mixture stirred for 30 min at RT.
4-(2-Methyl-oxiranyl)-pyrimidine (620 mg, 4.55 mmol) dissolved in
DMF (2 mL) was added dropwise and the reaction mixture was stirred
overnight at RT. The progress of reaction was monitored by TLC. The
mixture was quenched with ice-cold water and the mixture extracted
with EtOAc (3.times.30 mL). The combined organic layer was washed
with water (4.times.20 mL) followed by brine (1.times.20 mL), dried
over sodium sulfate and the solvent evaporated under vacuum. The
residue was washed with hexane and crystallized from ether: DCM and
hexane. .sup.1HNMR (CD.sub.3OD, Oxalate salt) .delta. (ppm): 9.10
(s, 1H), 8.50 (d, 1H), 7.50 (d, 1H), 7.36 (s, 1H), 7.10 (d, 1H),
6.95 (d, 1H), 4.40 (m, 4H), 3.60 (m, 2H), 3.40 (m, 1H), 3.20 (m,
1H), 3.05 (s, 3H), 1.60 (s, 3H).
Example 49
Preparation of
1-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyraz-
in-2-yl)propan-2-ol (Compound No. 1-27)
[0374] To a solution of 8-chloro
2-methyl-2,3,4,5-tetrahydro-1H-pyrido (4,3-b) indole (1.0 g, 4.54
mmol) in DMF (10 mL) was added sodium hydride (600 mg, 13.63 mmol).
After stirring for 10 min at RT, 2-(2-methyl oxiranyl)pyrazine (804
mg, 5.9 mmol) was added dropwise at 0-10.degree. C. and the
reaction mixture was stirred at RT for 16 h. The reaction mixture
was poured into ice water and extracted with EtOAc (3.times.150
mL). The organic layer was washed with water, dried over anhydrous
sodium sulfate and concentrated to afford crude product, which was
crystallized in ether-hexane to yield a yellow solid product as the
free base (1.2 g). .sup.1H NMR (DMSO, Oxalate salt) .delta. (ppm):
8.65 (s, 1H), 8.55 (s, 1H), 8.50 (d, 1H), 7.42 (s, 1H), 7.05 (d,
1H), 6.95 (d, 1H), 4.40 (m, 4H), 3.20 (m, 2H), 3.0 (m, 2H), 2.90
(s, 3H), 1.58 (s, 3H).
Example 50
Preparation of
1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyrazin-2--
yl)propan-2-ol (Compound No. 1-28)
[0375] To a stirred solution of
2,8-dimethyl-2,3,4,5-tetrahydro-1H-pyrido(4,3-b)indole (350 mg,
1.75 mmol) in DMF (4 mL) was added sodium hydride (210 mg, 5.25
mmol) followed by dropwise addition of 2-(2-methyl
oxiranyl)pyrazine (310 mg, 2.275 mmol) at 10.degree. C. and the
reaction mixture was further stirred at RT for 16 h. After
completion, the reaction mixture was poured into ice cooled water,
extracted with EtOAc (3.times.75 mL). The organic layer was washed
with water, dried over anhydrous sodium sulfate and concentrated
yielding crude product, which was re-crystallized in ether and
hexane to yield a yellow solid product (350 mg). .sup.1H NMR (DMSO,
Oxalate salt) .delta. (ppm): 8.65 (s, 1H), 8.55 (s, 1H), 8.50 (d,
1H), 7.10 (s, 1H), 6.90 (d, 1H), 6.78 (d, 1H), 4.30 (m, 4H), 3.20
(m, 2H), 3.0 (m, 2H), 2.90 (s, 3H), 2.30 (s, 3H), 1.50 (s, 3H).
Example 51
Preparation of
1-(8-methyl-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5(-
2H)-yl)-2-(pyridin-4-yl)propan-2-ol (Compound No. 1-29)
[0376] Step 1: To a stirred solution of
8-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indo-
le (0.9 g, 0.00319 mol) in dry THF (45 mL) was added
borane-dimethylsulfide solution (0.63 mL, 0.00638 mol) at 0.degree.
C. The reaction mass was heated at 80.degree. C. for 2 h. After
completion, the reaction mixture was cooled to RT and quenched with
MeOH (20 mL). The solvent was removed under reduced pressure to
yield
8-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indo-
le as a yellow colored oil (0.7 g, 82% yield).
[0377] Step 2: To a solution of
8-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3b]indol-
e (500 mg, 1.8 mmol) in DMF (10 mL) was added sodium hydride (216
mg, 4 mmol) and stirred for 10 min at RT followed by addition of
4-(2-methyl-oxiranyl)-pyridine (377 mg, 2.7 mmol) and stiffing
continued for 16 h. The reaction mixture was poured into ice water
and extracted with EtOAc. The organic layer was washed with water,
dried over anhydrous sodium sulfate and concentrated to afford
crude material, which was re-crystallized in ether and hexane to
yield
1-(8-methyl-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5(-
2H)-yl)-2-(pyridin-4-yl)propan-2-ol (320 mg). .sup.1H NMR (DMSO,
HCl salt) .delta. (ppm): 8.65 (d, 2H), 8.05 (d, 2H), 7.10 (m, 2H),
6.78 (d, 1H), 4.25 (m, 2H), 4.0 (s, 2H), 3.60 (m, 2H), 3.16 (m,
2H), 2.85 (m, 2H), 2.30 (s, 3H), 1.58 (s, 3H).
Example 52
Preparation of
1-(2-cyclopropyl-8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(-
pyridin-4-yl)propan-2-ol (Compound No. 1-30)
[0378] Step 1: A solution of (4-methylphenyl)hydrazine
hydrochloride (1.5 g, 0.00948 mol) and 1-cyclopropylpiperidin-4-one
(1.3 g, 0.00948 mol) in 7% sulfuric acid in dioxane (20 mL) was
heated at 80.degree. C. for 2 h. The progress of reaction was
monitored by TLC. After completion, the reaction mixture was cooled
to RT and the dioxane layer was decanted. The residue was basified
with 10% sodium hydroxide solution and extracted with EtOAc
(3.times.100 mL). The organic layer was dried over anhydrous sodium
sulfate and concentrated affording crude material, which was
purified by silica gel column chromatography (2% MeOH:DCM) to yield
2-cyclopropyl-8-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
(1.4 g, 66% yield).
[0379] Step 2: To a stirred solution of
2-cyclopropyl-8-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
(500 mg, 2.2 mmol) in DMF (10 mL) was added sodium hydride (264 mg,
6.6 mmol). After stirring for 10 min at RT,
4-(2-methyl-oxiranyl)-pyridine (448 mg, 3.3 mmol) was added and
stiffing continued for another 16 h. The reaction mixture was
poured into ice water and extracted with EtOAc. The organic layer
was washed with water, dried over anhydrous sodium sulfate and
concentrated to afford crude material, which was re-crystallized in
ether and hexane to yield
1-(2-cyclopropyl-8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(-
pyridin-4-yl)propan-2-ol (600 mg). .sup.1H NMR (CD.sub.3OD, TFA
salt) .delta. (ppm): 8.62 (d, 2H), 8.18 (d, 2H), 7.20 (s, 1H), 6.95
(d, 1H), 6.80 (d, 1H), 4.50 (m, 1H), 4.40 (s, 2H), 4.0 (m, 1H),
3.70 (m, 1H), 3.30 (m, 3H), 3.10 (m, 1H), 2.36 (s, 3H), 1.78 (s,
3H), 1.20 (m, 4H).
Example 53
Preparation of
1-(6-methoxy-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyri-
din-4-yl)propan-2-ol (Compound No. 1-31)
[0380] Step 1: To a stirred solution of (2-methoxyphenyl)hydrazine
hydrochloride (5 g, 0.0286 mol) and 1-methyl-4-piperidone (2.83 mL,
0.0229 mol) in ethanol (50 mL) was added ethanolic hydrochloric
acid (5 mL). The reaction mixture was heated at 80.degree. C. for 2
h. After completion, the reaction mixture was cooled to RT and
solvent removed under reduced pressure. The residue was basified
with 10% sodium hydroxide solution and extracted with EtOAc
(3.times.100 mL). The organic layer was dried over anhydrous sodium
sulfate and concentrated under reduced pressure to afford crude
material, which was purified by silica gel column chromatography
(6% MeOH:DCM) to yield
6-methoxy-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.5
g, 24% yield).
[0381] Step 2: To a stirred solution of
6-methoxy-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (500
mg, 2.3 mmol) in DMF (10 mL) was added sodium hydride (276 mg, 6.9
mmol) and stirred for 10 min at RT, followed by addition of
4-(2-methyl-oxiranyl)-pyridine (468 mg, 3.4 mmol) and stiffing
continued for another 16 h. The reaction mixture was poured into
ice water and extracted with EtOAc. The organic layer was washed
with water, dried over sodium sulfate and concentrated to afford
crude material, which was re-crystallized in ether and hexane to
yield
1-(6-methoxy-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(pyri-
din-4-yl)propan-2-ol. .sup.1H NMR (CD.sub.3OD, TFA salt) .delta.
(ppm): 8.60 (m, 2H), 7.95 (m, 2H), 6.95 (m, 2H), 6.50 (m, 1H), 4.65
(m, 2H), 4.30 (m, 2H), 3.90 (m, 2H), 3.80 (s, 3H), 3.60 (m, 2H),
3.10 (s, 3H), 1.70 (s, 3H).
Example 54
Preparation of
1-(7-isopropyl-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(py-
ridin-4-yl)propan-2-ol (Compound No. 1-32)
[0382] Step 1: A solution of (3-isopropylphenyl)hydrazine
hydrochloride (5 g, 0.0267 mol) and 1-methyl-4-piperidone (3.3 mL,
0.0267 mol) in 7% sulfuric acid in dioxane (100 mL) was heated at
80.degree. C. for 1 h. After completion, the reaction mixture was
cooled to RT and the organic layer decanted. The residue was
basified with 10% sodium hydroxide solution and extracted with
EtOAc (3.times.100 mL). The organic layer was dried over anhydrous
sodium sulfate and concentrated under reduced pressure affording
crude material, which was purified by silica gel column
chromatography (6% MeOH:DCM) to yield
7-isopropyl-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (1.1
g, 18% yield).
[0383] Step 2: To a solution of
7-isopropyl-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (500
mg, 2.1 mmol) in DMF (10 mL) was added sodium hydride (252 mg, 6.3
mmol). After stiffing for 10 min at RT,
4-(2-methyl-oxiranyl)-pyridine (444 mg, 3.2 mmol) was added and
stiffing continued for another 16 h. The reaction mixture was
poured into ice water and extracted with EtOAc. The organic layer
was washed with water, dried over sodium sulfate and concentrated
to afford crude product which was re-crystallized in ether and
hexane to yield
1-(7-isopropyl-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-
-2-(pyridin-4-yl)propan-2-ol. .sup.1H NMR (CD.sub.3OD, TFA salt)
.delta. (ppm): 8.60 (d, 2H), 8.05 (d, 2H), 7.25 (d, 1H), 6.90 (d,
1H), 6.78 (s, 1H), 4.65 (m, 1H), 4.42 (s, 2H), 4.30 (m, 1H), 3.90
(m, 1H), 3.60 (m, 2H), 3.30 (m, 1H), 3.10 (s, 3H), 2.85 (m, 1H),
1.80 (s, 3H), 1.18 (m, 6H).
Example 55
Preparation of
2-(pyridin-4-yl)-1-(2,3,8-trimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2-
H)-yl)propan-2-ol (Compound No. 1-33)
[0384] Step 1: To a solution of 4-tolyl hyadrazine hydrochloride
salt (1.39 g, 8.814 mmol) in dioxane (15 mL) was added a solution
of 1,2-dimethyl-piperidin-4-one (1.350 g, 10.62 mmol) in dioxane (5
mL) at RT followed by addition of sulfuric acid (0.69 mL). The
reaction mixture was stirred at 85.degree. C. for 1 h. After
completion of reaction, the reaction mixture was basified with
NaHCO.sub.3 solution and extracted with EtOAc (300 mL). The organic
layer was dried over sodium sulfate and concentrated yielding crude
material, which was re-crystallized with ether/hexane to yield
2,3,8-trimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (852
mg).
[0385] Step 2: To a solution of
2,3,8-trimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (500 mg,
2.3 mmol) in DMF (10 mL) was added sodium hydride (276 mg, 6.9
mmol). After stiffing for 10 min at RT,
4-(2-methyl-oxiranyl)-pyridine (473 mg, 3.5 mmol) was added and
stirring continued for another 16 h. The reaction mixture was
poured into ice water and extracted with EtOAc. The organic layer
was washed with water, dried over sodium sulfate and concentrated
to afford crude material, which was re-crystallized in ether-hexane
to yield
2-(pyridin-4-yl)-1-(2,3,8-trimethyl-3,4-dihydro-1H-pyrido[4,3-b]ind-
ol-5(2H)-yl)propan-2-ol. .sup.1H NMR (DMSO, HCl salt) .delta.
(ppm): 8.62 (d, 2H), 8.10 (d, 2H), 7.18 (s, 1H), 6.90 (m, 1H), 6.80
(m, 1H), 4.62 (m, 2H), 4.40 (m, 3H), 4.05 (m, 1H), 3.80 (m, 1H),
3.05 (s, 3H), 2.38 (s, 3H), 1.75 (d, 3H), 1.70-1.50 (m, 3H).
Example 56
Preparation of
1-(8-chloro-2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4-flu-
orophenyl)hexan-2-ol (Compound No. 1-64)
[0386] To a solution of
8-chloro-2,3,4,5-tetrahydro-2-methyl-1H-pyrido[4,3-b]indole (1.3 g,
5 mmol) in dimethylformamide (10 mL) was added sodium hydride (709
mg, 17.7 mmol) in portions followed by addition of
2-butyl-2-(4-fluorophenyl)oxirane (3.4 g, 17.7 mmol), and the
reaction mixture was stirred for 18 h at RT. After completion,
reaction mixture was poured into ice water and extracted with
EtOAc. The organic layer was washed with water, dried over
anhydrous sodium sulfate and concentrated under reduced pressure to
afford crude material, which was purified by silica gel (100-200
mesh) column chromatography using 1% MeOH-DCM as eluent. The pure
compound was converted into oxalate salt by treatment with oxalic
acid in ethanol. .sup.1H NMR (CDCl.sub.3, Oxalate salt) .delta.
(ppm): 7.30 (m, 3H), 7.10 (d, 1H), 6.95 (m, 3H), 4.20 (m, 1H), 4.0
(m, 1H), 3.62 (m, 2H), 2.70 (m, 3H), 2.50 (s, 3H), 2.20 (m, 1H),
2.0 (m, 1H), 1.80 (m, 1H), 1.22 (m, 3H), 1.0 (m, 1H), 0.80 (t,
3H).
Example 57
Preparation of
8-methyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2-(2,2,2-trifluoroethyl)-2,3,4-
,5-tetrahydro-1H-pyrido[4,3-b]indole (Compound No. 1-65)
[0387] To a solution of
8-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indo-
le (100 mg, 0.372 mmol) in DMF (2 mL) were added sodium hydride (50
mg, 1.11 mmol) and 2-(6-methylpyridin-3-yl)ethyl
4-methylbenzenesulfonate (271.3 mg, 0.932 mmol). The reaction
mixture was irradiated in a microwave reactor at 90.degree. C. for
1 h. The reaction mixture was cooled to RT, quenched with water and
extracted with EtOAc (3.times.10 mL). The organic layer was washed
with water (2.times.10 mL), dried over anhydrous sodium sulfate and
concentrated under reduced pressure to afford crude material, which
was purified by reverse phase HPLC. .sup.1H NMR (CD.sub.3OD, TFA
salt) .delta. (ppm): 8.16 (s, 1H), 8.1 (d, 1H), 7.65 (d, 1H), 7.2
(s, 1H), 7.0 (d, 1H), 6.9 (d, 1H), 4.48 (s, 2H), 4.4 (t, 2H), 4.17
(q, 2H), 3.62 (t, 2H), 3.2 (t, 2H), 3.08 (t, 2H), 2.64 (s, 3H), 2.4
(s, 3H).
Example 58
Preparation of Compound Nos. 1-53; 1-55; 1-56; 1-57; and 1-58
[0388] The following compounds are prepared according to General
Method 3. [0389]
1-(2-Ethyl-8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2--
(4-fluorophenyl)propan-2-ol (Compound No. 1-53); [0390]
1-(8-Methyl-2-(trifluoromethyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-y-
l)-2-(6-methylpyridin-3-yl)propan-2-ol (Compound No. 1-55); [0391]
1-(2-Cyclopropyl-8-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(-
2-methylpyridin-4-yl)propan-2-ol (Compound No. 1-56); [0392]
1-(8-Chloro-2-isopropyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)-2-(4--
chlorophenyl)propan-2-ol (Compound No. 1-57); and [0393]
2-(2,4-Difluorophenyl)-1-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol--
5(2H)-yl)propan-2-ol (Compound No. 1-58).
Example B1
Determination of the Ability of Compounds of the Invention to Bind
a Histamine Receptor
Histamine H.sub.1
[0394] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant histamine H.sub.1
receptor expressed in Chinese hamster ovary (CHO) cells (De Backer,
M. D. et al., Biochem. Biophys. Res. Comm 197(3):1601, 1993) in a
modified Tris-HCl buffer (50 mM Tris-HCl, pH 7.4, 2 mM MgCl.sub.2,
100 mM NaCl, 250 mM Sucrose) was used. Compounds of the invention
were incubated with 1.2 nM [.sup.3H]Pyrilamine for 180 min at
25.degree. C. Non-specific binding was estimated in the presence of
1 .mu.M pyrilamine. Receptor proteins were filtered and washed, the
filters were then counted to determine [.sup.3H]Pyrilamine
specifically bound. Compounds were screened at 1 .mu.M or lower,
using 1% DMSO as vehicle. Biochemical assay results are presented
as the percent inhibition of specific binding in Table 2.
Histamine H.sub.2
[0395] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant histamine H.sub.2
receptor expressed in Chinese hamster ovary (CHO) K1 cells (Ruat,
M., Proc. Natl. Acad. Sci. USA. 87(5):1658, 1990) in a 50 mM
Phosphate buffer, pH 7.4 was used. Compounds of the invention were
incubated with 0.1 nM [.sup.125I]Aminopotentidine for 120 min at
25.degree. C. Non-specific binding was estimated in the presence of
3 .mu.M Tiotidine. Receptor proteins were filtered and washed, the
filters were then counted to determine [.sup.125I]Aminopotentidine
specifically bound. Compounds were screened at 1 .mu.M or lower,
using 1% DMSO as vehicle. Biochemical assay results are presented
as the percent inhibition of specific binding in Table 2.
Histamine H.sub.3
[0396] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant histamine H.sub.3
receptor expressed in Chinese hamster ovary (CHO-K1) cells (Yanai K
et al. Jpn. J. Pharmacol. 65(2):107, 1994; Zhu Y et al. Mol.
Pharmacol. 59(3):434, 2001) in a modified Tris-HCl buffer (50 mM
Tris-HCl, pH 7.4, 5 mM MgCl.sub.2, 0.04% BSA) is used. Compounds of
invention are incubated with 3 nM
[.sup.3H]R(-)-.alpha.-Methylhistamine for 90 min at 25.degree. C.
Non-specific binding is estimated in the presence of 1 .mu.M
R(-)-.alpha.-Methylhistamine. Receptor proteins are filtered and
washed, the filters are counted to determine
[.sup.3H]R(-)-.alpha.-Methylhistamine specifically bound. Compounds
are screened at 1 .mu.M or lower, using 1% DMSO as vehicle.
Compounds of the invention are tested in this biochemical assay and
percent inhibition of specific binding is determined.
Example B2
Determination of the Ability of Compounds of the Invention to Bind
a Imidazoline I.sub.2 Receptor
Central Imidazoline I.sub.2
[0397] To evaluate in radioligand binding assays the activity of
compounds of the invention, rat central imidazoline I.sub.2
receptor obtained from Wistar Rat cerebral cortex (Brown, C. M. et
al., Br. J. Pharmacol. 99:803, 1990) in a modified Tris-HCl buffer
(50 mM Tris-HCl buffer, pH 7.4, 0.5 mM EDTA) is used. Compounds of
the invention are incubated with 2 nM [.sup.3H]Idazoxan for 30 min
at 25.degree. C. Non-specific binding is estimated in the presence
of 1 .mu.M Idazoxan. Receptor proteins are filtered and washed, the
filters are then counted to determine [.sup.3H]Idazoxan
specifically bound. Compounds are screened at 1 .mu.M or lower,
using 1% DMSO as vehicle. Compounds of the invention are tested in
this biochemical assay and percent inhibition of specific binding
is determined.
TABLE-US-00003 TABLE 2 Binding Data (% Inhibition) Histamine
Binding Histamine (1 .mu.M) Binding (0.1 .mu.M) Compound No.
H.sub.1 H.sub.2 H.sub.1 1-1 22 85 1-2 95 65 1-3 91 78 1-4 34/43 80
1-5 71 91 1-6 83 101 1-7 30 89 1-8 84 24 1-9 0 25 1-10 26 53 1-11
91 47 1-12 23 57 1-13 8 29 1-14 1 22 1-15 36 57 1-16 8 13 1-17 77
85 1-18 -11 9 1-19 23 1-20 61 1-21 -7 1-22 9 1-23 20 1-24 19 1-25
61 1-26 64 1-27 61 1-28 45 1-29 11 1-30 48 1-31 22 1-32 7 1-33 56
1-34 65 0 1-35 52 11 1-36 84 48 1-37 83 80 1-38 91 56 1-39 86 66
1-40 81 18 1-41 72 6 1-42 93 16 1-43 97 21 1-44 100 1-45 96 1-46 90
1-47 91 1-48 101 1-49 94 1-50 97 1-51 65 1-52 38 43 1-54 52 41 1-59
63 58 1-60 10 1-61 -7 1-62 3 1-63 18 1-64 30 89 1-65 11 1-66 -12
1-67 -2
Example B3
Determination of the Ability of Compounds of the Invention to Bind
an Adrenergic Receptor
Adrenergic .alpha..sub.1A
[0398] To evaluate in radioligand binding assays the activity of
compounds of the invention, rat adrenergic .alpha..sub.1A receptor
obtained from Wistar Rat submaxillary glands (Michel, A. D. et al.,
Br. J. Pharmacol. 98:883, 1989) in a modified Tris-HCl buffer (50
mM Tris-HCl buffer, pH 7.4, 0.5 mM EDTA) is used. Compounds of the
invention are incubated with 0.25 nM [.sup.3H]Prozosin for 60 min
at 25.degree. C. Non-specific binding is estimated in the presence
of 10 .mu.M phentolamine. Receptor proteins are filtered and
washed, the filters are then counted to determine [.sup.3H]Prozosin
specifically bound. Compounds of the invention are screened at 1
.mu.M or lower, using 1% DMSO as vehicle. Compounds of the
invention are tested in this biochemical assay and percent
inhibition of specific binding is determined.
Adrenergic .alpha..sub.1B
[0399] To evaluate in radioligand binding assays the activity of
compounds of the invention, rat adrenergic .alpha..sub.1B receptor
obtained from Wistar Rat liver (Garcia-S'ainz, J. A. et al.,
Biochem. Biophys. Res. Commun. 186:760, 1992; Michel A. D. et al.,
Br. J. Pharmacol. 98:883, 1989) in a modified Tris-HCl buffer (50
mM Tris-HCl buffer, pH 7.4, 0.5 mM EDTA) is used. Compounds of the
invention are incubated with 0.25 nM [.sup.3H]Prozosin for 60 min
at 25.degree. C. Non-specific binding is estimated in the presence
of 10 .mu.M phentolamine. Receptor proteins are filtered and
washed, the filters are then counted to determine [.sup.3H]Prozosin
specifically bound. Compounds are screened at 1 .mu.M or lower,
using 1% DMSO as vehicle. Compounds of the invention are tested in
this biochemical assay and percent inhibition of specific binding
is determined.
Adrenergic .alpha..sub.1D
[0400] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant adrenergic
.alpha..sub.1D receptor expressed in human embryonic kidney
(HEK-293) cells (Kenny, B. A. et al. Br. J. Pharmacol. 115(6):981,
1995) in a 50 mM Tris-HCl buffer, pH 7.4, was used. Compounds of
invention were incubated with 0.6 nM [.sup.3H]Prozosin for 60 min
at 25.degree. C. Non-specific binding was estimated in the presence
of 10 .mu.M phentolamine. Receptor proteins were filtered and
washed, the filters were then counted to determine
[.sup.3H]Prozosin specifically bound. Compounds were screened at 1
.mu.M or lower, using 1% DMSO as vehicle. Biochemical assay results
are presented as the percent inhibition of specific binding in
Table 3.
Adrenergic .alpha..sub.2A
[0401] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant adrenergic
.alpha..sub.2A receptor expressed in insect Sf9 cells (Uhlen S et
al. J. Pharmacol. Exp. Ther. 271:1558, 1994) in a modified Tris-HCl
buffer (50 mM Tris-HCl, pH 7.4, 12.5 mM MgCl.sub.2, 2 mM EDTA) was
used. Compounds of invention were incubated with 1 nM
[.sup.3H]MK-912 for 60 min at 25.degree. C. MK912 is
(2S-trans)-1,3,4,5',6,6',7,12b-octahydro-1',3'-dimethyl-spiro[2H-benzofur-
o[2,3-a]quinolizine-2,4'(1'H)-pyrimidin]-2'(3'H)-one hydrochloride
Non-specific binding was estimated in the presence of 10 .mu.M
WB-4101 (2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane
hydrochloride). Receptor proteins were filtered and washed, the
filters were then counted to determine [.sup.3H]MK-912 specifically
bound. Compounds were screened at 1 .mu.M or lower, using 1% DMSO
as vehicle. Biochemical assay results are presented as the percent
inhibition of specific binding in Table 3.
Adrenergic .alpha..sub.2B
[0402] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant adrenergic
.alpha..sub.2B receptor expressed in Chinese hamster ovary (CHO-K1)
cells (Uhlen S et al., Eur. J. Pharmacol. 343(1):93, 1998) in a
modified Tris-HCl buffer (50 mM Tris-HCl, pH 7.4, 12.5 mM
MgCl.sub.2, 1 mM EDTA, 0.2% BSA) was used. Compounds of the
invention were incubated with 2.5 nM [.sup.3H]Rauwolscine for 60
min at 25.degree. C. Non-specific binding was estimated in the
presence of 10 .mu.M Prozosin. Receptor proteins were filtered and
washed, the filters were then counted to determine
[.sup.3H]Rauwolscine specifically bound. Compounds were screened at
1 .mu.M or lower, using 1% DMSO as vehicle. Biochemical assay
results are presented as the percent inhibition of specific binding
in Table 3.
Adrenergic .alpha..sub.2C
[0403] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant adrenergic
.alpha..sub.2C receptor expressed in insect Sf9 cells (Uhlen S et
al. J. Pharmacol. Exp. Ther. 271:1558, 1994) in a modified Tris-HCl
buffer (50 mM Tris-HCl, pH 7.4, 12.5 mM MgCl.sub.2, 2 mM EDTA) is
used. Compounds of the invention are incubated with 1 nM
[.sup.3H]MK-912 for 60 min at 25.degree. C. Non-specific binding is
estimated in the presence of 10 .mu.M WB-4101. Receptor proteins
are filtered and washed, the filters are then counted to determine
[.sup.3H]MK-912 specifically bound. Compounds are screened at 1
.mu.M or lower, using 1% DMSO as vehicle. Compounds of the
invention are tested in this biochemical assay and percent
inhibition of specific binding is determined.
Example B4
Determination of the Ability of Compounds of the Invention to Bind
a Dopamine Receptor
Dopamine D.sub.2L
[0404] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant dopamine D.sub.2L
receptor expressed in Chinese hamster ovary (CHO) cells (Grandy, D.
K. et al. Proc. Natl. Acad. Sci. USA. 86:9762, 1989; Hayes, G. et
al., Mol. Endocrinol. 6:920, 1992) in a modified Tris-HCl buffer
(50 mM Tris-HCl, pH 7.4, 1.4 mM Ascorbic Acid, 0.001% BSA, 150 mM
NaCl) was used. Compounds of the invention were incubated with 0.16
nM [.sup.3H]Spiperone for 120 min at 25.degree. C. Non-specific
binding was estimated in the presence of 10 .mu.M Haloperidol.
Receptor proteins were filtered and washed, the filters were then
counted to determine [.sup.3H]Spiperone specifically bound.
Compounds were screened at 1 .mu.M or lower, using 1% DMSO as
vehicle. Biochemical assay results are presented as the percent
inhibition of specific binding in Table 3.
TABLE-US-00004 TABLE 3 Percent Inhibition of ligand binding to
aminergic G protein-coupled receptors by compounds of the
invention: Com- Adrenergic Dopa- pound (1 .mu.M) Adrenergic (0.1
.mu.M) mine No. .alpha..sub.1D .alpha..sub.2A .alpha..sub.2B
.alpha..sub.1A .alpha..sub.1B .alpha..sub.1D .alpha..sub.2A
.alpha..sub.2B .alpha..sub.2C (1 .mu.M) 1-1 49 83 86 13 1-2 88 98
104 36 1-3 58 94 98 32 1-4 57 93 88 1-5 75 94 96 1-66 -1 11 19 29
20 18 6 1-6 70 96 94 33 1-7 46 88 79 1-67 2 -2 23 26 -3 13 20 1-8
60 84 105 9 54 12 37 100 5 10 1-9 8 1-10 -8 12 7 28 86 19 8 1-11 12
60 12 41 101 26 15 1-12 1 1-13 -1 1-14 3 1-15 36 81 31 32 103 5 35
1-16 -5 1-17 0 55 18 64 64 39 2 1-18 -15 1-19 20 75 36 58 85 16 15
1-20 13 63 22 57 79 28 34 1-21 14 1-22 12 1-23 17 1-24 9 1-25 14
1-26 5 1-27 16 1-28 6 1-29 2 1-30 11 1-31 9 1-32 10 1-33 15 1-34 6
3 23 -4 1-35 18 19 59 4 1-36 52 43 92 73 1-37 56 87 87 85 1-38 56
90 92 44 1-39 57 88 92 57 1-40 53 31 63 3 1-41 74 58 89 -8 1-42 55
35 39 11 1-43 10 1-44 8 1-45 0 1-46 12 55 43 63 96 22 37 1-47 12
1-48 12 1-49 13 45 26 54 92 43 54 1-50 47 1-51 14 1-52 82 57 103 7
1-54 87 76 107 19 1-59 81 83 95 17 1-60 -8 -2 13 3 1 9 -14 1-61 1 0
14 -7 2 11 14 1-62 10 9 6 10 62 -5 9 1-63 8 5 -13 12 47 4 14 1-64
46 88 79 30 1-65 -10 -4 4 6 -9 -1 12
Example B5
Determination of the Ability of Compounds of the Invention to Bind
a Serotonin Receptor
Serotonin (5-Hydroxytryptamine) 5-HT.sub.1A
[0405] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant serotonin
(5-Hydroxytryptamine) 5-HT.sub.1A receptor expressed in Chinese
hamster ovary (CHO-K1) cells (Martin G R and Humphrey P P A.
Neuropharmacol. 33:261, 1994; May J A, et al. J. Pharmacol. Exp.
Ther. 306(1):301, 2003) in a modified Tris-HCl buffer (50 mM
Tris-HCl, pH 7.4, 0.1% Ascorbic Acid, 0.5 mM EDTA, 10 mM
MgSO.sub.4) is used. Compounds of invention are incubated with 1.5
nM [.sup.3H]8-OH-DPAT for 60 min at 25.degree. C. Non-specific
binding is estimated in the presence of 10 .mu.M Metergoline.
Receptor proteins are filtered and washed, the filters are then
counted to determine [.sup.3H]8-OH-DPAT specifically bound.
Compounds are screened at 1 .mu.M or lower, using 1% DMSO as
vehicle. Compounds of the invention are tested in this biochemical
assay and percent inhibition of specific binding is determined.
Serotonin (5-Hydroxytryptamine) 5-HT.sub.1B
[0406] To evaluate in radioligand binding assays the activity of
compounds of the invention, serotonin (5-Hydroxytryptamine)
5-HT.sub.1B receptor from Wistar Rat cerebral cortex (Hoyer et al.
Eur. J. Pharmacol. 118:1, 1985; Pazos et al., Eur. J. Pharmacol.
106:531, 1985) in a modified Tris-HCl buffer (50 mM Tris-HCl, pH
7.4, 154 mM NaCl, 10 .mu.M Pargyline, 30 .mu.M Isoprenaline) is
used. Compounds of invention are incubated with 10 pM
[.sup.125I]Cyanopindolol for 90 min at 37.degree. C. Non-specific
binding is estimated in the presence of 10 .mu.M Serotonin (5-HT).
Receptor proteins are filtered and washed, the filters are then
counted to determine [.sup.125I]Cyanopindolol specifically bound.
Compounds are screened at 1 .mu.M or lower, using 1% DMSO as
vehicle. Compounds of the invention are tested in this biochemical
assay and percent inhibition of specific binding is determined.
Serotonin (5-Hydroxytryptamine) 5-HT.sub.2A
[0407] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant serotonin
(5-Hydroxytryptamine) 5-HT.sub.2A receptor expressed in Chinese
hamster ovary (CHO-K1) cells (Bonhaus, D. W. et al. Br. J.
Pharmacol. 115:622, 1995; Saucier, C. and Albert, P. R., J.
Neurochem. 68:1998, 1997) in a 50 mM Tris-HCl buffer, pH 7.4, was
used. Compounds of the invention were incubated with 0.5 nM
[.sup.3H]Ketanserin for 60 min at 25.degree. C. Non-specific
binding was estimated in the presence of 1 .mu.M Mianserin.
Receptor proteins were filtered and washed, the filters were then
counted to determine [.sup.3H]Ketanserin specifically bound.
Compounds were screened at 1 .mu.M or lower, using 1% DMSO as
vehicle. Biochemical assay results are presented as the percent
inhibition of specific binding in Table 4.
Serotonin (5-Hydroxytryptamine) 5-HT.sub.2B
[0408] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant serotonin
(5-Hydroxytryptamine) 5-HT.sub.2B receptor expressed in Chinese
hamster ovary (CHO-K1) cells (Bonhaus, D. W. et al., Br. J.
Pharmacol. 115:622, 1995) in a modified Tris-HCl buffer (50 mM
Tris-HCl, pH 7.4, 4 mM CaCl.sub.2, 0.1% Ascorbic Acid) is used.
Compounds of invention are incubated with 1.2 nM [.sup.3H]Lysergic
acid diethylamide (LSD) for 60 min at 37.degree. C. Non-specific
binding is estimated in the presence of 10 .mu.M Serotonin (5-HT).
Receptor proteins are filtered and washed, the filters are then
counted to determine [.sup.3H]LSD specifically bound. Compounds are
screened at 1 .mu.M or lower, using 1% DMSO as vehicle. Compounds
of the invention are tested in this biochemical assay and percent
inhibition of specific binding is determined.
Serotonin (5-Hydroxytryptamine) 5-HT.sub.2C
[0409] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant serotonin
(5-Hydroxytryptamine) 5-HT.sub.2C receptor expressed in Chinese
hamster ovary (CHO-K1) cells (Wolf, W. A. and Schutz, J. S., J.
Neurochem. 69:1449, 1997) in a modified Tris-HCl buffer (50 mM
Tris-HCl, pH 7.4, 0.1% Ascorbic Acid, 10 .mu.M Pargyline) was used.
Compounds of the invention were incubated with 1 nM
[.sup.3H]Mesulergine for 60 min at 25.degree. C. Non-specific
binding was estimated in the presence of 1 .mu.M Mianserin.
Receptor proteins were filtered and washed, the filters were then
counted to determine [.sup.3H]Mesulergine specifically bound.
Compounds were screened at 1 .mu.M or lower, using 1% DMSO as
vehicle. Biochemical assay results are presented as the percent
inhibition of specific binding in Table 4.
Serotonin (5-Hydroxytryptamine) 5-HT.sub.3
[0410] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant serotonin
(5-Hydroxytryptamine) 5-HT.sub.3 receptor expressed in human
embryonic kidney (HEK-293) cells (Miller K et al. Synapase. 11:58,
1992; Boess F G et al. Neuropharmacology. 36:637, 1997) in a
modified Tris-HCl buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 5 mM
MgCl.sub.2) is used. Compounds of invention are incubated with 0.69
nM [.sup.3H]GR-65630 for 60 min at 25.degree. C. Non-specific
binding is estimated in the presence of 10 .mu.M MDL-72222.
Receptor proteins are filtered and washed, the filters are then
counted to determine [.sup.3]GR-65630 specifically bound. Compounds
are screened at 1 .mu.M or lower, using 1% DMSO as vehicle.
Compounds of the invention are tested in this biochemical assay and
percent inhibition of specific binding is determined.
Serotonin (5-Hydroxytryptamine) 5-HT.sub.4
[0411] To evaluate in radioligand binding assays the activity of
compounds of the invention, serotonin (5-Hydroxytryptamine)
5-HT.sub.4 receptor from Duncan Hartley derived Guinea pig striatum
(Grossman C J et al., Br. J. Pharmacol. 109:618, 1993) in a 50 mM
Tris-HCl, pH 7.4, is used. Compounds of invention are incubated
with 0.7 nM [.sup.3H]GR-113808 for 30 min at 25.degree. C.
Non-specific binding is estimated in the presence of 30 .mu.M
Serotonin (5-HT). Receptor proteins are filtered and washed, the
filters are then counted to determine [.sup.3H]GR-113808
specifically bound. Compounds are screened at 1 .mu.M or lower,
using 1% DMSO as vehicle. Compounds of the invention are tested in
this biochemical assay and percent inhibition of specific binding
is determined.
Serotonin (5-Hydroxytryptamine) 5-HT.sub.5A
[0412] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant serotonin
(5-Hydroxytryptamine) 5-HT.sub.5A receptor expressed in Chinese
hamster ovary (CHO-K1) cells (Rees, S. et al., FEBS Lett. 355:242,
1994) in a modified Tris-HCl buffer (50 mM Tris-HCl, pH 7.4, 10 mM
MgCl.sub.2, 0.5 mM EDTA) was used. Compounds of the invention were
incubated with 1.7 nM [.sup.3H]Lysergic acid diethylamide (LSD) for
60 min at 37.degree. C. Non-specific binding was estimated in the
presence of 100 .mu.M Serotonin (5-HT). Receptor proteins were
filtered and washed, the filters were then counted to determine
[.sup.3H]LSD specifically bound. Compounds were screened at 1 .mu.M
or lower, using 1% DMSO as vehicle. Compounds of the invention were
tested in this biochemical assay and percent inhibition of specific
binding was determined. Biochemical assay results are presented as
the percent inhibition of specific binding in Table 4.
Serotonin (5-Hydroxytryptamine) 5-HT.sub.6
[0413] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant serotonin
(5-Hydroxytryptamine) 5-HT6 receptor expressed in human HeLa cells
(Monsma, F. J. Jr. et al., Mol. Pharmacol. 43:320, 1993) in a
modified Tris-HCl buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM
Ascorbic Acid, 0.001% BSA) was used. Compounds of the invention
were incubated with 1.5 nM [3H]Lysergic acid diethylamide (LSD) for
120 min at 37.degree. C. Non-specific binding was estimated in the
presence of 5 .mu.M Serotonin (5-HT). Receptor proteins were
filtered and washed, the filters were then counted to determine
[3H]LSD specifically bound. Compounds were screened at 1 .mu.M or
lower, using 1% DMSO as vehicle. Biochemical assay results are
presented as the percent inhibition of specific binding in Table
4.
Serotonin (5-Hydroxytryptamine) 5-HT.sub.7
[0414] To evaluate in radioligand binding assays the activity of
compounds of the invention, human recombinant serotonin
(5-Hydroxytryptamine) 5-HT.sub.7 receptor expressed in Chinese
hamster ovary (CHO) cells (Roth, B. L. et al., J. Pharmacol. Exp.
Ther. 268:1403, 1994; Shen, Y. et al., J. Biol. Chem. 268:18200,
1993) in a modified Tris-HCl buffer (50 mM Tris-HCl, pH 7.4, 10 mM
MgCl.sub.2, 0.5 mM EDTA) was used. Compounds of invention were
incubated with 5.5 nM [.sup.3H]Lysergic acid diethylamide (LSD) for
2 h at 25.degree. C. Non-specific binding was estimated in the
presence of 10 .mu.M Serotonin (5-HT). Receptor proteins were
filtered and washed, the filters were then counted to determine
[.sup.3]LSD specifically bound. Compounds were screened at 1 .mu.M
or lower, using 1% DMSO as vehicle. Biochemical assay results are
presented as the percent inhibition of specific binding in Table
4.
TABLE-US-00005 TABLE 4 Percent Inhibition of ligand binding to
aminergic G protein-coupled receptors by compounds of the
invention: Compound Serotonin (1 .mu.M) Serotonin (0.1 .mu.M) No.
5-HT.sub.2A 5-HT.sub.2C 5-HT.sub.6 5-HT.sub.7 5-HT.sub.2A
5-HT.sub.2C 5-HT.sub.5A 5-HT.sub.6 5-HT.sub.7 1-1 97 98 93 42 60 51
35 1-2 91 97 93 100 1-3 99 98 85 103 1-4 97/100 95/98 82/87 95/98
1-5 102 95 100 79 1-66 77 84 31 72 19 1-6 97 95 100 42 1-7 98 95 95
48 1-67 39 51 -11 25 -8 1-8 86 74 72 77 1-9 77 80 32 30 1-10 91 93
47 54 1-11 82 78 72 74 1-12 82 65 31 48 1-13 82 83 26 41 1-14 74 72
12 37 1-15 102 99 98 94 1-16 50 66 9 45 1-17 96 91 87 82 1-18 71 52
31 47 1-19 98 94 45 69 1-20 91 81 38 78 1-21 68 44 3 40 1-22 71 47
7 16 1-23 62 43 32 18 1-24 36 8 10 12 1-25 17 16 4 10 1-26 23 -1 11
4 1-27 40 33 25 30 1-28 30 17 20 31 1-29 11 3 2 2 1-30 14 4 1 6
1-31 8 5 -7 -1 1-32 -6 -6 -1 31 1-33 43 56 -1 40 1-34 0 16 6 1-35
90 75 14 1-36 98 94 71 1-37 98 97 71 73 1-38 100 101 57 81 1-39 98
104 62 95 1-40 78 91 24 1-41 66 41 14 59 1-42 87 90 43 63 1-43 47
49 22 66 1-44 16 45 46 74 1-45 51 50 18 78 1-46 71 83 45 93 1-47 46
70 19 85 1-48 30 40 50 86 1-49 78 96 38 95 1-50 77 -1 30 95 1-51 77
92 4 15 1-52 88 89 43 1-54 77 90 65 1-59 96 99 54 1-60 67 67 26 48
16 1-61 81 88 5 68 -12 1-62 43 33 6 28 30 1-63 21 25 15 25 25 1-64
98 95 95 48 1-65 -10 6 -12 -6 -15
Example B6
Determination of Serotonin (5-Hydroxytryptamine) 5-HT.sub.2A
Agonist/Antagonist Activity of Compounds of the Invention
[0415] To determine for agonist or antagonist activity of compounds
of the invention in functional assays, human recombinant serotonin
5-HT.sub.2A receptor expressed in human embryonic kidney (HEK-293)
cells (Jerman J C, Brough S J, Gager T, Wood M, Coldwell M C, Smart
D and Middlemiss D N. Eur. J. Pharmacol. 414:23-30, 2001) is used.
Cells are suspended in DMEM buffer, and distributed in microplates.
A cytoplasmic calcium fluorescent indicator which varies
proportionally to the free cytosolic Ca.sup.2+ ion concentration is
mixed with probenecid in HBSS buffer complemented with 20 mM HEPES
(pH 7.4), added into each well and equilibrated with the cells for
30 min at 37.degree. C. followed by 30 min at 22.degree. C.
[0416] To measure agonist effects, compounds of the invention,
reference agonist or HBSS buffer (basal control) is added to the
cells and changes in fluorescence intensity are measured using a
microplate reader. For stimulated control measurements, 5-HT at 100
nM is added in separate assay wells.
[0417] The results are expressed as a percent of the control
response to 100 nM 5-HT. The standard reference agonist is 5-HT,
which is tested in each experiment at several concentrations to
generate a concentration-response curve from which its EC.sub.50
value is calculated.
[0418] To measure antagonist effects, the addition of the compounds
of the invention, reference antagonist or HBSS buffer is followed
by the addition of 3 nM 5-HT or HBSS buffer (basal control) prior
the fluorescence measurements. The results are expressed as a
percent inhibition of the control response to 3 nM 5-HT. The
standard reference antagonist is ketanserin, which is tested in
each experiment at several concentrations to generate a
concentration-response curve from which its IC.sub.50 value is
calculated. Compounds are screened at 3 .mu.M or lower, using DMSO
as vehicle.
Example B7
Determination of Serotonin (5-Hydroxytryptamine) 5-HT.sub.6
Agonist/Antagonist Activity of Compounds of the Invention
[0419] To determine for agonist or antagonist activity of compounds
of the invention in functional assays, human recombinant 5-HT.sub.6
receptor is transfected in CHO cells (Kohen, R., Metcalf, M. A.,
Khan, N., Druck, T., Huebner, K., Lachowicz, J. E., Meltzer, H. Y.,
Sibley, D. R., Roth, B. L., and Hamblin, M. W. "Cloning,
characterization and chromosomal localization of a human 5-HT.sub.6
serotonin receptor," J. Neurochem. 66:47, 1996) and the activity of
compounds of the invention is determined by measuring their effects
on cAMP production using the Homogeneous Time Resolved Fluorescence
(HTRF) detection method. Cells are suspended in HBSS buffer
complemented with HEPES 20 mM (pH 7.4) and 500 .mu.M IBMX, and then
distributed in microplates and incubated for 45 min at 37.degree.
C. in the absence (control) or presence of compounds of the
invention or the reference agonist or antagonist.
[0420] For agonist determinations, stimulated control measurement,
separate assay wells contain 10 .mu.M 5-HT. Following incubation,
the cells are lysed and the fluorescence acceptor (D2-labeled cAMP)
and fluorescence donor (anti-cAMP antibody labeled with europium
cryptate) are added. After 60 min at RT, the fluorescence transfer
is measured at lex=337 nm and lem=620 and 665 nm using a microplate
reader. The cAMP concentration is determined by dividing the signal
measured at 665 nm by that measured at 620 nm (ratio).
[0421] The results are expressed as a percent of the control
response to 10 .mu.M 5-HT. The standard reference agonist is 5-HT,
which is tested in each experiment at several concentrations to
generate a concentration-response curve from which its EC.sub.50
value is calculated.
[0422] For antagonist determinations, the reference agonist 5-HT is
added at a final concentration of 100 nM. For basal control
measurements, separate assay wells do not contain 5-HT. Following
45 min incubation at 37.degree. C., the cells are lysed and the
fluorescence acceptor (D2-labeled cAMP) and fluorescence donor
(anti-cAMP antibody labeled with europium cryptate) are added.
[0423] After 60 min at RT, the fluorescence transfer is measured as
mentioned above. The results are expressed as a percent inhibition
of the control response to 100 nM 5-HT. The standard reference
antagonist is methiothepin
Example B8
Determination of Dopamine D.sub.2L Antagonist Activity of
Compounds
[0424] To determine for agonist or antagonist activity of compounds
of the invention in functional assays, human recombinant dopamine
D.sub.2L receptor stably expressed in Chinese hamster ovary (CHO)
cells (Senogles, S E et al. J. Biol. Chem. 265(8):4507, 1990) is
used. Compounds of invention are pre-incubated with the membranes
(0.1 mg/mL) and 10 mM GDP in modified HEPES buffer (20 mM HEPES, pH
7.4, 100 mM NaCl, 10 mM MgCl.sub.2, 1 mM DTT, 1 mM EDTA) for 20 min
and Scintillation Proximity Assay (SPA) beads are added for another
60 min at 30.degree. C. The reaction is initiated by 0.3 nM
[.sup.35S]GTP.gamma.S for an additional 15 min incubation period.
Increase of [.sup.35S]GTP.gamma.S binding by 50% or more (350%)
relative to the 1 mM dopamine response by compounds of the
invention indicates possible dopamine D.sub.2L receptor agonist
activity Inhibition of a 10 .mu.M dopamine-induced increase of
[.sup.35S]GTP.gamma.S binding response by 50% or more (350%) by
compounds of the invention indicates receptor antagonist activity.
Compounds are screened at 3 .mu.M or lower, using 0.4% DMSO as
vehicle. Assay results are presented as the percent response of
specific binding.
Example B9
Determination of Dopamine D.sub.2S Antagonist Activity of Compounds
of the Invention
[0425] To determine for agonist or antagonist activity of compounds
of the invention in functional assays, human recombinant dopamine
D.sub.2S receptor stably expressed in Chinese hamster ovary (CHO)
cells (Gilliland S L and Alper R H. Naunyn-Schmiedeberg's Archives
of Pharmacology 361:498, 2000) is used. Compounds of invention are
pre-incubated with the membranes (0.05 mg/mL) and 3 .mu.M GDP in
modified HEPES buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM
MgCl.sub.2, 1 mM DTT, 1 mM EDTA) for 20 min and Scintillation
Proximity Assay (SPA) beads are then added for another 60 min at
30.degree. C. The reaction is initiated by 0.3 nM
[.sup.35S]GTP.gamma.S for an additional 30 min incubation period.
Increase of [.sup.35S]GTP.gamma.S binding by 50% or more (350%)
relative to the 100 .mu.M dopamine response by compounds of the
invention indicates possible dopamine D.sub.2S receptor agonist
activity Inhibition of a 3 .mu.M dopamine-induced increase of
[.sup.35S]GTP.gamma.S binding response by 50% or more (350%) by
compounds of the invention indicates receptor antagonist activity.
Compounds are screened at 3 .mu.M or lower, using 0.4% DMSO as
vehicle. Assay results are presented as the percent response of
specific binding.
Example B 10
Determination for Agonist or Antagonist Activity of Compounds of
the Invention in a Histamine H1 Functional Assay
[0426] To determine for agonist or antagonist activity of compounds
of the invention in functional assays, human recombinant Histamine
H.sub.1 receptor expressed in human embryonic kidney (HEK-293)
cells (Miller, T. R., Witte, D. G., Ireland, L. M., Kang, C. H.,
Roch, J. M., Masters, J. N., Esbenshade, T. A And Hancock, A. A. J.
Biomol. Screen. 4:249-258, 1999) is used. Cells are suspended in
DMEM buffer, and then distributed in microplates. A cytoplasmic
calcium fluorescent indicator--which varies proportionally to the
free cytosolic Ca.sup.2+ ion concentration--is mixed with
probenecid in HBSS buffer complemented with 20 mM HEPES (pH 7.4)
and is then added into each well and equilibrated with the cells
for 30 min at 37.degree. C. and then for another 30 min at
22.degree. C. To measure agonist effects, compounds of the
invention, reference agonist or HBSS buffer (basal control) are
added to the cells and changes in fluorescence intensity are
measured using a microplate reader. For stimulated control
measurements, histamine at 10 .mu.M is added in separate assay
wells.
[0427] The results are expressed as a percent of the control
response to 10 .mu.M histamine. The standard reference agonist is
histamine, which is tested in each experiment at several
concentrations to generate a concentration-response curve from
which its EC.sub.50 value is calculated.
[0428] To measure antagonist effects, the addition of the compounds
of the invention, reference antagonist or HBSS buffer is followed
by the addition of 300 nM histamine or HBSS buffer (basal control)
prior the fluorescence measurements. The results are expressed as
percent inhibition of the control response to 300 nM histamine. The
standard reference antagonist is ketanserin, which is tested in
each experiment at several concentrations to generate a
concentration-response curve from which its IC.sub.50 value is
calculated. Compounds are screened at 3 .mu.M or lower, using DMSO
as vehicle.
Example B11
Increase of Neurite Outgrowth
Neurite Outgrowth in Cortical Neurons
[0429] Compounds are tested to determine their ability to stimulate
neurite outgrowth of cortical neurons. Standard methods are used to
isolate cortical neurons. For the isolation of primary rat cortical
neurons, the fetal brain from a pregnant rat at 17 days of
gestation is prepared in Leibovitz's medium (L15; Gibco). The
cortex is dissected out, and the meninges are removed. Trypsin
(Gibco) is used to dissociate cortical C with DNAse I. The cells
are triturated for 30 min with a pipette in Dulbecco's Modified
Eagle Media ("DMEM"; Gibco) with 10% Fetal Bovine Serum ("FBS")
(Gibco) and centrifuged at 350.times.g for 10 min at RT. The cells
are suspended in Neurobasal medium supplemented with 2% B27 (Gibco)
and 0.5 mM L-glutamine (Gibco). The cells are maintained at 30,000
cells per well of poly-L-lysine coated plates at 37.degree. C. in
5% CO.sub.2-95% air atmosphere. After adhesion, a vehicle control
or compounds of the invention are added at different concentrations
to the medium. BDNF (50 ng/mL) is used as a positive control for
neurite growth. After treatment, cultures are washed in
phosphate-buffered saline ("PBS"; Gibco) and fixed in
glutaraldehyde 2.5% in PBS. Cells are fixed after 3 days growth.
Several pictures (.about.80) of cells with neurites are taken per
condition with a camera. The length measurements are made by
analysis of the pictures using software from Image-Pro Plus
(France). The results are expressed as mean (s.e.m.). Statistical
analysis of the data is performed using one way analysis of
variance (ANOVA).
Neurite Outgrowth in Rat Mixed Cortical Cultures
[0430] Cortical mixed cultures are prepared from E18 Wistar rat
embryos. The cortices are dissected out and the tissue is cut to
small pieces. The cells are separated by 15-min incubation with
DNase and papain. The cells are collected by centrifugation (1500
rpm, 5 min). The tissue is triturated with a pipette and the cells
are plated using the micro-islet protocol (20,000 cells in 25 .mu.L
medium) on poly-L-lysine coated 48 wells, in MEM supplemented with
2 mM glutamine, 0.1 .mu.g/mL gentamicin, 10% heat-inactivated fetal
bovine serum (FBS-HI) and 10% heat-inactivated horse serum (HS-HI).
After the cells attach to the well, 250 .mu.L medium is added to
the wells. Four hours after plating the medium is changed to fresh
medium (MEM with supplements and 5% HS-HI) containing test compound
at 0.5, 5 and 50 nM concentrations. As positive controls BDNF (50,
100 and/or 150 ng/mL), and/or NGF (50 ng/mL and/or 100 ng/mL) are
used. After 2 days in vitro, the cell's conditioned media are
collected from plates before fixing the cells. The media samples
are centrifuged 13,000 rpm 3 min to get rid of cell debris. The
samples are stored at -20.degree. C. for later analysis. Cells are
formaldehyde-fixed and processed for immunocytochemistry. BDNF
levels in the conditioned media are determined with a BDNF ELISA
using the manufacturers (Promega, BDNF Emax.RTM. ImmunoAssay
System, catalog number: G7610) instructions.
[0431] The cultures are fixed with 4% formaldehyde in 0.01M PBS for
30 min and washed once with PBS. The fixed cells are first
permeabilized and non-specific binding is blocked by a 30-min
incubation with blocking buffer containing 1% bovine serum albumin
and 0.3% Triton X-100 in PBS. Rabbit anti-MAP-2 (dilution 1:1000,
AB5622, Chemicon, in blocking buffer) is used as a primary
antibody. The cells are incubated with the primary antibody for 48
h at +4.degree. C., washed with PBS and incubated with secondary
antibody goat anti-rabbit IgG conjugated to Alexa Fluor568 (1:200,
A11036, Molecular Probes) for 2 h at RT. The immunopositive cells
are visualized by a fluorescence microscope equipped with
appropriate filter set, and documented by a high resolution image
capturing. The number of cells per field (4 field per well) are
counted, and the neurite outgrowth is quantified using Image Pro
Plus software.
[0432] The number of wells per compound concentration used is 6
(n=6). All data are presented as mean.+-.standard deviation (SD) or
standard error of mean (SEM), and differences are considered to be
statistically significant at the p<0.05 level. Statistical
analysis is performed using StatsDirect statistical software.
Differences between group means are analyzed by using 1-way-ANOVA
followed by Dunnet's test (comparison to the vehicle treated
group).
Example B12
Use of an In Vivo Model to Evaluate the Ability of Compounds to
Enhance Cognition, Learning and Memory in Scopolamine Treated
Rats
[0433] The two-trial object recognition paradigm developed by
Ennaceur and Delacour in the rat is used as a model of
episodic/short-term memory. Ennaceur, A., and Delacour, J. (1988),
Behav. Brain Res. 31:47-59. The paradigm is based on spontaneous
exploratory activity of rodents and does not involve rule learning
or reinforcement. The novel object recognition paradigm is
sensitive to the effects of ageing and cholinergic dysfunction.
See, e.g., Scali, C., et al., (1994), Neurosci. Letts. 170:117-120;
and Bartolini, L., et al., (1996), Biochem. Behav. 53:277-283.
[0434] Male Sprague-Dawley rats between six and seven weeks old,
weighing between 220-300 grams are obtained, e.g., from Centre
d'Elevage (Rue Janvier, B. P. 55, Le Genest-Saint-Isle 53940,
France). The animals are housed in groups of 2 to 4 in
polypropylene cages (with a floor area of 1032 cm.sup.2) under
standard conditions: at RT (22.+-.2.degree. C.), under a 12 h
light/12 h dark cycle, with food and water provided ad libitum
Animals are permitted to acclimate to environmental conditions for
at least 5 days before the experiment begins, and are numbered on
their tails with indelible marker.
[0435] The experimental arena is a square wooden box (60
cm.times.60 cm.times.40 cm) painted dark blue, with 15 cm.times.15
cm black squares under a clear plexiglass floor. The arena and
objects placed inside the arena are cleaned with water between each
trial to eliminate any odor trails left by rats. The arena is
placed in a dark room illuminated only by halogen lamps directed
towards the ceiling in order to produce a uniformly dim light in
the box of approximately 60 lux. The day before testing, animals
are allowed to freely explore the experimental arena for 3 min in
the presence of two objects (habituation). Animals to be tested are
placed in the experimental room at least 30 min before testing.
[0436] Novel object recognition test is comprised of two trials
separated by an interval of 120 min or 24 h. When agents that
disrupt memory such as the cholinergic antagonist scopolamine are
used an inter-trial interval of 120 min is preferred. Alternatively
a 24 h inter-trial interval is used when studying effect of natural
forgetting on novel object recognition task. During the first, or
acquisition, trial (T.sub.1), rats are placed in the arena, where
two identical objects have been previously placed. The time
required for each animal to complete 15 sec of object exploration
is determined, with a cut-off time of 4 min. Exploration is
considered to be directing the nose at a distance less than 2
centimeters ("cm") from the object and/or touching the object.
During the second, or testing, trial (T.sub.2), one of the objects
presented in the first trial is replaced with an unknown or novel
object, while the second, familiar object is left in place. Rats
are placed back in the arena for 3 min, and exploration of both
objects is determined. Locomotor activity of rats (number of times
rats cross grid lines visible under the clear plexiglass floor) is
scored for during T.sub.1 and T.sub.2. At the conclusion of the
experiments, the rats are sacrificed by an overdose of
pentobarbital given intraperitoneally.
[0437] The following parameters are measured as part of the novel
object recognition task: (1) time required to achieve 15 sec of
object exploration during T.sub.1; (2) locomotor activity during
T.sub.1 (number of crossed lines); (3) time spent in active
exploration of the familiar object during T.sub.2 (T.sub.Familiar);
(4) time spent in active exploration of the novel object during
T.sub.2 (T.sub.Novel); and (5) locomotor activity during T.sub.2
(number of crossed lines). The difference between time spent in
active exploration of the novel object during T.sub.2 and time
spent in active exploration of the familiar object during T.sub.2
(.DELTA.T.sub.Novel-T.sub.Familiar) is evaluated. The percent of
animals in each group with T.sub.Novel-T.sub.Familiar greater than
or equal to 5 sec is also derived; described as percent of good
learners.
[0438] Animals not meeting a minimal level of object exploration
are excluded from the study as having naturally low levels of
spontaneous exploration. Thus, only rats exploring the objects for
at least five sec (T.sub.Novel+T.sub.Familiar>5 sec) are
included in the study.
[0439] Animals are randomly assigned to groups of 14. Compounds of
the invention and controls are administered to animals the groups
as follows: Solutions of compounds are prepared freshly each day at
a concentration of 0.25 mg/mL using purified water or saline as
vehicle. Donepezil, used as a positive control, and scopolamine are
administered simultaneously in a single solution of saline (5
mL/kg) prepared freshly each day. Scopolamine is purchased from
Sigma Chemical Co. (Catalog No.S-1875; St. Quentin Fallavier,
France) is dissolved in saline to a concentration of 0.06
mg/mL.
[0440] Donepezil or its vehicle and scopolamine are administered
intraperitoneally 40 min before the acquisition trial (T.sub.1).
Compounds or their vehicle are administered by gavage 25 min before
the acquisition trial (T.sub.1), e.g., 5 min after administration
of scopolamine. The volume of administration is 5 mL/kg body weight
for compounds administered intraperitoneally, and 10 mL/kg for
compounds administered orally. Recognition scores and percent of
good learners for compounds of the invention are determined.
Example B13
Use of an In Vivo Model to Determine the Ability of Compounds to
Treat, Prevent and/or Delay the Onset and/or the Development of
Schizophrenia in PCP Treated Animals
[0441] In vivo models of schizophrenia can be used to determine the
ability of the compounds described herein to treat and/or prevent
and/or delay the onset and/or the development of schizophrenia.
[0442] One exemplary model for testing the activity of one or more
compounds described herein to treat and/or prevent and/or delay the
onset and/or development of schizophrenia employs phencyclidine
(PCP), which is administered to the animal (e.g., non-primate (rat)
or primate (monkey)), resulting in dysfunctions similar to those
seen in schizophrenic humans. See Jentsch et al., 1997, Science
277:953-955 and Piercey et al., 1988, Life Sci. 43(4):375-385).
Standard experimental protocols may be employed in this or in other
animal models. One protocol involves PCP-induced hyperactivity.
[0443] Male mice (various strains, e.g., C57B1/6J) from appropriate
vendor (for example, Jackson Laboratories (Bar Harbor, Me.) are
used. Mice are received at 6-weeks of age. Upon receipt, mice are
assigned unique identification numbers (tail marked) and are group
housed with 4 mice/cage in OPTI mouse ventilated cages. All animals
remain housed in groups of four during the remainder of the study.
All mice are acclimated to the colony room for at least two weeks
prior to testing and are subsequently tested at an average age of 8
weeks. During the period of acclimation, mice are examined on a
regular basis, handled, and weighed to assure adequate health and
suitability. Animals are maintained on a 12/12 light/dark cycle.
The room temperature is maintained between 20 and 23.degree. C.
with a relative humidity maintained between 30% and 70%. Food and
water are provided ad libitum for the duration of the study. In
each test, animals are randomly assigned across treatment
groups.
[0444] The open filed (OF) test assesses locomotor behavior, e.g.,
to measure mouse locomotor activity at baseline and in response to
pharmacological agents. The open field chambers are Plexiglas
square chambers (27.3.times.27.3.times.20.3 cm; Med Associates
Inc., St Albans, Vt.) surrounded by infrared photobeams
(16.times.16.times.16) to measure horizontal and vertical activity.
The analysis is configured to divide the open field into a center
and periphery zone such that the infrared photobeams allow
measurement of activity in the center and periphery of the field.
Distance traveled is measured from horizontal beam breaks as the
mouse moved whereas rearing activity is measured from vertical beam
breaks.
[0445] Mice (10 to 12 animals per treatment group) are brought to
the activity experimental room for at least 1 h acclimation to the
experimental room conditions prior to testing. Eight animals are
tested in each run. Mice are administered vehicle (e.g., 10% DMSO
or 5% PEG200 and 1% Tween 80), compound of the invention, clozapine
(positive control, 1 mg/kg ip) and placed in the OF chambers for 30
min following which they are injected with either water or PCP and
placed back in the OF chambers for a 60-min session. At the end of
each OF test session the OF chambers are thoroughly cleaned.
PCP Hyperactivity Mouse Model of Schizophrenia
[0446] The test compound at the desired dose is dissolved in
appropriate vehicle, e.g., 5% PEG200, 1% Tween80 and administered
orally 30 min prior to PCP injection. Clozapine (1 mg/kg) is
dissolved in 10% DMSO and administered i.p. 30 min prior to PCP
injection. PCP (5 mg/kg) is dissolved in sterile injectable saline
solution and administered i.p.
[0447] Data are analyzed by analysis of variance (ANOVA) followed
by post-hoc comparisons with Fisher Tests when appropriate.
Baseline activity is measured during the first 30 min of the test
prior to PCP injection. PCP-induced activity is measured during the
60 min following PCP injection. Statistical outliers that fell
above or below 2 standard deviations from the mean are removed from
the final analyses. An effect is considered significant if
p<0.05. Total distances traveled and total rearing following PCP
administration are compared between groups treated with compounds
and groups treated with vehicle and positive control clozapine.
[0448] Protocol is as described above with the exception of the
treatment groups which are as follows: All injections are at a dose
volume of 10 mL/kg. The test compound at the desired dose is
dissolved in Phosphate Buffered Saline (PBS) and administered
orally 30 min. prior to PCP injection. Clozapine (0.5 and 1.0
mg/kg) is dissolved in 10% DMSO and administered i.p. 30 min. prior
to Phencyclidine (PCP) injection. PCP (5.0 mg/kg) is dissolved in
sterile injectable saline and administered i.p. Total distances
traveled for is determined.
Example Bb 14
Use of an In Vivo Model to Determine the Ability of Compounds to
Treat, Prevent and/or Delay the Onset and/or the Development of
Schizophrenia in Amphetamine Treated Animals
[0449] Male mice (various strains e.g., C57B1/6J) from appropriate
supplier (for example Jackson Laboratories, Bar Harbor, Me.) are
used. Mice typically are received at 6-weeks of age. Mice are
acclimated to the colony room for at least two weeks prior to
testing. During the period of acclimation, mice are examined on a
regular basis, handled, and weighed to assure adequate health and
suitability and maintained on a 12/12 light/dark cycle. The room
temperature is maintained between 20 and 23.degree. C. with a
relative humidity maintained between 30% and 70%. Food and water
are provided ad libitum for the duration of the study. In each
test, animals are randomly assigned between treatment groups.
[0450] The open field test (OF) is used to assess motor activity.
The open field chambers are plexiglass square chambers (e.g.,
27.3.times.27.3.times.20.3 cm; Med Associates Inc., St Albans, Vt.)
surrounded by infrared photobeam sources (16.times.16.times.16).
The enclosure is configured to split the open field into a center
and periphery zone and the photocell beams are set to measure
activity in the center and in the periphery of the OF chambers.
Horizontal activity (distance traveled) and vertical activity
(rearing) are measured from consecutive beam breaks.
[0451] On the day of testing, animals are brought to the
experimental room for at least 1 h acclimation prior to start of
treatment. Animals are administered with vehicle, haloperidol
(positive control, 0.1 mg/kg ip) or test compound and placed in the
OF. The time of administration of client compound to each animal is
recorded. Baseline activity is recorded for 30 min following which
mice receive amphetamine (4 mg/kg) or water and are placed back in
the OF chambers for a 60-min session. At the end of each open field
test session the OF chambers are thoroughly cleaned. Typically ten
to twelve mice are tested in each group. Test compound doses
typically range from 0.01 mg/kg to 60 mg/kg.
[0452] Data are analyzed by analysis of variance (ANOVA) followed
by post-hoc comparisons with Fisher Tests when appropriate.
Baseline activity is measured during the first 30 min of the test
prior to amphetamine injection. Amphetamine-induced activity is
measured during the 60 min following amphetamine injection.
Statistical outliers that fall above or below 2 standard deviations
from the mean are removed from the final analyses. An effect is
considered significant if p<0.05. Total distance traveled and
total rearing following amphetamine administration are compared
between groups treated with compound and groups treated with
vehicle and positive control haloperidol.
Example B15
Use of the In Vivo Conditioned Avoidance Response (CAR) Model to
Determine the Ability of Compounds to Treat, Prevent and/or Delay
the Onset and/or the Development of Schizophrenia
[0453] All currently approved antipsychotic agents (typical and
atypical) are known to have the ability to selectively suppress
conditioned avoidance response (CAR) behavior in the rat. This
evidence makes CAR one of the primary tests to assess antipsychotic
activity of novel compounds.
[0454] Rats (various strains, 2 months of age) are trained and
tested in a computer-assisted, two-way active avoidance apparatus
(shuttle box). This box consists of two compartments of equal size
divided by a stainless steel partition containing an opening of
7.times.7 cm. Each compartment is equipped with an electrified grid
floor made of stainless steel rods spaced 1 cm apart. Rats trained
to avoid the foot shock are placed each day in the shuttle box for
a 4 min habituation period followed by 30 trials spaced by
inter-trial interval varying at random between 20 and 30 sec. Each
trial consists of a 10-sec stimulus light (conditioned stimulus,
CS) followed by a 10-sec foot shock (unconditioned stimulus, US) in
presence of the light presented in the compartment where the rat is
located. If the animal leaves the compartment prior to the delivery
of the foot shock, the response is considered an avoidance
response. If the rat does not change compartment during the 10-sec
light period and during the 10-sec shock+light period, an escape
failure is recorded. This test requires animals to be trained 5
days/week. On each training day, rats are submitted to one training
session of 30-trials. Treatment with test compound is initiated
only when rats reach an avoidance performance of at least 80% on at
least two consecutive training sessions. The test compound is
administered orally at various doses and various pre-treatment
times (depending upon specific pharmacokinetic properties).
[0455] Compounds with antipsychotic profile inhibit conditioned
avoidance responses with or without increases in escape failures.
Statistical analysis is performed using a Friedman two-way ANOVA by
ranks followed by the Wilcoxon matched-pairs signed-ranks test to
test each dose of the test compound administered versus vehicle
control treated rats.
Example B16
An Animal Model of the Negative Symptoms of Schizophrenia:
Subchronic PCP-Induced Social Interaction Deficits
[0456] Phencyclidine (PCP) administered to humans as well to
experimental animals induces full-spectrum of schizophrenia
symptoms, including negative symptoms and cognitive deficits. A
major symptom of schizophrenia is considered to be social
isolation/withdrawal as part of the cluster of negative symptoms.
Subchronic treatment with PCP in rats leads to the development of
clear signs of social withdrawal as measured by deficits in the
interaction time with a cage intruder rat. Male Sprague Dawley rats
(about 150 g, obtained from different vendors, for example Harlan,
Ind.) are used in this study. Upon receipt, rats are group housed
in OPTI rat ventilated cages. Rats are housed in groups of 2-3 per
cage for the remainder of the study. During the period of
acclimation, rats are examined on a regular basis, handled, and
weighed to assure adequate health and suitability. Rats are
maintained on a 12/12 light/dark cycle with the light on at 7:00
a.m. The room temperature is maintained between 20-23.degree. C.
with a relative humidity maintained between 30-70%. Food and water
are provided ad libitum for the duration of the study. Animals are
randomly assigned across treatment groups and balanced by age.
[0457] For five days prior to test, rats are injected twice daily
with either PCP (2 mg/kg; s.c) or saline (s.c). On day 6 and
following a 30 min pretreatment with vehicle, clozapine (2.5 mg/kg
ip dissolved in 5% PEG:5% Tween 80) as positive control and test
compound at desired dose dissolved in appropriate vehicle, a pair
of rats, unfamiliar to each other, receiving the same treatment are
placed in a white plexiglas open field arena
(24''.times.17''.times.8'') and allowed to interact with each other
for 6 min. Social interactions (`SI`) include: sniffing the other
rat; grooming the other rat; climbing over or under or around the
other rat; following the other rat; or exploring the ano-genital
area of the other rat. Passive contact and aggressive contact are
not considered a measure of social interaction. The time the rats
spent interacting with each other during the 6 min test is recorded
by a trained observer. The social interaction chambers are
thoroughly cleaned between the different rats. Data are analyzed by
analysis of variance (ANOVA) followed by post-hoc analysis (e.g.,
Fischer, Dunnett) when appropriate. An effect is considered
significant if p<0.05.
Example B17
An Animal Model of Extrapyramidal Syndrome (EPS): Measurement of
Catalepsy in the Mouse Bar Test
[0458] Antipsychotic drugs are known to induce extrapyramidal
syndrome (EPS) in animals and in humans. An animal model considered
to be predictive of EPS is the mouse bar test, which measures
cataleptic responses to pharmacological agents. Male mice (various
strains) from appropriate vendor (for example, Jackson Laboratories
(Bar Harbor, Me.) are used. Mice are received at 6-weeks of age.
Upon receipt, mice are assigned unique identification numbers (tail
marked) and are group housed with 4 mice per cage in OPTI mouse
ventilated cages. All animals remain housed in groups of four
during the remainder of the study. All mice are acclimated to the
colony room for at least two weeks prior to testing and are
subsequently tested at an average age of 8 weeks. During the period
of acclimation, mice are examined on a regular basis, handled, and
weighed to assure adequate health and suitability. Animals are
maintained on a 12/12 light/dark cycle. The room temperature is
maintained between 20-23.degree. C. with a relative humidity
maintained between 30-70%. Food and water are provided ad libitum
for the duration of the study. In each test, animals are randomly
assigned across treatment groups.
[0459] In the mouse bar test, the front paws of a mouse are placed
on a horizontal bar raised 2'' above a Plexiglas platform and time
is recorded for up to 30 sec per trial. The test ends when the
animal's front paws return to the platform or after 30 sec. The
test is repeated 3 times and the average of 3 trials is recorded as
index of catalepsy. In these studies the typical antipsychotic
agent haloperidol (2 mg/kg ip dissolved in 10% DMSO) is used as
positive control and induces rigidity and catalepsy as measured by
time spent holding on the bar. 30 min prior to the trial, test
compound at desired dose and dissolved in appropriate vehicle is
administered PO, vehicle and positive control haloperidol (2 mg/kg
ip) are administered to separate groups of mice. Catalepsy
responses are measure 30 min, 1 h and 3 h following treatments. A
trained observer is measuring time spent holding onto the bar
during the 30 sec trial. Data are analyzed by analysis of variance
(ANOVA) followed by post-hoc analysis (e.g., Fischer, Dunnett) when
appropriate. An effect is considered significant if p<0.05.
Example B18
An Animal Model to Test the Anxiolytic Effects of Compounds Using
the Elevated Plus Maze (EPM) Test
[0460] This study may be used to test the anxiolytic properties of
compounds detailed herein using the elevated plus maze (EPM) test
in C57B1/6J mice.
[0461] Male C57B1/6J mice from Jackson Laboratories (Bar Harbor,
Me.) are used for the open field study. Mice are received at
6-weeks of age. Upon receipt, mice are assigned unique
identification numbers (tail marked) and are group housed with 4
mice/cage in OPTI mouse ventilated cages. All animals remain housed
in groups of four during the remainder of the study. All mice are
acclimated to the colony room for approximately 2 week prior to
testing and are subsequently tested at an average age of 8 weeks of
age. During the period of acclimation, mice and rats are examined
on a regular basis, handled, and weighed to assure adequate health
and suitability. Animals are maintained on a 12 h/12 h light/dark
cycle. The room temperature is maintained between 20 and 23.degree.
C. with a relative humidity maintained between 30% and 70%. Chow
and water are provided ad libitum for the duration of the study. In
each test, animals are randomly assigned across treatment groups.
All animals are euthanized after the completion of the study.
[0462] Compounds may be dissolved in 5% PEG200/H.sub.2O and
administered orally at a dose volume of 10 mL/kg 30 min prior to
test; 2) Diazepam (2.5 mg/kg) is dissolved in 45%
hydroxypropyl-.beta.-cyclodextrin and administered orally at a dose
volume of 10 mL/kg 30 min prior to test.
[0463] The elevated plus maze test assesses anxiety. The maze
(Hamilton Kinder) consists of two closed arms (14.5 h.times.5
w.times.35 cm length) and two open arms (6 w.times.35 l cm) forming
a cross, with a square center platform (6.times.6 cm). All visible
surfaces are made of black acrylic. Each arm of the maze is placed
on a support column 56 cm above the floor. Antistatic black vinyl
curtains (7' tall) surround the EPM to make a 5'.times.5''
enclosure Animals are brought to acclimate to the experimental room
at least 1 h before the test. Mice are placed in the center of the
elevated plus maze facing the closed arm for a 5-min run. All
animals are tested once. The time spent, distance traveled and
entries in each arm are automatically recorded by a computer. The
EPM is thoroughly cleaned after each mouse.
[0464] Data are analyzed using analysis of variance (ANOVA)
followed by Fisher's LSD post hoc analysis when appropriate. An
effect is considered significant if p<0.05.
[0465] All references throughout, such as publications, patents,
patent applications and published patent applications, are
incorporated herein by reference in their entireties.
[0466] Although the foregoing invention has been described in some
detail by way of illustration and example for purposes of clarity
of understanding, it is apparent to those skilled in the art that
certain minor changes and modifications will be practiced.
Therefore, the description and examples should not be construed as
limiting the scope of the invention.
* * * * *